377 results on '"Hospital CUF Descobertas"'
Search Results
2. Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
- Author
-
Fundação para a Ciência e a Tecnologia, Hospital Cuf Descobertas, and Rune Matthiesen, Principal Investigator
- Published
- 2021
3. Automated Screen for Fetal Aneuploidy (FAST1)
- Author
-
Brugmann University Hospital, University of British Columbia, Royal Prince Alfred Hospital, Sydney, Australia, Hospital Universitario Virgen de la Arrixaca, Hospital CUF Descobertas, Lisbon, Portugal, and University College London Hospitals
- Published
- 2018
4. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
- Author
-
Karin C. Lødrup Carlsen, L. Cecchi, F. Portejoie, T. Vontetsianos, Olivier Vandenplas, M. van Hague, D. Mora Bogado, M. Illario, Dana Wallace, L. Namazova-Baranova, E. Asayag, I. Ribeirinho, E. Costa, Shona Pedersen, Inger Kull, Davor Plavec, M. Morais-Almeida, Mickael Bewick, N.H. Chavannes, I. J. Ansotegui, G. De Carlo, K. S. Bennoor, Faradiba Sarquis Serpa, S. Arnavielle, F. Corti, Moises A. Calderon, Martín Bedolla-Barajas, Mette Sørensen, Isabella Annesi-Maesano, Elaine Colgan, Przemyslaw Kardas, M. van Eerd, Jorge Maspero, Valérie Siroux, Isabelle Momas, Ralph Mösges, Yves Dauvilliers, T. Keil, T. Bieber, Marit Westman, Rachel Nadif, O. Pfaar, A.C. Carvalho Coehlo, R. M. Cortés-Grimaldo, I. Skrindo, Piotr Kuna, Nicola Scichilone, Antonella Muraro, Kimihiro Okubo, Paulo Augusto Moreira Camargos, C. Cartier, Oliver Pfaar, K. Ohta, Barbara P. Yawn, Igor Kaidashev, Michel Thibaudon, X. Basagana, I. Kaidashev, Bilun Gemicioglu, S. Genova, Hae-Sim Park, J.J. Matta Campos, Simon Walker, Ulf Darsow, Fulvio Braido, J. Salimäki, T. Zuberbier, Raphaël Chiron, Mohammad Reza Masjedi, G.D. Marshall, Branislava Milenkovic, W. J. Fokkens, Eric D. Bateman, Robert M. Naclerio, Steve Montefort, M. de Fátima Emerson, T. Werfel, Cemal Cingi, A. Szylling, Martin Wagenmann, I. Baiardini, L. T. T. Le, N. Khaltaev, Ki-Suck Jung, Agnieszka Lipiec, Panayiotis K. Yiallouros, A Valero, R. Gerth van Wijk, L. Hernández, Marek L. Kowalski, C. Zubrinich, Sinthia Bosnic-Anticevich, Miguel A. Sierra, Erik Melén, T. Haahtela, Rute Almeida, Violeta Kvedariene, R. Pawankar, T.A. Popov, Flore Amat, Sanna Toppila-Salmi, M. Gotua, A. Sheikh, A. Bedbrook, Torsten Zuberbier, B. De Martino, Gérard Dray, Francesca Avolio, E. Mandajieva, B. Samolinski, Petr Panzner, P. Kuna, Philippe-Jean Bousquet, T. D. Nyembue, Luo Zhang, Leyla Namazova-Baranova, Ana Maria Carriazo, João Fonseca, E. Van Ganse, Roland Buhl, M. Bochenska Marciniak, Cristiana Stellato, J. da Silva, J. E. Gereda, Han-Jung Park, M.C. Costa-Dominguez, W. Carr, Dirceu Solé, S. Forti, Nanshan Zhong, Jordi Sunyer, Alain Didier, Y. Z. Chen, Thomas B. Casale, Jim Phillips, Isabelle Bosse, Manuel Teixeira Veríssimo, D. Y. Wang, U. Trama, Cristina Bárbara, David Somekh, T. Camuzat, R. N. Naclerio, Enrico Novellino, Leszek Klimek, M. Rodriguez Gonzalez, Holger J. Schünemann, Mario Barbagallo, D. Larenas-Linnemann, Mario Sánchez-Borges, Massimo Triggiani, Y. Okamoto, E. Mathieu-Dupas, N. Di Carluccio, S. Toppila-Salmi, Omer Kalayci, Rudolf Valenta, J. Coll, F. de Blay, Wienczyslawa Czarlewski, W. Pohl, Piotr Wroczyński, Kian Fan Chung, Nikolaos G. Papadopoulos, Pascal Demoly, Hubert Blain, M. Crescenzo, O. Kalayci, Leocadio Rodríguez-Mañas, G. Moda, L. Cox, Z. Gutter, A. Mair, Andrew Bush, Maria-Dolores Mogica-Martinez, Giorgio Walter Canonica, Antonio Valero, Daniel Laune, A. Zurkuhlen, Paul C. Potter, D. Wallace, Gabrielle L. Onorato, Mihaela Zidarn, E.P. Prokopakis, Anne Lise Courbis, Sergio Bonini, Ruta Dubakiene, A. Papi, Y. El-Gamal, Jacques Mercier, Wytske Fokkens, Rodolphe Bourret, S. Palkonen, A. Yorgancioglu, G. Vezzani, J. A. Rizzo, D. Plavec, D. Caillot, G. De Feo, E. Menditto, Caterina Bucca, A. C. Pozzi, Hironori Sagara, I. Grisle, I. Pin, Christopher E. Brightling, Ludger Klimek, F.F. Morato-Castro, Désirée Larenas-Linnemann, Alessandro Vatrella, A. A. Cruz, Guy Joos, E.D. Bateman, Erendira Rodriguez-Zagal, H. Douagui, T. To, Edgardo Jares, C. Bindslev-Jensen, G. Levato, J. O. B. Hourihane, R. Rajabian-Soderlund, C. Odzhakova, J. Bousquet, M. T. Ventura, Arzu Yorgancioglu, Osman M. Yusuf, H. J. Zar, Giovanni Rolla, Sebastian L. Johnston, M.S. Dykewicz, Esben Eller, A. Gamkrelidze, Filip Raciborski, Renzo Angles, Rafael Stelmach, M. Nogues, David Price, Mário Morais-Almeida, Tari Haahtela, Teresa To, D. Conforti, Stephen R. Durham, S. Gonzalez Diaz, V. Cardona, Werner Aberer, B. Milenkovic, Luigi Napoli, K. C. Bergmann, P W Hellings, M. Lessa, P. Panzner, Alfonso M. Cepeda Sarabia, M. Guidacci, A.L. Matos, Todor A. Popov, C. Suppli Ulrik, Diana Deleanu, N. de Paula Motta Rubini, Carsten Bindslev-Jensen, I. Majer, Ioana Agache, B. A. Barreto, R. Picard, Erkka Valovirta, A. Fink-Wagner, L. Colas, João O. Malva, Thomas Keil, M. T. Burguete Cabañas, Bolesław Samoliński, M.H. Garcia-Cruz, L.P. Boulet, K. Nekam, Edyta Krzych-Fałta, P. Devillier, J. Ferreira de Mello, Jussi Karjalainen, I. Bogus-Buczynska, Susan Waserman, Marcus Maurer, Tomas Chivato, Elena Bacci, M. Przemecka, Olga Lourenço, José Miguel Fuentes-Pérez, M. Zidarn, Talant Sooronbaev, J.M. Anto, W. Czarlewski, R. Murray, Luís Nogueira-Silva, G. Passalacqua, E. Chkhartishvili, Oscar Mayora, Victoria Cardona, M. Sondermann, Piotr Lacwik, S. Ouedraogo, I. Baroni, Artur Z. Białoszewski, G Scadding, J. Strozek, R. Emuzyte, Neven Miculinic, Ruby Pawankar, Ken Ohta, I. Agache, J.L. Gálvez-Romero, Nikos G. Papadopoulos, E. O. Meltzer, I. Annesi-Maesano, E. De Manuel Keenoy, Jorge A. Luna-Pech, Ana Margarida Pereira, Paul Potter, M. Ortega Cisneros, J. Li, K. F. Rabe, M. Rottem, Mikael Benson, Ali Fuat Kalyoncu, Dermot Ryan, Dieter Maier, C.Y. García-Cobas, S. Bialek, G. Du Toit, S. Shamai, S. Mavale-Manuel, Rojin Rajabian-Soderlund, Maddalena Illario, Philippe Devillier, F. Rodenas, Emmanuel P. Prokopakis, De Yun Wang, Niels H. Chavannes, E.H.D. Bel, Bianca Beghe, Sietze Reitsma, John Wright, O. Lourenço, L.T.T. Le, Josep M. Antó, T. Casale, Paul K. Keith, K. C. Lødrup Carlsen, P. Demoly, Mikael Kuitunen, Marc Humbert, A. M. Cepeda Sarabia, Ignacio J. Ansotegui, M.C. Rizzo, Davide Caimmi, Milan Sova, Nick A. Guldemond, P. Yakovliev, Judah A. Denburg, Jaime Correia de Sousa, Elisabete Melo-Gomes, Aziz Sheikh, I. Bosse, M. M. Ciaravolo, S. Di Capua Ercolano, Alpana Mair, P. Lieberman, Isabella Pali-Schöll, Leif Bjermer, G. De Vries, M. Roman Rodriguez, Johanna Salimäki, Carmen Panaitescu, F. Mihaltan, Giulia De Feo, F. E. R. Simons, A. Blua, B. Mahboub, D. Ryan, M. Bewick, Anabela Mota-Pinto, J.A. Fonseca, Neil Wilson, Marek Jutel, Dennis M. Williams, M. Akdis, Menachem Rottem, Marcello Persico, J. C. Ivancevich, Nelson Rosario, A. Farsi, Alvaro A. Cruz, Liguo Zhang, Anna Bedbrook, L. Bertorello, Magnus Wickman, Marilyn Urrutia-Pereira, O. Spranger, René Maximiliano Gómez, C. Bachert, Renaud Louis, Musa Khaitov, C. Stellato, Constantinos Pitsios, Roland Buonaiuto, A. Romano, Sîan A Williams, R. Puy, Daniela Rivero-Yeverino, Y. Mohammad, J. Farrell, Jan Brozek, Ricardo Pio Monti, E. Paulino, J. Correia de Sousa, Miguel Alejandro Medina-Ávalos, Jocelyne Just, Peter Valentin Tomazic, Jean-François Ferrero, Antoine Magnan, S. Waserman, J Rosado-Pinto, Maciek Kupczyk, C.S. Bosnic-Anticevich, T. Dedeu, Tommi Vasankari, R. Mösges, Robin O'Hehir, Ema Paulino, Peter Hellings, A. Neou, M. Wickman, D. Lauri, Jean Bousquet, A. Ciceran, Jacques Bouchard, Yehia El-Gamal, M.G. Dominguez-Silva, M.R. Alberti, Jean-Louis Pépin, Kimi Okubo, Juan Carlos Ivancevich, Patrik Eklund, Benoit Pugin, C. Dario, Mussa Khaitov, Luisa Brussino, A.G. Chuchalin, Elísio Costa, Susanna Palkonen, Lars Münter, Pedro Carreiro-Martins, R.E. Pulido Ross, Ettore Novellino, Kai-Håkon Carlsen, María Antonieta Guzmán, G.W. Canonica, Gabriel Onorato, Giuseppe De Carlo, R.E. Roller-Wirnsberger, Brian J. Lipworth, M. A. Guzman, J.N. Tebyriçá, Adnan Custovic, Yoshitaka Okamoto, Rimantas Stukas, P. Manning, J. Sastre-Dominguez, Caroline L.S. George, Robyn E O'Hehir, K. Maciej, Bassam Mahboub, J. F. Fontaine, Arũnas Valiulis, Xavier Rodó, D. Vicheva, G. Canfora, Vitalis Briedis, S. Rodrigues Valle, Mark S. Dykewicz, Joanne Rimmer, G. Castellano, B. Pigearias, A. L. Boner, Yunuen Rocío Huerta-Villalobos, Christine Rolland, H. Neffen, H. Arshad, Javier Gómez-Vera, P. Moura Santo, Frederic Viart, F. Blasi, J. Garcia-Aymerich, Lorenzo Cecchi, V. Niedeberger, Giorgio Ciprandi, F. Caballero-Fonseca, Jean-François Fontaine, J Mullol, Maurizio Romano, M. Viegi, Mario E. Zernotti, Arunas Valiulis, Anna Asarnoj, Antonio Nieto, J. Lavrut, D. Dokic, V. Kvedariene, Ewa Jassem, Cezmi A. Akdis, Ruth Murray, Claus Bachert, Peter Schmid-Grendelmeier, Emilie Burte, Joaquim Mullol, Guido Iaccarino, J. Kleine-Tebbe, P. V. Tomazic, E. Eller, Alessandro Fiocchi, H.J. Schunemann, M. Sorlini, C. Robalo-Cordeiro, Ana-Maria Todo-Bom, J. Brozek, Marco Nalin, Matteo Bonini, J. C. Sisul, S.E. Dahlen, F. Amat, Juan Carlos Sisul, Jawad Hajjam, Ana Todo-Bom, Enrica Menditto, Bousquet J., Hellings P.W., Agache I., Amat F., Annesi-Maesano I., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bedbrook A., Bennoor K., Bewick M., Bindslev-Jensen C., Bosnic-Anticevich S., Bosse I., Brozek J., Brussino L., Canonica G.W., Cardona V., Casale T., Cepeda Sarabia A.M., Chavannes N.H., Cecchi L., Correia de Sousa J., Costa E., Cruz A.A., Czarlewski W., De Carlo G., De Feo G., Demoly P., Devillier P., Dykewicz M.S., El-Gamal Y., Eller E.E., Fonseca J.A., Fontaine J.-F., Fokkens W.J., Guzman M.-A., Haahtela T., Illario M., Ivancevich J.-C., Just J., Kaidashev I., Khaitov M., Kalayci O., Keil T., Klimek L., Kowalski M.L., Kuna P., Kvedariene V., Larenas-Linnemann D., Laune D., Le L.T.T., Carlsen K.L., Lourenco O., Mahboub B., Mair A., Menditto E., Milenkovic B., Morais-Almeida M., Mosges R., Mullol J., Murray R., Naclerio R., Namazova-Baranova L., Novellino E., O'Hehir R.E., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Palkonen S., Panzner P., Papadopoulos N.G., Park H.-S., Paulino E., Pawankar R., Pfaar O., Plavec D., Popov T.A., Potter P., Prokopakis E.P., Rottem M., Ryan D., Salimaki J., Samolinski B., Sanchez-Borges M., Schunemann H.J., Sheikh A., Sisul J.-C., Rajabian-Soderlund R., Sooronbaev T., Stellato C., To T., Todo-Bom A.-M., Tomazic P.-V., Toppila-Salmi S., Valero A., Valiulis A., Valovirta E., Ventura M.-T., Wagenmann M., Wang D.Y., Wallace D., Waserman S., Wickman M., Yorgancioglu A., Zhang L., Zhong N., Zidarn M., Zuberbier T., Aberer W., Akdis C.A., Akdis M., Alberti M.R., Almeida R., Angles R., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Basagana X., Bedolla-Barajas M., Beghe B., Bel E.H., Bergmann K.C., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bouchard J., Boulet L.P., Bourret R., Braido F., Briedis V., Brightling C.E., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillot D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Castellano G., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Cortes-Grimaldo R.M., Corti F., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Dahlen S.E., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., Dedeu T., de Fatima Emerson M., De Vries G., De Martino B., de Paula Motta Rubini N., Deleanu D., Denburg J.A., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Eklund P., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Aymerich J., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., George C., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Hajjam J., Hernandez L., Hourihane J.O., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Jutel M., Kalyoncu A.F., Karjalainen J., Kardas P., Keith P.K., Khaltaev N., Kleine-Tebbe J., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Lauri D., Lavrut J., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Luna-Pech J.A., Maciej K., Magnan A., Maier D., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Medina-Avalos M.A., Melen E., Melo-Gomes E., Meltzer E.O., Mercier J., Miculinic N., Mihaltan F., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Monti R., Mora Bogado D., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Nadif R., Nalin M., Napoli L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Nyembue T.D., Odzhakova C., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Papi A., Passalacqua G., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Pohl W., Portejoie F., Pozzi A.C., Price D., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Sagara H., Sastre-Dominguez J., Scadding G.K., Scichilone N., Schmid-Grendelmeier P., Serpa F.S., Shamai S., Sierra M., Simons F.E.R., Siroux V., Skrindo I., Sole D., Somekh D., Sondermann M., Sova M., Sorensen M., Sorlini M., Spranger O., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., van Eerd M., van Ganse E., van Hague M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi M., Vicheva D., Vontetsianos T., Walker S., Werfel T., Westman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zernotti M.E., Zubrinich C., Zurkuhlen A., Bousquet, Jean, Hellings, Peter W., Agache, Ioana, Amat, Flore, Annesi-Maesano, Isabella, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Clau, Bateman, Eric D., Bedbrook, Anna, Bennoor, Kazi, Bewick, Mickael, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victoria, Casale, Thoma, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, Giulia, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben E., Fonseca, Joao A., Fontaine, Jean-Françoi, Fokkens, Wytske J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan-Carlo, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Kalayci, Omer, Keil, Thoma, Klimek, Ludger, Kowalski, Marek L., Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Desiree, Laune, Daniel, Le, Lan T. T., Carlsen, Karin Lodrup, Lourenço, Olga, Mahboub, Bassam, Mair, Alpana, Menditto, Enrica, Milenkovic, Branislava, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Murray, Ruth, Naclerio, Robert, Namazova-Baranova, Leyla, Novellino, Ettore, O'Hehir, Robyn E., Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimi, Onorato, Gabrielle L., Palkonen, Susanna, Panzner, Petr, Papadopoulos, Nikos G., Park, Hae-Sim, Paulino, Ema, Pawankar, Ruby, Pfaar, Oliver, Plavec, Davor, Popov, Ted A., Potter, Paul, Prokopakis, Emmanuel P., Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Samolinski, Boleslaw, Sanchez-Borges, Mario, Schunemann, Holger J., Sheikh, Aziz, Sisul, Juan-Carlo, Rajabian-Söderlund, Rojin, Sooronbaev, Talant, Stellato, Cristiana, To, Teresa, Todo-Bom, Ana-Maria, Tomazic, Peter-Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Aruna, Valovirta, Erkka, Ventura, Maria-Teresa, Wagenmann, Martin, Wang, De Yun, Wallace, Dana, Waserman, Susan, Wickman, Magnu, Yorgancioglu, Arzu, Zhang, Luo, Zhong, Nanshan, Zidarn, Mihaela, Zuberbier, Torsten, Bousquet, J., Hellings, P. W., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Alberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Basagana, X., Bateman, E. D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Białoszewski, A. Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosnic-Anticevich, C. S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillot, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Cardona, V., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda Sarabia, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Cruz, A. A., Custovic, A., Czarlewski, W., Dahlen, S. E., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fátima Emerson, M., De Feo, G., De Vries, G., De Martino, B., de Paula Motta Rubini, N., Deleanu, D., Demoly, P., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fokkens, W. J., Fonseca, J. A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Gálvez-Romero, J. L., Gamkrelidze, A., Garcia-Aymerich, J., García-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioğlu, B., Genova, S., George, C., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gómez-Vera, J., González Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzmán, M. A., Haahtela, T., Hajjam, J., Hernández, L., Hourihane, J. O. 'B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ivancevich, J. C., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Klimek, L., Kowalski, M. L., Kuitunen, M., Kull, I., Kuna, P., Kupczyk, M., Kvedariene, V., Krzych-Fałta, E., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenço, O., Luna-Pech, J. A., Maciej, K., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M. A., Melén, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Monti, R., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mösges, R., Mota-Pinto, A., Moura Santo, P., Mullol, J., Münter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Palkonen, S., Panzner, P., Papadopoulos, N. G., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pépin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Mañas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimäki, J., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Serpa, F. S., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyriçá, J. N., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hague, M., Vandenplas, O., Ventura, M. T., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, M., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Laboratory of clinical immunology, Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia [Bilbao], Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hacettepe University = Hacettepe Üniversitesi, Mechanobiology Institute [Singapore] (MBI), National University of Singapore (NUS), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], Department of Dermatology [Graz, Austria], Medical University Graz, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Ghent University Hospital, Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), IMIM-Hospital del Mar, Generalitat de Catalunya, University of Cape Town, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Centre de gérontologie, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Woolcock Institute of Medical Research [Sydney], The University of Sydney, Université Laval [Québec] (ULaval), Departments of Clinical Epidemiology and Biostatistics and Medicine [Ontario], Service greffe de moelle osseuse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Royal Brompton Hospital, Région Languedoc-Roussillon-Midi-Pyrénées, Vall d'Hebron University Hospital [Barcelona], University of South Florida [Tampa] (USF), Università degli Studi di Firenze = University of Florence (UniFI), University of Michigan, Department of Atmospheric, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Russian State Medical University, Universidade do Porto, Instituto de Biologia Molecular e Celular (IBMC), UCB Pharma, Colombes, Hôpital Gui de Chauliac [CHU Montpellier], CHU Strasbourg, European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Università degli Studi di Salerno = University of Salerno (UNISA), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Linköping University (LIU), Department of Dermatology and Allergy Centre, Odense University Hospital, Vilnius University [Vilnius], Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, Institut d'Electronique du Solide et des Systèmes (InESS), Centre National de la Recherche Scientifique (CNRS), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Center for Allergy and Immunology Research [Tbilisi], Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Swedish Meteorological and Hydrological Institute (SMHI), CORYSS-TESS, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Biologie des organismes marins et écosystèmes (BOME), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), NRC Institute of immunology FMBA, Moscow Russian federation, Allergy and Asthma Center Westend, German Society for Otorhinolaryngology HNS, Rheinische Friedrich-Wilhelms-Universität Bonn, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Medical University of Łódź (MUL), Hospital Medica Sur, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Applied Physical Chemistry Laboratory (APCLab), Institute of Geophysics and Planetary Physics [Los Angeles] (IGPP), University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Institute of Oceanology [China], University of Beira Interior [Portugal] (UBI), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Pulmonary and allergy unit, American University of Sharjah-Rashid Hospital-Dubai Health Authority (DHA), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), 'Federico II' University of Naples Medical School, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Allergy and Clinical Immunology Department, Hospital CUF Descobertas, Universität zu Köln = University of Cologne, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Section of Otolaryngology-Head & Neck Surgery (OHNS), University of Chicago, Department of Pharmacy Naples, Université de Naples, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Dept. of Electronic Engineering, Chubu University, Department of Otorhinolaryngology, Chiba University Hospital, Department of Allergology and Clinical Immunology, Charles University [Prague] (CU)-Medical Faculty in Pilsen, Department of Earth and Planetary Sciences [Cambridge, USA] (EPS), Harvard University, Allergy and Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe), Department of Pediatrics, Nippon Medical School, Centre Hospitalier Universitaire [Grenoble] (CHU), Department of Otorhinolaryngology, Head and Neck Surgery [Mannheim, Germany], University Hospital Mannheim, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Children’s Hospital Srebrnjak [Zagreb, Croatia], Department of Physics [UMIST Manchester], University of Manchester Institute of Science and Technology (UMIST), Laboratori Nazionali del Sud (LNS), Getafe University Hospital, Madrid, Karl-Franzens-Universität Graz, Ecologie comportementale (EC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes (UR)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Allergy Asthma and Immunology [Haifa, Israel], Ha'Emek Medical Center, Afula-Rappaport Faculty of Medicine, University of Edinburgh, Medical University of Warsaw - Poland, Department of Allergy and Clinical Immunology [Caracas, Venezuela], Centro Médico Docente La Trinidad, Department of Computer Science [Haifa], University of Haifa [Haifa], Allergy and Respiratory Research Group, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), National Centre of Cardiology and Internal Medicine, Ministry of Health Kyrgyz Republic, Réseau National de Surveillance Aérobiologique (RNSA), Berkeley Seismological Laboratory, Division of Clinical Immunology and Allergy, University of Naples Federico II = Università degli studi di Napoli Federico II, CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, Vilnius University Clinic of Children's Diseases, Suomen Terveystalo Allergy Clinic, Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre d'EPistémologie et d'ERgologie Comparatives (CEPERC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institute for Climate and Atmospheric Science [Leeds] (ICAS), School of Earth and Environment [Leeds] (SEE), University of Leeds-University of Leeds, Nova Southeastern University (NSU), Department of Otolaryngology, National University of Singapore (NUS)-Yong Loo Lin School of Medicine, Sachs' Children's Hospital, IAES, Department of Pulmonology, Manisa Celal Bayar University, Center for Evolutionary and Theoretical Immunology [Albuquerque, New Mexico] (CETI), The University of New Mexico [Albuquerque], National Key State Laboratory for ThermoStructural Composites (TSCM), Northwestern Polytechnical University [Xi'an] (NPU), Respiratory and Allergic Diseases, University Clinic of Respiratory and Allergic Diseases Golnik, University Hospital of Cologne [Cologne], Supported by the European Innovation Partnership on Active and Healthy Ageing and POLLAR (EIT Health, European Union)., European Project: 643803,H2020,H2020-HCO-2014,PROEIPAHA(2015), UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidemiology of Allergic and Respiratory Diseases Department [Paris] (EPAR), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Université Pierre et Marie Curie - Paris 6 (UPMC), University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Salerno (UNISA), Institut de Physique du Globe de Paris (IPGP), Centre National de la Recherche Scientifique (CNRS)-Université de La Réunion (UR)-Université Paris Diderot - Paris 7 (UPD7)-IPG PARIS-Institut national des sciences de l'Univers (INSU - CNRS), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]-Epidemiology and Health Economics, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN), University of California-University of California, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospital CUF-Descobertas, Universität zu Köln, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Harvard University [Cambridge], University of Genoa (UNIGE), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Graz, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université Claude Bernard Lyon 1 (UCBL), Centro Medico-Docente La Trinidad, Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Università degli studi di Napoli Federico II, Center for Evolutionary and theoretical Immunology, Biology, National Institute for Health Research, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Karl-Franzens-Universität [Graz, Autriche], Department of Dermatology, Allergology and Venereology, Clinicum, University of Helsinki, Children's Hospital, Faculty of Law, HUS Children and Adolescents, HUS Inflammation Center, University Hospitals Leuven [Leuven], Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, University of Zürich [Zürich] (UZH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of South Florida (USF), Università degli Studi di Firenze = University of Florence [Firenze], Laboratoire Magmas et Volcans (LMV), Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Universidade do Porto [Porto], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin -Epidemiology and Health Economics, Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre de Biologie pour la Gestion des Populations (UMR CBGP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Sondra, CentraleSupélec, Université Paris-Saclay (COmUE) (SONDRA), ONERA-CentraleSupélec-Université Paris Saclay (COmUE), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), RNSA, Centre d'EPistémologie et d'ERgologie Comparatives - UMR 7304 (CEPERC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), National Institute for Nuclear Physics (INFN), Université Laval, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Università degli Studi di Firenze [Firenze], University of Salerno (UNISA), Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), École normale supérieure - Paris (ENS Paris)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Universidade do Minho, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, uBibliorum, and Internal Medicine
- Subjects
Allergy ,Medicina Básica [Ciências Médicas] ,asthma -- guideline ,Allergic asthma ,DECISION-MAKING ,Allergic Rhinitis and Its Impact on Asthma ,GUIDELINES ,Medical and Health Sciences ,Medical Records ,0302 clinical medicine ,Health care ,Immunology and Allergy ,030212 general & internal medicine ,asthma ,Change management ,rhinitis ,Immunology ,MASK-RHINITIS ,ComputingMilieux_MISCELLANEOUS ,Rinitis ,mobilne aplikacije ,upravljanje sprememb ,Medical record ,GLOBAL STRATEGY ,WORK PRODUCTIVITY ,Telemedicine ,mobile applications ,3. Good health ,Asma alérgica ,rhiniti ,1107 Immunology ,Ciências Médicas::Medicina Básica ,klinične poti ,allergic -- guideline ,Life Sciences & Biomedicine ,Human ,PATIENT PARTICIPATION ,Allergic Rhinitis ,medicine.medical_specialty ,animal structures ,multimorbidity ,EUROPEAN INNOVATION PARTNERSHIP ,Change Management ,[object Object] ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Asthma/diagnosis ,CHRONIC DISEASES ,MACVIA-ARIA ,03 medical and health sciences ,medicine ,multimorbidnost ,QUALITY ,Humans ,critical pathways ,astma -- smernica ,Patient participation ,Asma ,udc:616.2 ,Asthma ,Science & Technology ,ARIA ,business.industry ,Multimorbidity ,Rhinitis, Allergic ,Settore MED/09 - MEDICINA INTERNA ,change management ,Mobile Airways Sentinel Network (MASK) Study Group ,Guideline ,ta3121 ,medicine.disease ,Rinite alérgica ,Rhinitis, Allergic/diagnosis ,Integrated care ,alergijski rinitis -- smernica ,Allergic Rhinitis and Its Impact on Asthma, asthma, Change management, rhinitis, Immunology and Allergy, Immunology ,030228 respiratory system ,Family medicine ,3121 General medicine, internal medicine and other clinical medicine ,Medical Record ,Clinical Medicine ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Impact on Asthma - Abstract
Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional., EAACI -European Academy of Allergy and Clinical Immunology(undefined), info:eu-repo/semantics/acceptedVersion
- Published
- 2018
5. Economic burden of drug-induced anaphylaxis: what can we do better?
- Author
-
Barbara, Cardoso, Teresa, Moscoso, Mário, Morais-Almeida, Pascal, Demoly, Luciana K, Tanno, Hospital CUF Descobertas, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Médecine de précision par intégration de données et inférence causale (PREMEDICAL), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Desbrest de santé publique (IDESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Subjects
MESH: Drug Hypersensitivity ,MESH: Humans ,MESH: Anaphylaxis / epidemiology ,Immunology ,MESH: Health Care Costs ,Financial Stress ,Health Care Costs ,MESH: Cost of Illness ,MESH: Absenteeism ,Drug Hypersensitivity ,MESH: Anaphylaxis / prevention & control ,Cost of Illness ,Absenteeism ,Humans ,Immunology and Allergy ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,MESH: Anaphylaxis / diagnosis ,MESH: Financial Stress ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Anaphylaxis - Abstract
International audience; Purpose of review: This systematic review evaluates published data related to the economic burden of drug-induced anaphylaxis (DIA) to understand preventive cost saving measures that could reduce the burden of these conditions.Recent findings: Although DIA has a relevant societal impact, there are limited and heterogenous available data related to its cost. Direct costs related to the management of acute phase of DIA was estimated by $529.6 to $3 125, depending on the number of emergency room visits/hospitalizations, emergency kits and transports in ambulance. Direct costs of investigations of DIA varied from $288 to $2 292.95 and the desensitization was estimated by $6 796. Main variables for this were: personnel, allergy screening procedures, medical consumables and space cost. The mean indirect cost was based on a mean absenteeism of 3 days per DIA corresponding to $381.2.Summary: More than reviewing the published data, we were able to identify variables that, if correctly managed, can reduce the economic burden of DIA, such as adjusting the timing of referral and etiological diagnosis, identification of potential risk and/or co-factors, correct written recommendations to patients. The evidence presented highlights the need of optimization of healthcare patients to patients suffering from DIA.
- Published
- 2022
6. Operational definitions of asthma in recent epidemiological studies are inconsistent
- Author
-
Luís Filipe Azevedo, Ana Sá-Sousa, João Fonseca, António Bugalho-Almeida, Jean Bousquet, Mário Morais-Almeida, Tiago Jacinto, Carlos Robalo-Cordeiro, Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, Allergy Unit, CUF Porto Hospital, Health Information and Decision Sciences Department (CIDES), Allergy and Clinical Immunology Department, Hospital CUF Descobertas, Hospitais da Universidade de Coimbra, Clínica Universitária de Pneumologia, Universidade de Lisboa, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), This work had financial support of the Sociedade Portuguesa de Alergologiae Imunologia Clínica, Sociedade Portuguesa de Pneumologia and FundaçãoCiência e Tecnologia (PTDC/SAU-SAP/119192/2010)., Taibi, Nadia, Universidade do Porto, Hospital CUF-Descobertas, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Allergy ,Pediatrics ,National Health and Nutrition Examination Survey ,Epidemiology ,Immunology ,Population ,Review ,03 medical and health sciences ,0302 clinical medicine ,Web of knowledge ,immune system diseases ,030225 pediatrics ,Environmental health ,medicine ,Prevalence ,Immunology and Allergy ,education ,Asma ,Asthma ,education.field_of_study ,Operational definition ,business.industry ,Definition ,medicine.disease ,3. Good health ,respiratory tract diseases ,030228 respiratory system ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Prevalence studies ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
OBJECTIVE: The best combination of questions to define asthma in epidemiological asthma studies is not known. We summarized the operational definitions of asthma used in prevalence studies and empirically assess how asthma prevalence estimates vary depending on the definition used. METHODS: We searched the Thomson Reuters ISI Web of knowledge and included (1) cross-sectional studies (2) on asthma prevalence (3) conducted in the general population and (4) containing an explicit definition of asthma. The search was limited to the 100 most-cited papers or published since January 2010. For each paper, we recorded the asthma definition used and other variables. Then we applied the definitions to the data of the Portuguese National Asthma survey (INAsma) and of the 2005-2006 National Health and Nutrition Examination Survey (NHANES) computing asthma prevalence estimates for the different definitions. RESULTS: Of 1738 papers retrieved, 117 were included for analysis. Lifetime asthma, diagnosed asthma and current asthma were defined in 8, 12 and 29 different ways, respectively. By applying definitions of current asthma on INAsma and NHANES data, the prevalence ranged between 5.3%-24.4% and 1.1%-17.2%, respectively. CONCLUSIONS: There is considerable heterogeneity in the definitions of asthma used in epidemiological studies leading to highly variable estimates of asthma prevalence. Studies to inform a standardized operational definition are needed. Meanwhile, we propose a set of questions to be reported when defining asthma in epidemiological studies. info:eu-repo/semantics/publishedVersion
- Published
- 2014
7. COVID-19 pandemic
- Author
-
W. J. Fokkens, Jürgen Schwarze, Cezmi A. Akdis, J Mullol, W. Czarlewski, Claudia Traidl-Hoffmann, Claus Bachert, D. Larenas-Linnemann, Tomas Chivato, M. Gotua, Mateo Bonini, Ludger Klimek, Vincenzo Patella, A. A. Cruz, Stephanie Dramburg, Kari C. Nadeau, H W Fritsch, K. Ohta, Thomas Eiwegger, Robert M. Naclerio, Antti Lauerma, A. Yorgancioglu, Aslı Gelincik, Piotr Kuna, Oliver Pfaar, Carmen Riggioni, Violeta Kvedariene, Markus Ollert, Sinthia Bosnic-Anticevich, V. Cardona, S. Del Giacco, Sanna Toppila-Salmi, Helen A. Brough, Heimo Breiteneder, Valérie Hox, B. Samolinski, Zuzana Diamant, G.W. Canonica, Lihong Zhang, María José Torres, Y. Okamoto, Liam O'Mahony, Radosław Gawlik, Jolanta Walusiak-Skorupa, Sharon Chinthrajah, Winfried Rief, T. Haatela, M. Morais-Almeida, Ioana Agache, Manfred Schedlowski, I Skypala, R. Brehler, D. Y. Wang, João Fonseca, I. J. Ansotegui, Robyn E O'Hehir, Oscar Palomares, Charlotte G. Mortz, J. C. Ivancevich, C. Suppli Ulrik, M. T. Ventura, P M Matricardi, S Untersmayr, Gabrielle L. Onorato, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Vanitha Sampath, Arũnas Valiulis, Marek Jutel, Luisa Brussino, Pedro Carreiro-Martins, Jean Bousquet, Nikolaos G. Papadopoulos, A. Bedbrook, Torsten Zuberbier, Karin Hoffmann-Sommergruber, Edward F. Knol, Ear, Nose and Throat, AII - Inflammatory diseases, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Philipps Universität Marburg = Philipps University of Marburg, Allergologie, Stimm und Sprachstörungen [Wiesbaden, Germany], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], University of Wrocław [Poland] (UWr), ALL-MED, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Medizinische Universität Wien = Medical University of Vienna, Stanford University, Skane University Hospital [Malmo], Lund University [Lund], Charles University [Prague] (CU), University Medical Center Groningen [Groningen] (UMCG), Univ Toronto, Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Mol Med, Toronto, ON M5G 0A4, Canada, The Hospital for sick children [Toronto] (SickKids), University of Toronto, Amsterdam UMC - Amsterdam University Medical Center, Alfred Health, Victoria University [Melbourne], University College Cork (UCC), Sean N. Parker Center for Allergy and Asthma Research [Stanford], Stanford Medicine, Stanford University-Stanford University, University Clinics of Essen, University of Essen, Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], Helmholtz Zentrum München = German Research Center for Environmental Health, University Hospital Augsburg, National University of Singapore (NUS), Beijing Tongren Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), Evelina London Children's Hospital, King‘s College London, CEU-San Pablo University and HM-Hospitals School of Medicine, University of Cagliari, Medical University of Silesia (SUM), Istanbul University, Cliniques Universitaires Saint-Luc [Bruxelles], University Medical Center [Utrecht], Helsinki University Central Hospital, University of Helsinki, Odense University Hospital (OUH), Luxembourg Institute of Health (LIH), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Hospital Sant Joan de Déu [Barcelona], Institut de Recerca Pediàtrica Hospital Sant Joan de Déu [Barcelona, Spain], University of Edinburgh, NHS Foundation Trust [London], The Royal Marsden, Nofer Institute of Occupational Medicine (NIOM), Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], Woolcock Institute of Medical Research [Sydney], The University of Sydney, University of Turin, Mauriziano Umberto I Hospital, Humanitas University [Milan] (Hunimed), Vall d'Hebron University Hospital [Barcelona], Hospital de Dona Estefania, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Federal University of Bahia School of Medicine, Global Alliance Against Chronic Respiratory Diseases (GARD-WHO), Medical Consulting Czarlewski, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, MEDIDA, Lda, David Tvildiani Medical University (DTMU), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Barlicki University Hospital, Vilnius University [Vilnius], Hospital Medica Sur [Mexico City, Mexico], Pantai Hospital [Kuala Lumpur], Hospital CUF Descobertas, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Epidemiología y Salud Pública (CIBERESP), Johns Hopkins University School of Medicine [Baltimore], Fukujuji Hospital, Tokyo National Hospital, Chiba Rosai Hospital, Chiba University Hospital, Royal Manchester Children's Hospital, University of Manchester [Manchester], General Children's Hospital of Athens P & A Kyriakou, 'Santa Maria della Speranza' Hospital, Centro Hospitalar e Universitário [Coimbra], Coimbra Institute for Clinical and Biomedical Research [Coimbra, Portugal] (iCBR - Faculty of Medicine), University of Coimbra [Portugal] (UC), Medical University of Warsaw - Poland, Hvidovre Hospital, University of Copenhagen = Københavns Universitet (UCPH), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Transilvania University of Brasov, Salvy-Córdoba, Nathalie, Department of Dermatology, Allergology and Venereology, and HUS Inflammation Center
- Subjects
0301 basic medicine ,viruses ,Eaaci Position Paper ,Medizin ,Cochrane Library ,GUIDELINES ,FOOD ALLERGY ,allergen immunotherapy ,allergy clinic ,anaphylaxis ,asthma ,clinical trials ,COVID-19 ,Position Paper ,psychological impact ,SARS-CoV-2 ,Allergists ,Health Personnel ,Humans ,Hypersensitivity ,Information Technology ,Patient Care Team ,Triage ,SARS‐CoV‐2 ,DESENSITIZATION ,0302 clinical medicine ,MESH: Patient Care Team ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,HDE ALER ,Pandemic ,Health care ,Immunology and Allergy ,ATOPIC-DERMATITIS ,MESH: COVID-19 ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,allergen immunotherapy (AIT) ,virus diseases ,DRUG HYPERSENSITIVITY REACTIONS ,3. Good health ,INFECTIONS ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Triage ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,Allergen immunotherapy ,medicine.medical_specialty ,MESH: Information Technology ,MESH: Hypersensitivity ,Immunology ,education ,MEDLINE ,DIAGNOSIS ,psychological COVID ,03 medical and health sciences ,MESH: Allergists ,COVID‐19 ,medicine ,MESH: SARS-CoV-2 ,ddc:610 ,RHINOSINUSITIS ,MESH: Humans ,business.industry ,Clinical trial ,Coronavirus ,EXACERBATIONS ,030104 developmental biology ,030228 respiratory system ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Family medicine ,3121 General medicine, internal medicine and other clinical medicine ,Position paper ,MESH: Health Personnel ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
BackgroundThe Coronavirus disease 2019 (COVID‐19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS‐CoV‐2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.MethodThe scientific information on COVID‐19 was analyzed by a literature search in Medline, Pubmed, national and international guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library and the Internet.ResultsBased on diagnostic and treatment standards developed by EAACI, on international information regarding COVID‐19, on guidelines of the World Health Organization (WHO) and other international organizations as well as on previous experience, a panel of experts including clinicians, psychologists, IT experts and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” inititiative have developed recommendations for the optimal management of allergy clinics during the current COVID‐19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies.ConclusionsThis international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients whilst ensuring necessary safety in the current COVID‐19 pandemic.
- Published
- 2021
8. WAO-ARIA consensus on chronic cough – Part III
- Author
-
Philip W. Rouadi, Samar A. Idriss, Jean Bousquet, Tanya M. Laidlaw, Cecilio R. Azar, Mona S. Al-Ahmad, Anahi Yañez, Maryam Ali Y. Al-Nesf, Talal M. Nsouli, Sami L. Bahna, Eliane Abou-Jaoude, Fares H. Zaitoun, Usamah M. Hadi, Peter W. Hellings, Glenis K. Scadding, Peter K. Smith, Mario Morais-Almeida, René Maximiliano Gómez, Sandra N. Gonzalez Diaz, Ludger Klimek, Georges S. Juvelekian, Moussa A. Riachy, Giorgio Walter Canonica, David Peden, Gary W.K. Wong, James Sublett, Jonathan A. Bernstein, Lianglu Wang, Luciana K. Tanno, Manana Chikhladze, Michael Levin, Yoon-Seok Chang, Bryan L. Martin, Luis Caraballo, Adnan Custovic, Jose Antonio Ortego-Martell, Olivia J.Ly Lesslar, Erika Jensen-Jarolim, Motohiro Ebisawa, Alessandro Fiocchi, Ignacio J. Ansotegui, Beirut Eye & ENT Specialist Hospital (BESH), Eye & Ear Hospital [Beirut], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Brigham and Women’s Hospital [Boston, MA], Harvard Medical School [Boston] (HMS), American University of Beirut Faculty of Medicine and Medical Center (AUB), Middle East Institute of Health, Clemenceau Medical Center (CMC), Kuwait University, Investigaciones en Alergia y Enfermedades Respiratorias (InAER), Hamad Medical Corporation [Doha, Qatar], International Cough Institute (ICI), Louisiana State University (LSU), LAU Medical Center-Rizk Hospital, University Hospitals Leuven [Leuven], Department of Microbiology, Immunology and Transplantation [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Ghent University Hospital, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), The Royal National Throat, Nose and Ear Hospital, Griffith University [Brisbane], Hospital CUF Descobertas, Facultad de Ciencias de la Salud [Salta], Universidad Nacional de Salta (UNSA), Universidad Autonoma de Nuevo Leon [Mexique] (UANL), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Saint George Hospital University Medical Center [UOB LIBAN], University of Balamand [Liban] (UOB), Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], UNC School of Medicine, The Chinese University of Hong Kong [Hong Kong], University of Louisville School of Medicine, University of Cincinnati College of Medicine, Peking Union Medical College Hospital [Beijing] (PUMCH), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Akaki Tsereteli State University, University of Cape Town, Seoul National University Bundang Hospital (SNUBH), The Ohio State University Wexner Medical Center., University of Cartagena, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Universidad Autónoma del Estado de Hidalgo (UAEH), LifeSpan medicine, Medizinische Universität Wien = Medical University of Vienna, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna, University of Vienna [Vienna]-University of Vienna [Vienna]-Medical University Vienna, University of Vienna [Vienna]-University of Vienna [Vienna], Sagamihara National Hospital [Kanagawa, Japan], Bambino Gesù Children’s Hospital [Rome, Italy], Hospital Quirónsalud Bizkaia [Bilbao], and Salvy-Córdoba, Nathalie
- Subjects
EXHALED NITRIC-OXIDE ,Pulmonary and Respiratory Medicine ,Cough specialty care ,Chronic cough management ,Allergy ,AIRWAY INFLAMMATION ,Upper airway cough syndrome ,Immunology ,MUCOSAL EOSINOPHILIC INFLAMMATION ,GASTROESOPHAGEAL-REFLUX DISEASE ,INHALED CORTICOSTEROIDS ,Lower airway disease ,Speech therapy ,QUALITY-OF-LIFE ,CHEST GUIDELINE ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Neuromodulators ,VARIANT ASTHMA ,Cough primary care ,Science & Technology ,CLINICAL-PRACTICE GUIDELINE ,Reflux cough ,REFRACTORY CHRONIC COUGH ,Life Sciences & Biomedicine ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology - Abstract
BACKGROUND: Chronic cough management necessitates a clear integrated care pathway approach. Primary care physicians initially encounter the majority of chronic cough patients, yet their role in proper management can prove challenging due to limited access to advanced diagnostic testing. A multidisciplinary approach involving otolaryngologists and chest physicians, allergists, and gastroenterologists, among others, is central to the optimal diagnosis and treatment of conditions which underly or worsen cough. These include infectious and inflammatory, upper and lower airway pathologies, or gastro-esophageal reflux. Despite the wide armamentarium of ancillary testing conducted in cough multidisciplinary care, such management can improve cough but seldom resolves it completely. This can be due partly to the limited data on the role of tests (eg, spirometry, exhaled nitric oxide), as well as classical pharmacotherapy conducted in multidisciplinary specialties for chronic cough. Other important factors include presence of multiple concomitant cough trigger mechanisms and the central neuronal complexity of chronic cough. Subsequent management conducted by cough specialists aims at control of cough refractory to prior interventions and includes cough-specific behavioral counseling and pharmacotherapy with neuromodulators, among others. Preliminary data on the role of neuromodulators in a proof-of-concept manner are encouraging but lack strong evidence on efficacy and safety. OBJECTIVES: The World Allergy Organization (WAO)/Allergic Rhinitis and its Impact on Asthma (ARIA) Joint Committee on Chronic Cough reviewed the recent literature on management of chronic cough in primary, multidisciplinary, and cough-specialty care. Knowledge gaps in diagnostic testing, classical and neuromodulator pharmacotherapy, in addition to behavioral therapy of chronic cough were also analyzed. OUTCOMES: This third part of the WAO/ARIA consensus on chronic cough suggests a management algorithm of chronic cough in an integrated care pathway approach. Insights into the inherent limitations of multidisciplinary cough diagnostic testing, efficacy and safety of currently available antitussive pharmacotherapy, or the recently recognized behavioral therapy, can significantly improve the standards of care in patients with chronic cough. ispartof: WORLD ALLERGY ORGANIZATION JOURNAL vol:15 issue:5 ispartof: location:United States status: published
- Published
- 2022
9. WAO-ARIA consensus on chronic cough – Part 1
- Author
-
Philip W. Rouadi, Samar A. Idriss, Jean Bousquet, Tanya M. Laidlaw, Cecilio R. Azar, Mona Sulaiman AL-Ahmad, Anahí Yáñez, Maryam Ali Y. AL-Nesf, Talal M. Nsouli, Sami L. Bahna, Eliane Abou-Jaoude, Fares H. Zaitoun, Usamah M. Hadi, Peter W. Hellings, Glenis K. Scadding, Peter K. Smith, Mario Morais-Almeida, R. Maximiliano Gómez, Sandra N. González Díaz, Ludger Klimek, Georges S. Juvelekian, Moussa A. Riachy, Giorgio Walter Canonica, David Peden, Gary W.K. Wong, James Sublett, Jonathan A. Bernstein, Lianglu Wang, Luciana Kase Tanno, Manana Chikhladze, Michael Levin, Yoon-Seok Chang, Bryan L. Martin, Luis Caraballo, Adnan Custovic, José Antonio Ortega-Martell, Erika Jensen-Jarolim, Motohiro Ebisawa, Alessandro Fiocchi, Ignacio J. Ansotegui, Salvy-Córdoba, Nathalie, Beirut Eye & ENT Specialist Hospital (BESH), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Université de Montpellier (UM), Brigham and Women’s Hospital [Boston, MA], Harvard Medical School [Boston] (HMS), American University of Beirut Faculty of Medicine and Medical Center (AUB), Middle East Institute of Health, Clemenceau Medical Center (CMC), Kuwait University, Investigaciones en Alergia y Enfermedades Respiratorias (InAER), Hamad Medical Corporation [Doha, Qatar], International Cough Institute (ICI), Louisiana State University (LSU), LAU Medical Center-Rizk Hospital, VIB-KU Leuven Center for Microbiology [Leuven, Belgium], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), University Hospitals Leuven [Leuven], Ghent University Hospital, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), The Royal National TNE Hospital, University College of London [London] (UCL), Griffith University [Brisbane], Hospital CUF Descobertas, Catholic University of Salta, Universidad Autonoma de Nuevo Leon [Mexique] (UANL), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Saint George Hospital University Medical Center [UOB LIBAN], University of Balamand [Liban] (UOB), Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), The Chinese University of Hong Kong [Hong Kong], University of Louisville School of Medicine, University of Cincinnati College of Medicine, Peking Union Medical College Hospital [Beijing] (PUMCH), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Akaki Tsereteli State University, University of Cape Town, Seoul National University Hospital, The Ohio State University Wexner Medical Center., University of Cartagena, Imperial College London, Universidad Autónoma del Estado de Hidalgo (UAEH), Medizinische Universität Wien = Medical University of Vienna, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna, University of Vienna [Vienna]-University of Vienna [Vienna]-Medical University Vienna, University of Vienna [Vienna]-University of Vienna [Vienna], Sagamihara National Hospital [Kanagawa, Japan], Bambino Gesù Children’s Hospital [Rome, Italy], and Hospital Quirónsalud Bizkaia [Bilbao]
- Subjects
Pulmonary and Respiratory Medicine ,Allergy ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Immunology ,INDUCED ENHANCEMENT ,ION-CHANNEL ,Pathogenesis ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Article ,PAIN HYPERSENSITIVITY ,HYPERSENSITIVITY SYNDROME ,CENTRAL SENSITIZATION ,Chronic cough ,TRP channel ,Immunology and Allergy ,Science & Technology ,THERAPEUTIC TARGET ,Chemoreceptors ,RECEPTOR SUBTYPES ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,RC581-607 ,GENE-RELATED PEPTIDE ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,respiratory tract diseases ,P2X3 ,DISTINCT POPULATIONS ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,CENTRAL MECHANISMS ,Immunologic diseases. Allergy ,Life Sciences & Biomedicine ,Mechanoreceptors - Abstract
BACKGROUND: Cough features a complex peripheral and central neuronal network. The function of the chemosensitive and stretch (afferent) cough receptors is well described but partly understood. It is speculated that chronic cough reflects a neurogenic inflammation of the cough reflex, which becomes hypersensitive. This is mediated by neuromediators, cytokines, inflammatory cells, and a differential expression of neuronal (chemo/stretch) receptors, such as transient receptor potential (TRP) and purinergic P2X ion channels; yet the overall interaction of these mediators in neurogenic inflammation of cough pathways remains unclear. OBJECTIVES: The World Allergy Organization/Allergic Rhinitis and its Impact on Asthma (WAO/ARIA) Joint Committee on Chronic Cough reviewed the current literature on neuroanatomy and pathophysiology of chronic cough. The role of TRP ion channels in pathogenic mechanisms of the hypersensitive cough reflex was also examined. OUTCOMES: Chemoreceptors are better studied in cough neuronal pathways compared to stretch receptors, likely due to their anatomical overabundance in the respiratory tract, but also their distinctive functional properties. Central pathways are important in suppressive mechanisms and behavioral/affective aspects of chronic cough. Current evidence strongly suggests neurogenic inflammation induces a hypersensitive cough reflex marked by increased expression of neuromediators, mast cells, and eosinophils, among others. TRP ion channels, mainly TRP V1/A1, are important in the pathogenesis of chronic cough due to their role in mediating chemosensitivity to various endogenous and exogenous triggers, as well as a crosstalk between neurogenic and inflammatory pathways in cough-associated airways diseases. ispartof: WORLD ALLERGY ORGANIZATION JOURNAL vol:14 issue:12 ispartof: location:United States status: published
- Published
- 2021
10. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model
- Author
-
Paolo Maria Matricardi, Ludger Klimek, Thomas B. Casale, Oliver Pfaar, Miguel Tortajada-Girbés, Ignacio J. Ansotegui, Cristoforo Incorvaia, Pascal Demoly, Marek Jutel, Petra Zieglmayer, Maximiliano Gómez, Philippe Devillier, Philippe Gevaert, Jean Bousquet, Petr Panzner, Giorgio Walter Canonica, Mona Al-Ahmad, Ralph Mösges, Stefania Arasi, Alain Didier, Piotr Kuna, Carmen Vidal, Peter Schmid-Grendelmeier, Carla Irani, Oxana Kurbacheva, Moises A. Calderon, Frédéric de Blay, Ulrich Wahn, Enrico Heffler, Alessandro Fiocchi, Adam T. Fox, Hae-Sim Park, Ruby Pawankar, Davide Caimmi, Claus Bachert, Natalija Novak, Margitta Worm, Nikolaos G. Papadopoulos, Silvia Scurati, Andrzej Bozek, Mário Morais-Almeida, Giovanni Passalacqua, Catherine Bos, Yoshitaka Okamoto, Natalia Ilina, Efstrathios Karagiannis, Robin O'Hehir, J. Christian Virchow, Adnan Custovic, ASST Pini-CTO, Kuwait University, Al-Rashed Allergy Center [Kuwait City], Hospital Quirónsalud Bizkaia [Bilbao], Bambino Gesù Children’s Hospital [Rome, Italy], Ghent University Hospital, Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Stallergenes Greer (France, Antony), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Silesian Medical University, Katowice, Poland, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, University of South Florida [Tampa] (USF), University of Manchester [Manchester], University Hospital of South Manchester, CHU Strasbourg, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université de Montpellier (UM), Hôpital Foch [Suresnes], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Guy's and St Thomas' Hospital [London], Hospital San Bernardo, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Humanitas University [Milan] (Hunimed), Federal Institute of Immunology of Russia [Moscou], Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Wrocław Medical University, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Barlicki University Hospital, Medical University of Łódź (MUL), Monash University [Melbourne], Federal Medical-Biological Agency of Russia, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Hospital CUF Descobertas, University of Cologne, University Hospital Bonn, Chiba University Hospital, Charles University [Prague] (CU), Royal Manchester Children's Hospital, General Children's Hospital of Athens P & A Kyriakou, Ajou University School of Medicine, Ospedale Policlinico San Martino [Genoa], Università degli studi di Genova = University of Genoa (UniGe), Nippon Medical School [Tokyo, Japan], Philipps Universität Marburg = Philipps University of Marburg, University hospital of Zurich [Zurich], Dr Peset University Hospital, Universitat de València (UV), Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), University of Rostock, Herrada, Anthony, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], Wroclaw Medical University [Wrocław, Pologne], University of Genoa (UNIGE), and Philipps Universität Marburg
- Subjects
Allergen immunotherapy ,Endotype ,MESH: Allergens ,MESH: Hypersensitivity ,Immunology ,Disease ,Bioinformatics ,MESH: Precision Medicine ,03 medical and health sciences ,0302 clinical medicine ,molecular diagnosis ,Hypersensitivity ,Immunology and Allergy ,Medicine ,Humans ,Precision Medicine ,MESH: Desensitization, Immunologic ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,MESH: Humans ,business.industry ,Mechanism (biology) ,MESH: Genomics ,Genomics ,personalized medicine ,Allergens ,treatable traits ,Molecular diagnostics ,Omics ,3. Good health ,Biomarker (cell) ,omics ,allergen immunotherapy ,030228 respiratory system ,Desensitization, Immunologic ,Personalized medicine ,business ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,030215 immunology - Abstract
International audience; The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.
- Published
- 2021
11. Anaphylaxis and COVID-19 vaccines: Real-time interest using Google Trends
- Author
-
Luciana Kase Tanno, Rita Aguiar, Bernardo Camacho, Ignacio J. Ansotegui, Mário Morais-Almeida, Hospital CUF Descobertas, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Hospital Quirónsalud Bizkaia [Bilbao], and Salvy-Córdoba, Nathalie
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Population ,Google Trends ,COViD-19 ,Article ,WHO, World Health Organization ,Pandemic ,medicine ,MESH: COVID-19 ,Immunology and Allergy ,RSV, Relative Search Volume ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Intensive care medicine ,education ,Anaphylaxis ,USA, United States of America ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,education.field_of_study ,Health professionals ,business.industry ,pandemic ,Vaccination ,GT, Google Trends ,Absolute risk reduction ,RC581-607 ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,vaccines ,medicine.disease ,MESH: Anaphylaxis ,[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Relative risk ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Immunologic diseases. Allergy ,business ,MESH: COVID-19 vaccines ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology - Abstract
Background Effective vaccines are key components in overcoming the COVID-19 pandemic, so understanding the possible allergic reactions they might cause is essential. Data so far shows that the relative risk of a severe allergic reaction is slightly increased when compared with the overall risk of anaphylaxis due to vaccines, albeit the absolute risk remaining quite low. However, it is also important to be aware of what the population is searching for online, especially regarding controversial topics such as the CoViD-19 vaccines and severe allergic reactions that may result. Methods We conducted a Google Trends worldwide online search to look for any increase in Relative Search Volume (RSV) in the last 5 years regarding the search terms: “Anaphylaxis” and “Vaccine anaphylaxis”. Results We found that there was a major increase in the “Anaphylaxis” and “Vaccine anaphylaxis” RSV in December 2020, continuing up to January 2021, worldwide and in four selected countries. Conclusions We believe this sudden interest in anaphylaxis is related to reports of severe allergic reactions to these vaccines. This can lead to hesitancy in regards to vaccination, and our duty as health professionals is to recommend vaccination and assure that the vaccines are administered in well-equipped vaccination centres, assuring registries of all adverse / allergic reactions.
- Published
- 2021
12. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA
- Author
-
Jere Reijula, De Yun Wang, Ralph Mösges, Tomohisa Iinuma, Jean Luc Fauquert, Nelson Rosario, Yehia El-Gamal, René Maximiliano Gómez, Tari Haahtela, Vincenzo Patella, Lorenzo Cecchi, Petr Panzner, Yoshitaka Okamoto, Oliver Pfaar, Luis Caraballo, Paulo Augusto Moreira Camargos, Filip Raciborski, Florin Mihaltan, Ken Ohta, Brian J. Lipworth, Kimi Okubo, Juan Carlos Ivancevich, Fulvio Braido, Ioana Agache, Frederico S. Regateiro, Neven Miculinic, Tuula Vasankari, R. Emuzyte, Arunas Valiulis, Yousser Mohammad, Torsten Zuberbier, Osman M. Yusuf, Ewa Jassem, Cezmi A. Akdis, Jean Bousquet, Alessandro Fiocchi, Jan Hagemann, Claus Bachert, Davor Plavec, K. S. Bennoor, Marek Jutel, Désirée Larenas-Linnemann, Stephen Montefort, Stefano Del Giacco, Przemyslaw Kardas, Erkka Valovirta, Mark S. Dykewicz, Antonio Valero, Wienczyslawa Czarlewski, Thomas B. Casale, Gabrielle L. Onorato, Omer Kalayci, Ludger Klimek, Joaquin Sastre, João Fonseca, Siân Williams, Karl Christian Bergmann, Marek Niedoszytko, Bilun Gemicioglu, Mario E. Zernotti, Musa Khaitov, H. Neffen, Robert M. Naclerio, Joaquim Mullol, Ana Pereira, Piotr Kuna, Michael Makris, Maria Teresa Ventura, Ioanna Tsiligianni, Dirceu Solé, Arzu Yorgancioglu, Charlotte Suppli-Ulrik, M. Gotua, Emmanuel P. Prokopakis, Dana Wallace, Jorge Maspero, Wytske Fokkens, Eckard Hamelmann, Antonino Romano, Dejan Dokic, Todor A. Popov, Violeta Kvedariene, Derek K. Chu, Anna Bedbrook, Dermot Ryan, Motohiro Ebisawa, Tomas Chivato, Giovanni Passalacqua, Menachem Rottem, Mário Morais-Almeida, Victoria Cardona, Bolesław Samoliński, Cristiana Stellato, Nikolaos G. Papadopoulos, Milan Sova, Jaime Correia-de-Sousa, Sietze Reitsma, Cemal Cingi, Francesca Puggioni, Robyn E O'Hehir, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, HUS Internal Medicine and Rehabilitation, Department of Public Health, Clinicum, Keuhkosairauksien yksikkö, Helsinki University Hospital Area, University of Helsinki, University Medical Center of the Johannes Gutenberg-University Mainz, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), University of Wrocław [Poland] (UWr), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Transilvania University of Brasov, Humboldt University Of Berlin, Medical Consulting Czarlewski, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MASK-air, Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], National Institute of Diseases of the Chest and Hospital (NIDCH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ospedale Policlinico San Martino [Genoa], Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), University of Cartagena, Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Vall d'Hebron University Hospital [Barcelona], Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], CEU-San Pablo University and HM-Hospitals School of Medicine, McMaster University [Hamilton, Ontario], Eskisehir Osmangazi University, Universidade do Minho = University of Minho [Braga], Life and Health Sciences Research Institute [Braga] (ICVS), University of Minho [Braga], The International Primary Care Respiratory Group (IPCRG), Università degli Studi di Cagliari = University of Cagliari (UniCa), Sts. Cyril and Methodius University, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital [Kanagawa, Japan], Ain Shams University (ASU), Vilnius University [Vilnius], Service de Pédiatrie Générale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Bambino Gesù Children’s Hospital [Rome, Italy], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, CUF Porto Hospital, Cerrahpasa Faculty of Medicine, Istanbul University, ALAS Medical Institute, Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Universität Bielefeld = Bielefeld University, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Medical University of Gdańsk, Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Medical University of Łódź (MUL), Federal Medicobiological Agency [Moscow, Russian Federation], Hospital Medica Sur [Mexico City, Mexico], Ninewells Hospital and Medical School [Dundee], University General Hospital ' Attikon ' [Athens, Greece], Argentine Association of Allergy and Immunology, Marius Nasta Institute of Pneumology, Tishreen University, Université de Damas = Damascus University, University of Malta [Malta], Hospital CUF Descobertas, Clinical Research International Ltd [Hamburg, Germany] (CRI), Johns Hopkins University School of Medicine [Baltimore], Nemours/Alfred I. du Pont Hospital for Children, Monash University [Melbourne], Tokyo National Hospital, Nippon Medical School [Tokyo, Japon], Medicine Charles University and General Faculty Hospital in Prague, Royal Manchester Children's Hospital, University of Manchester [Manchester], Università degli studi di Genova = University of Genoa (UniGe), 'Santa Maria della Speranza' Hospital, Philipps Universität Marburg = Philipps University of Marburg, J.J. Strossmayer University of Osijek, Children’s Hospital Srebrnjak [Zagreb, Croatia], St. Ivan Rilski University Hospital, University of Crete [Heraklion] (UOC), IRCCS Humanitas [Rozzano, Italy], Medical University of Warsaw - Poland, Centro Hospitalar e Universitário [Coimbra], Amsterdam UMC - Amsterdam University Medical Center, Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Clinica G.B. Morgagni (Fondazione Mediterranea), Pontifical Catholic University of Paraná (PUCPR), Pontifícia Universidade Católica do Paraná (PUCPR), Ha’Emek Medical Center [Afula, Israel], Pediatric Endocrine Institute [Afula, Israel], Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Edinburgh, Federal University of Sao Paulo (Unifesp), University Hospital Olomouc [Czech Republic], University of Salerno (UNISA), Copenhagen University Hospital, Universitat de Barcelona (UB), European Academy of Paediatrics (EAP/UEMS-SP), University of Turku, Suomen Terveystalo Allergy Clinic, Finnish Lung Health Association, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Nova Southeastern University (NSU), Yong Loo Lin School of Medicine [Singapore], Department of Biology, Faculty of Sciences & Liberal Arts, Celal Bayar University, Manisa Celal Bayar University, The Allergy & Asthma Institute, Pakistan (IPCRG), Universidad Nacional de Villa María, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Allergiezentrum Wiesbaden, Salvy-Córdoba, Nathalie, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
0301 basic medicine ,Allergy ,MESH: Asthma ,Common Cold ,allergic rhinitis ,common cold ,cough ,COVID-19 ,smell ,Consensus ,Humans ,SARS-CoV-2 ,Asthma ,Rhinitis, Allergic ,Disease ,Care ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Immunology and Allergy ,MESH: COVID-19 ,Rhinitis ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Common cold ,3. Good health ,MESH: Rhinitis, Allergic ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Original Article ,medicine.symptom ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Signs and symptoms ,Asymptomatic ,03 medical and health sciences ,Allergic ,COVID‐19 ,Internal medicine ,medicine ,MESH: SARS-CoV-2 ,MESH: Consensus ,MESH: Humans ,business.industry ,Rhinitis, Sinusitis, and Upper Airway Disease ,CARE ,medicine.disease ,030104 developmental biology ,030228 respiratory system ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,3121 General medicine, internal medicine and other clinical medicine ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,ORIGINAL ARTICLES ,Airway ,business ,MESH: Common Cold - Abstract
Background Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001). Conclusions This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.
- Published
- 2021
13. Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic
- Author
-
Liang Lu Wang, Alessandro Fiocchi, Michael Levin, James L. Sublett, José Antonio Ortega-Martell, Mario Sánchez-Borges, Motohiro Ebisawa, Yoon-Seok Chang, Luciana Kase Tanno, Manana Chikhladze, Luis Caraballo, Ignacio J. Ansotegui, Jonathan Berstein, Bryan Martin, Pascal Demoly, Giovanni Passalacqua, Sandra Nora González-Díaz, Gianenrico Senna, Marco Caminati, Jean-François Fontaine, Philip W. Rouadi, Anahí Yáñez, Mário Morais-Almeida, Gary Wong, David B. Peden, Gestionnaire, Hal Sorbonne Université, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ohio State University [Columbus] (OSU), University of Cincinnati (UC), Hospital CUF Descobertas, University of Cape Town, IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Centro Médico Docente La Trinidad, Clínica el Avila, University of Cartagena, The Chinese University of Hong Kong [Hong Kong], Universidad Autónoma del Estado de Hidalgo (UAEH), Beirut Eye & ENT Specialist Hospital (BESH), Investigaciones en Alergia y Enfermedades Respiratorias (InAER), Peking Union Medical College Hospital [Beijing] (PUMCH), University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Akaki Tsereteli State University, Universidad Autonoma de Nuevo Leon [Mexique] (UANL), Centre Hospitalier Universitaire de Reims (CHU Reims), University of Louisville, Seoul National University [Seoul] (SNU), Università degli studi di Genova = University of Genoa (UniGe), Hospital Quirónsalud Bizkaia [Bilbao], Sagamihara National Hospital [Kanagawa, Japan], Università degli studi di Verona = University of Verona (UNIVR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Epidemiology of Allergic and Respiratory Diseases Department [Paris] (EPAR), University of Genoa (UNIGE), and University of Verona (UNIVR)
- Subjects
Allergy ,[SDV]Life Sciences [q-bio] ,Asia Pacific ,AP, Asia Pacific ,Coding (therapy) ,Disease ,WHO ,LABA, long-acting beta-agonist ,0302 clinical medicine ,prevention ,EMA ,European Medicines Agency ,Pandemic ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,030223 otorhinolaryngology ,World Allergy Organization ,CDC, Centers for Disease Control and Prevention ,Allergen immunotherapy ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,AFR/ME ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,treatment ,AIT ,Food and Drug Administration ,3. Good health ,Europe ,WAO ,inhaled steroids ,LA ,ANAFORCAL, French Association for Continuing Education in Allergology ,AFR/ME, Africa and Middle East ,AIT, Allergen immunotherapy ,COVID-19 ,DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms ,EMA, European Medicines Agency ,EU, Europe ,FDA, Food and Drug Administration ,ICD, International Classification of Diseases ,LA, Latin America ,NA, North America ,SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ,WAO, World Allergy Organization ,WHO, World Health Organization ,allergen immunotherapy ,allergy ,asthma ,biological agents ,coronavirus ,FDA ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,severe acute respiratory syndrome coronavirus 2 ,Pulmonary and Respiratory Medicine ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,Immunology ,LABA ,Context (language use) ,World Health Organization ,Article ,03 medical and health sciences ,Biological agents ,International Classification of Diseases ,medicine ,Centers for Disease Control and Prevention ,Social media ,Africa and Middle East ,SARS-CoV-2 ,business.industry ,ICD ,ANAFORCAL ,Drug Reaction with Eosinophilia and Systemic Symptoms ,medicine.disease ,Asthma ,Coronavirus ,long-acting beta-agonist ,Latin America ,030228 respiratory system ,Family medicine ,North America ,French Association for Continuing Education in Allergology ,NA ,Inhaled steroids ,Prevention ,Treatment ,Allergists ,DRESS ,EU ,business ,lcsh:RC581-607 ,AP ,CDC - Abstract
International audience; Background: The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic.Methods: We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context.Results: Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as "I have no data" or "I don't know" to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations.Conclusion: The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
- Published
- 2021
14. Update on asthma prevalence in severe COVID-19 patients
- Author
-
Mário Morais-Almeida, Cláudia S. Sousa, Jean Bousquet, Miguel T. Barbosa, Rita Aguiar, Hospital CUF Descobertas, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Berlin Institute of Health (BIH), and Retiveau, Nolwenn
- Subjects
Pediatrics ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,MESH: Asthma ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,virus ,Comorbidity ,medicine.disease_cause ,Lower risk ,Risk Assessment ,Internal medicine ,Epidemiology ,Pandemic ,Correspondence ,Prevalence ,Medicine ,Humans ,Immunology and Allergy ,MESH: COVID-19 ,MESH: SARS-CoV-2 ,infections ,Limited evidence ,Respiratory system ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,MESH: Prevalence ,Asma ,Coronavirus ,Asthma ,MESH: Humans ,business.industry ,SARS-CoV-2 ,Outbreak ,virus diseases ,COVID-19 ,medicine.disease ,Biobank ,respiratory tract diseases ,Phenotype ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,epidemiology ,business ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology - Abstract
To the Editor,We read carefully the research letter “Is asthma protective of COVID-19?” by Carli et al recently published.1Important topic for asthma patients in the coronavirus disease 2019 (COVID-19) pandemic were considered, including that until recently weak evidence that patients with chronic respiratory disorders are at a lower risk of being infected or becoming severely ill with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Reflecting only about previous reports from China and Italy where asthma was underrepresented in COVID-19 patients, the authors accept the heterogeneous condition that it is asthma, speculating that T2-immunity, interferon-mediated immune responses and increased number of eosinophils in the airways could have a protective effect against COVID-19 severity.1The epidemiology of COVID-19 is changing rapidly with new data. More recent reports from the United States of America and from several European countries, in particular the United Kingdom (UK), states a higher asthma prevalence in patients with COVID-19, suggesting that asthma is more common in COVID-19 patients than it was previously reported in Asia and in the first European surveys.2Data from the UK Biobank, a large prospective case-control study, found an asthma prevalence of 17,9% in 605 COVID-19 hospitalized patients, mostly of them adults, surpassing the prevalence of asthma in the general population.3Besides that, in the OpenSAFELY Collaborative Study (UK), it was found a significant increased risk of severe CoViD-19 in patients with asthma, including death, in particular related with the recent use of oral corticosteroid (OCS).4 These findings can indicate an increased asthma severity and/or poor control and, in accordance with data from previous coronavirus outbreaks, that systemic corticosteroids were associated with a higher viral load.5We agree with Carli et al1 that further studies focused on asthma and its different phenotypes are needed to provide a better understanding of the impact of SARS-CoV-2 infection in patients with asthma.6 Nevertheless, for the moment, it seems crucial that patients with asthma do not stop their controller medication, that may lead to a higher risk of asthma exacerbations, increased OCS use and higher probability to emergency room access and hospitalization that represent themselves significant risk factors for coronavirus exposure and spread.In conclusion, according with the available data, patients with asthma must still be included in the high-risk groups for COVID-19 and more data are needed to understand the relationship between asthma and COVID-19.
- Published
- 2020
15. WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates in COVID-19
- Author
-
Lianglu Wang, Sami L. Bahna, Luis Caraballo, Jean Bousquet, David B. Peden, Sandra Nora González Díaz, Luciana Kase Tanno, Georges S. Juvelekian, Giorgio Walter Canonica, Ludger Klimek, Ignacio J. Ansotegui, Yoon-Seok Chang, Jose Antonio Ortego-Martell, Adnan Custovic, Moussa A. Riachy, Bryan Martin, Samar A. Idriss, Peter K. Smith, Gary W.K. Wong, René Maximiliano Gómez, Erika Jensen-Jarolim, Mona Al-Ahmad, Tanya M. Laidlaw, Jonathan A. Bernstein, Cecilio Azar, Philip W. Rouadi, Alessandro Fiocchi, Michael Levin, Eliane Abou-Jaoude, Motohiro Ebisawa, Talal M. Nsouli, Mário Morais-Almeida, Usamah Hadi, Maryam Ali Al-Nesf, Fares Zaitoun, Glenis Scadding, James L. Sublett, Manana Chikhladze, Anahí Yáñez, Peter Hellings, Beirut Eye & ENT Specialist Hospital (BESH), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Brigham and Women’s Hospital [Boston, MA], Harvard Medical School [Boston] (HMS), American University of Beirut [Beyrouth] (AUB), Middle East Institute of Health, Clemenceau Medical Center (CMC), Kuwait University, Investigaciones en Alergia y Enfermedades Respiratorias (InAER), Hamad Medical Corporation [Doha, Qatar], International Cough Institute (ICI), Louisiana State University (LSU), LAU Medical Center-Rizk Hospital, American University of Beirut Faculty of Medicine and Medical Center (AUB), Department of Microbiology, Immunology and Transplantation [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), University Hospitals Leuven [Leuven], Ghent University Hospital, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), The Royal National Throat, Nose and Ear Hospital [London, UK], University College of London [London] (UCL), Griffith University [Brisbane], Hospital CUF Descobertas, Catholic University of Salta, Universidad Autonoma de Nuevo Leon [Mexique] (UANL), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Saint George Hospital University Medical Center [UOB LIBAN], University of Balamand [Liban] (UOB), Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), The Chinese University of Hong Kong [Hong Kong], University of Louisville, University of Cincinnati College of Medicine, Peking Union Medical College Hospital [Beijing] (PUMCH), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Akaki Tsereteli State University, University of Cape Town, Seoul National University Bundang Hospital (SNUBH), The Ohio State University Wexner Medical Center., University of Cartagena, Imperial College London, Universidad Autónoma del Estado de Hidalgo (UAEH), Medizinische Universität Wien = Medical University of Vienna, Sagamihara National Hospital [Kanagawa, Japan], Bambino Gesù Children’s Hospital [Rome, Italy], Hospital Quirónsalud Bizkaia [Bilbao], and Salvy-Córdoba, Nathalie
- Subjects
Pulmonary and Respiratory Medicine ,Allergy ,Upper airway cough syndrome ,medicine.medical_treatment ,Cough reflex ,Immunology ,GASTROESOPHAGEAL-REFLUX DISEASE ,AIRWAY COUGH ,Lower airway disease ,OBSTRUCTIVE PULMONARY-DISEASE ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,TRP CHANNELS ,Article ,CLINICAL CHARACTERISTICS ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,CHEST GUIDELINE ,medicine ,Immunology and Allergy ,Continuous positive airway pressure ,VARIANT ASTHMA ,Cough phenotypes ,COPD ,Science & Technology ,POSTNASAL-DRIP-SYNDROME ,business.industry ,Type 2 inflammation ,RC581-607 ,medicine.disease ,Obstructive sleep apnea ,respiratory tract diseases ,ALLERGIC RHINITIS ,Chronic cough ,Upper respiratory tract infection ,BRONCHIAL HYPERRESPONSIVENESS ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,GERD ,Reflex ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Multifactorial cough ,Immunologic diseases. Allergy ,medicine.symptom ,business ,Life Sciences & Biomedicine ,COVID 19 ,Reflux-cough - Abstract
BACKGROUND: Chronic cough can be triggered by respiratory and non-respiratory tract illnesses originating mainly from the upper and lower airways, and the GI tract (ie, reflux). Recent findings suggest it can also be a prominent feature in obstructive sleep apnea (OSA), laryngeal hyperresponsiveness, and COVID-19. The classification of chronic cough is constantly updated but lacks clear definition. Epidemiological data on the prevalence of chronic cough are informative but highly variable. The underlying mechanism of chronic cough is a neurogenic inflammation of the cough reflex which becomes hypersensitive, thus the term hypersensitive cough reflex (HCR). A current challenge is to decipher how various infectious and inflammatory airway diseases and esophageal reflux, among others, modulate HCR. OBJECTIVES: The World Allergy Organization/Allergic Rhinitis and its Impact on Asthma (WAO/ARIA) Joint Committee on Chronic Cough reviewed the current literature on classification, epidemiology, presenting features, and mechanistic pathways of chronic cough in airway- and reflux-related cough phenotypes, OSA, and COVID-19. The interplay of cough reflex sensitivity with other pathogenic mechanisms inherent to airway and reflux-related inflammatory conditions was also analyzed. OUTCOMES: Currently, it is difficult to clearly ascertain true prevalence rates in epidemiological studies of chronic cough phenotypes. This is likely due to lack of standardized objective measures needed for cough classification and frequent coexistence of multi-organ cough origins. Notwithstanding, we emphasize the important role of HCR as a mechanistic trigger in airway- and reflux-related cough phenotypes. Other concomitant mechanisms can also modulate HCR, including type2/Th1/Th2 inflammation, presence or absence of deep inspiration-bronchoprotective reflex (lower airways), tissue remodeling, and likely cough plasticity, among others. ispartof: WORLD ALLERGY ORGANIZATION JOURNAL vol:14 issue:12 ispartof: location:United States status: published
- Published
- 2021
16. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
- Author
-
Niels H. Chavannes, Oliver Pfaar, Peter Valentin Tomazic, Antonio Valero, Jean-François Fontaine, Sara Shamai, Gabrielle L. Onorato, Jane da Silva, Ralph Mösges, I. Annesi-Maesano, Piotr Kuna, Violeta Kvedariene, Sanna Toppila-Salmi, Arunas Valiulis, Rute Almeida, Philippe Devillier, Rafael Stelmach, Regina Roller-Wirnsberger, Sietze Reitsma, Tari Haahtela, Ioana Agache, Ruth Murray, Claus Bachert, Gert De Vries, Michael Makris, Esben Eller, Carsten Bindslev-Jensen, Josep M. Antó, João O. Malva, R. Emuzyte, Benoit Pugin, Arzu Yorgancioglu, Ana Todo-Bom, Enrica Menditto, Wienczyslawa Czarlewski, Isabelle Bosse, Ana Margarida Pereira, Mário Morais-Almeida, Cemal Cingi, Emmanuel P. Prokopakis, Ingrid Kull, José Miguel Fuentes-Pérez, Mike Bewick, João Fonseca, Alvaro A. Cruz, Aziz Sheikh, Annabelle Bédard, Mark S. Dykewicz, Xavier Basagaña, Anna Bedbrook, Sinthia Bosnic-Anticevich, Ludger Klimek, Jean Bousquet, Magnus Wickman, Joaquim Mullol, Susan Waserman, Cristiana Stellato, Dermot Ryan, Judith Garcia-Aymerich, Erik Melén, Dana Wallace, Yunuen Rocío Huerta-Villalobos, Thomas B. Casale, Sylvie Arnavielhe, Bilun Gemicioglu, Daniel Laune, Fotis Psarros, Nikos G. Papadopoulos, Bolesław Samoliński, Maria Teresa Ventura, Erkka Valovirta, Robyn E O'Hehir, Peter Hellings, V. Cardona, Michiel van Eerd, Pascal Demoly, Wytske Fokkens, Elísio Costa, Ignacio J. Ansotegui, Désirée Larenas-Linnemann, ISGlobal, Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, KYomed INNOV, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, Medical Consulting Czarlewski, Levallois, France, Medical Communications Consultant, MedScript, Dundalk, and OPC, Cambridge, United Kingdom, Center for Health Technology and Services Research–CINTESIS, Faculdade de Medicina, Universidade do Porto, and Medida, Porto, Portugal, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, and the Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Allergy Unit, CUF-Porto Hospital and Institute, and the Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Porto, Portugal, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, CIRFF, Federico II University, Naples, Italy, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, ProAR–Nucleo de Excelencia em Asma, Federal University of Bahia, and the WHO GARD Planning Group, Brazil, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis, Brazil, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Hospital General Region 1, Dr Carlos Mc Gregor Sanchez Navarro' IMSS, Mexico City, Mexico, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Vilnius University Institute of Clinical Medicine, Clinic of Children's Diseases, and the Institute of Health Sciences, Department of Public Health, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Center for Rhinology and Allergology, Wiesbaden, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, and CRI-Clinical Research International, Hamburg, Germany, University Hospital, Montpellier, France, Department of Otorhinolaryngology, Head and Neck Surgery, Section for Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and UPMC Sorbonne Université, Medical School Saint Antoine, Paris, France, Allergist, La Rochelle, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Allergist, Reims, France, Allergy Section, Department of Internal Medicine, Hospital Vall'dHebron & ARADyAL Research Network, Barcelona, Spain, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, iQ4U Consultants, London, United Kingdom, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland, Allergy Unit 'D Kalogeromitros', 2nd Department of Dermatology and Venereology, National & Kapodistrian University of Athens, 'Attikon' University Hospital, Athens, Greece, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, and UK Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Otorhinolaryngology University of Crete School of Medicine, Heraklion, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa (and the GARD Executive Committee), Manisa, Turkey, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, Woolcock Emphysema Centre and Local Health District, Glebe, Australia, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, and the Department of Immunology, Monash University, Melbourne, Australia, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, and the Academic Medical Center, University of Amsterdam, and Euforea, Brussels, Belgium, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, and Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Peercode BV, Geldermalsen, Netherlands, Transylvania University Brasov, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Mo, United States, Division of Allergy/Immunology, University of South Florida, Tampa, Fla, United States, Nova Southeastern University, Fort Lauderdale, Fla, United States, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, and Euforea, Brussels, Belgium, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), Hôpital Foch [Suresnes], Kyomed, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), MedScript Ltd, Universidade do Porto, Centre for Research in Health Technologies and Information Systems (CINTESIS), Instituto de Biologia Molecular e Celular (IBMC), University of Coimbra [Portugal] (UC), Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, 'Federico II' University of Naples Medical School, Università degli studi di Bari Aldo Moro (UNIBA), Universidade Federal da Bahia (UFBA), Hospital Medica Sur, Vilnius University [Vilnius], Vilnius University Clinic of Children's Diseases, Medical University of Łódź (MUL), Medical University of Warsaw - Poland, Center for Rhinology and Allergology, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Vall d'Hebron University Hospital [Barcelona], Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Medical University Graz, iQ4U consultants Ltd, University of Edinburgh, University of Helsinki, Suomen Terveystalo Allergy Clinic, Eskisehir Osmangazi University, Cerrahpasa Faculty of Medicine, Istanbul University, Department of Pulmonology, Manisa Celal Bayar University, Woolcock Institute of Medical Research [Sydney], The University of Sydney, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Ghent University Hospital, University Hospitals Leuven [Leuven], Department of Dermatology and Allergy Centre, Odense University Hospital, Institute of Environmental Medicine [Stockholm, Sweden], Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Peercode (Développement de l'application) Oudenhof 4c 4191 NW Geldermalsen, Pays-Bas., Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Department of Allergy and Immunology, Hospital Quiròn Bizkaia Erandio, Saint Louis University School of Medicine [St Louis], University of South Florida [Tampa] (USF), Nova Southeastern University (NSU), McMaster University [Hamilton, Ontario], Hôpital Arnaud de Villeneuve [CHRU Montpellier], Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, Ear, Nose and Throat, AII - Inflammatory diseases, Bedard, A., Basagana, X., Anto, J. M., Garcia-Aymerich, J., Devillier, P., Arnavielhe, S., Bedbrook, A., Onorato, G. L., Czarlewski, W., Murray, R., Almeida, R., Fonseca, J., Costa, E., Malva, J., Morais-Almeida, M., Pereira, A. M., Todo-Bom, A., Menditto, E., Stellato, C., Ventura, M. T., Cruz, A. A., Stelmach, R., da Silva, J., Larenas-Linnemann, D., Fuentes-Perez, J. M., Huerta-Villalobos, Y. R., Emuzyte, R., Kvedariene, V., Valiulis, A., Kuna, P., Samolinski, B., Klimek, L., Mosges, R., Pfaar, O., Shamai, S., Annesi-Maesano, I., Bosse, I., Demoly, P., Fontaine, J. -F., Cardona, V., Mullol, J., Valero, A., Roller-Wirnsberger, R. E., Tomazic, P. V., Chavannes, N. H., Fokkens, W. J., Reitsma, S., Bewick, M., Ryan, D., Sheikh, A., Haahtela, T., Toppila-Salmi, S., Valovirta, E., Makris, M., Papadopoulos, N. G., Prokopakis, E. P., Psarros, F., Cingi, C., Gemicioglu, B., Yorgancioglu, A., Bosnic-Anticevich, S., O'Hehir, R. E., Bachert, C., Hellings, P. W., Pugin, B., Bindslev-Jensen, C., Eller, E., Kull, I., Melen, E., Wickman, M., De Vries, G., van Eerd, M., Agache, I., Ansotegui, I. J., Dykewicz, M. S., Casale, T., Wallace, D., Waserman, S., Laune, D., and Bousquet, J.
- Subjects
Male ,Allergy ,Lydia Becker Institute ,Visual Analog Scale ,IMPACT ,Efficiency ,THERAPY ,Allergic rhinitis ,law.invention ,corticosteroids ,FLUTICASONE ,0302 clinical medicine ,Randomized controlled trial ,law ,Adrenal Cortex Hormones ,conjunctiviti ,conjunctivitis ,Immunology and Allergy ,AZELASTINE ,030212 general & internal medicine ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Child ,Aged, 80 and over ,treatment ,Middle Aged ,WORK PRODUCTIVITY ,Mobile Applications ,3. Good health ,Child, Preschool ,GUIDED SELF-MANAGEMENT ,Histamine H1 Antagonists ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Symptom Assessment ,medicine.drug ,Adult ,corticosteroid ,medicine.medical_specialty ,antihistamines ,MASK ,Adolescent ,Visual analogue scale ,Immunology ,Mometasone furoate ,antihistamine ,Fluticasone propionate ,03 medical and health sciences ,Young Adult ,ResearchInstitutes_Networks_Beacons/lydia_becker_institute_of_immunology_and_inflammation ,asthma ,mobile health ,Allergic rhiniti ,medicine ,QUALITY ,Humans ,Asthma ,Aged ,business.industry ,Infant, Newborn ,Infant ,medicine.disease ,Azelastine ,Rhinitis, Allergic ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,Physical therapy ,Observational study ,business ,TRADITIONAL TREATMENT - Abstract
Demoly, Pascal/0000-0001-7827-7964; Chavannes, Niels/0000-0002-8607-9199; Basagana, Xavier/0000-0002-8457-1489; N.G., Papadopoulos/0000-0002-4448-3468; Almeida, Rute/0000-0001-7755-5002; Pereira, Ana Margarida/0000-0002-5468-0932; Gemicioglu, Bilun/0000-0001-5953-4881; Bedard, Annabelle/0000-0002-7842-8889; Anto, J M/0000-0002-4736-8529; Fonseca, Joao Almeida/0000-0002-0887-8796; Rodo, Xavier/0000-0003-4843-6180; stelmach, rafael/0000-0002-5132-1934; J, Garcia-Aymerich/0000-0002-7097-4586; orlando, valentina/0000-0002-8209-8878; Cardona, Victoria/0000-0003-2197-9767; yorgancioglu, arzu/0000-0002-4032-0944; Bindslev-Jensen, Carsten/0000-0002-8940-038X; VENTURA, Maria Teresa/0000-0002-2637-4583; O'Hehir, Robyn/0000-0002-3489-7595; Costa, Elisio/0000-0003-1158-1480; Malva, Joao/0000-0002-5438-4447; Pugin, Benoit/0000-0001-7132-9477; Psarros, Fotis/0000-0002-2928-150X; Kuna, Piotr/0000-0003-2401-0070 WOS:000473432800017 PubMed ID: 30951790 Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible. Sanofi AventisSanofi-Aventis; GlaxoSmithKlineGlaxoSmithKline; North Portugal Regional Operational Programme; European Regional Development Fund (ERDF)European Union (EU); Mundipharm; Teva Pharma; AstraZenecaAstraZeneca; Boehringer IngelheimBoehringer Ingelheim; Chiesi; MEDA Pharma; Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NovartisNovartis; Chiesi, DBV Technologies; UCBUCB Pharma SA; SanofiSanofi-Aventis; Adamed; FAES, Berlin Chemie; ALK-Abello; Allergopharma, Allergy Therapeutics; ServierServier; ASIT biotech; Hulka; Leti and Stallergenes; Roxall, Atmos, Bionorica; ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics; Biomay, Nuvo, Circassia; Novartis Pharma; Mundipharma; RocheRoche Holding; Erkko Foundation; Hal Allergy B. V.; Teva; Meda, Stallergenes; Cipla; Mundipharma, Mylan; Sanofi-AventisSanofi-Aventis P. Devillier reports personal fees from Sanofi Aventis, GlaxoSmithKline, AstraZeneca, Chiesi, Meda Pharma, and Menarini outside the submitted work. R. Almeida reports grants from Project NORTE-01-0145-FEDER-000016 (NanoSTIMA) by the North Portugal Regional Operational Programme (NORTE 2020) under the Portugal 2020 Partnership Agreement and through the European Regional Development Fund (ERDF) during the conduct of the study. A. Todo-Bom reports grants and personal fees from GlaxoSmithKline, Mundipharm, and Novartis; personal fees from Teva Pharma and AstraZeneca; and grants from Leti and Bial outside the submitted work. A. A. Cruz reports grants and personal fees from AstraZeneca; grants from GlaxoSmithKline; personal fees from Boehringer Ingelheim, Chiesi, Novartis, Eurofarma, MEDA Pharma, and Boston Scientific outside the submitted work. R. Stelmach reports grants from the Sao Paulo Research Foundation and MSD; grants and personal fees from Novartis, grants, personal fees, and nonfinancial support from AstraZeneca and Chiesi; and personal fees and nonfinancial support from Boehringer Ingelheim outside the submitted work. D. Larenas-Linnemann reports personal fees from Armstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GlaxoSmithKline, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, and UCB and grants from Sanofi, AstraZeneca, Novartis, UCB, GlaxoSmithKline, TEVA, Boehringer Ingelheim, and Chiesi outside the submitted work. V. Kvedariene has received payment for consultancy from GlaxoSmithKline and for lectures from StallergensGreer and Berlin-Chemie outside the submitted work. P. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Chiesi, FAES, Berlin Chemie, Novartis, Polpharma, and Allergopharma outside the submitted work. R. Mosges reports personal fees from ALK-Abello, Allergopharma, Allergy Therapeutics, Hexal, Servier, Klosterfrau, Stada, UCB, and Friulchem; grants from ASIT biotech, Nuvo, Bayer, FAES, GlaxoSmithKline, MSD, Johnson & Johnson, Meda, Optima, Ursapharm, BitopAG, and Hulka; grants and personal fees from Bencard; grants from Leti and Stallergenes; grants, personal fees and nonfinancial support from Lofarma; nonfinancial support from Roxall, Atmos, Bionorica, Otonomy, and Ferrero; and personal fees and nonfinancial support from Novartis outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, and Lofarma; grants from Biomay, Nuvo, Circassia, and GlaxoSmithKline; and personal fees from Novartis Pharma, MEDA Pharma, Indoor Biotechnologies, and Pohl-Boskamp outside the submitted work. T. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma outside the submitted work. S. Toppila-Salmi reports other support from Biomedical Systems and Roche and grants from the Erkko Foundation outside the submitted work. N. G. Papadopoulos reports grants from Gerolymatos and personal fees from Hal Allergy B. V., Novartis Pharma AG, Menarini, Hal Allergy B. V., and Mylan outside the submitted work. S. Bosnic-Anticevich reports personal fees from Teva, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, and AstraZeneca outside the submitted work. C. Bachert reports personal fees from Meda, Stallergenes, and ALK-Abello (speaker). I. J. Ansotegui reports personal fees from Hikma, Roxall, AstraZeneca, Menarini, UCB, Faes Farma, Sanofi, and Mundipharma outside the submitted work. D.; Wallace reports other from Mylan Pharmaceutical Company outside the submitted work being co-chair of the AAAAI/ACAAI Joint Task Force on Practice Parameters. J. Bousquet reports personal fees and other support from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach outside the submitted work and other support from Kyomed. The rest of the authors declare that they have no relevant conflicts of interest.
- Published
- 2018
17. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)
- Author
-
Bousquet, J. and Agache, I. and Aliberti, M.R. and Angles, R. and Annesi-Maesano, I. and Anto, J.M. and Arnavielhe, S. and Asayag, E. and Bacci, E. and Bedbrook, A. and Bachert, C. and Baroni, I. and Barreto, B.A. and Bedolla-Barajas, M. and Bergmann, K.C. and Bertorello, L. and Bewick, M. and Bieber, T. and Birov, S. and Bindslev-Jensen, C. and Blua, A. and Bochenska Marciniak, M. and Bogus-Buczynska, I. and Bosnic-Anticevich, S. and Bosse, I. and Bourret, R. and Bucca, C. and Buonaiuto, R. and Burguete Cabanas, M.T. and Caillaud, D. and Caimmi, D.P. and Caiazza, D. and Camargos, P. and Canfora, G. and Cardona, V. and Carriazo, A.M. and Cartier, C. and Castellano, G. and Chavannes, N.H. and Cecci, L. and Ciaravolo, M.M. and Cingi, C. and Ciceran, A. and Colas, L. and Colgan, E. and Coll, J. and Conforti, D. and Correia de Sousa, J. and Cortés-Grimaldo, R.M. and Corti, F. and Costa, E. and Courbis, A.L. and Cousein, E. and Cruz, A.A. and Custovic, A. and Cvetkovski, B. and Dario, C. and da Silva, J. and Dauvilliers, Y. and De Blay, F. and Dedeu, T. and De Feo, G. and De Martino, B. and Demoly, P. and De Vries, G. and Di Capua Ercolano, S. and Di Carluccio, N. and Doulapsi, M. and Dray, G. and Dubakiene, R. and Eller, E. and Emuzyte, R. and Espinoza-Contreras, J.G. and Estrada-Cardona, A. and Farrell, J. and Farsi, A. and Ferrero, J. and Fokkens, W.J. and Fonseca, J. and Fontaine, J.F. and Forti, S. and Gálvez-Romero, J.L. and García-Cobas, C.I. and Garcia Cruz, M.H. and Gemicioğlu, B. and Gerth van Wijk, R. and Guidacci, M. and Gómez-Vera, J. and Guldemond, N.A. and Gutter, Z. and Haahtela, T. and Hajjam, J. and Hellings, P.W. and Hernández-Velázquez, L. and Illario, M. and Ivancevich, J.C. and Jares, E. and Joos, G. and Just, J. and Kalayci, O. and Kalyoncu, A.F. and Karjalainen, J. and Keil, T. and Khaltaev, N. and Klimek, L. and Kritikos, V. and Kull, I. and Kuna, P. and Kvedariene, V. and Kolek, V. and Krzych-Fałta, E. and Kupczyk, M. and Lacwik, P. and La Grutta, S. and Larenas-Linnemann, D. and Laune, D. and Lauri, D. and Lavrut, J. and Lessa, M. and Levato, G. and Lewis, L. and Lieten, I. and Lipiec, A. and Louis, R. and Luna-Pech, J.A. and Magnan, A. and Malva, J. and Maspero, J.F. and Matta-Campos, J.J. and Mayora, O. and Medina-Ávalos, M.A. and Melén, E. and Menditto, E. and Millot-Keurinck, J. and Moda, G. and Morais-Almeida, M. and Mösges, R. and Mota-Pinto, A. and Mullol, J. and Muraro, A. and Murray, R. and Noguès, M. and Nalin, M. and Napoli, L. and Neffen, H. and O'Hehir, R.E. and Onorato, G.L. and Palkonen, S. and Papadopoulos, N.G. and Passalacqua, G. and Pépin, J.L. and Pereira, A.M. and Persico, M. and Pfaar, O. and Pozzi, A.C. and Prokopakis, E. and Pugin, B. and Raciborski, F. and Rimmer, J. and Rizzo, J.A. and Robalo-Cordeiro, C. and Rodríguez-González, M. and Rolla, G. and Roller-Wirnsberger, R.E. and Romano, A. and Romano, M. and Romano, M.R. and Salimäki, J. and Samolinski, B. and Serpa, F.S. and Shamai, S. and Sierra, M. and Sova, M. and Sorlini, M. and Stellato, C. and Stelmach, R. and Strandberg, T. and Stroetmann, V. and Stukas, R. and Szylling, A. and Tan, R. and Tibaldi, V. and Todo-Bom, A. and Toppila-Salmi, S. and Tomazic, P. and Trama, U. and Triggiani, M. and Valero, A. and Valovirta, E. and Valiulis, A. and van Eerd, M. and Vasankari, T. and Vatrella, A. and Ventura, M.T. and Verissimo, M.T. and Viart, F. and Williams, S. and Wagenmann, M. and Wanscher, C. and Westman, M. and Wickman, M. and Young, I. and Yorgancioglu, A. and Zernotti, E. and Zuberbier, T. and Zurkuhlen, A. and De Oliviera, B. and Senn, A., MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France, VIMA, INSERM U 1168, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Faculty of Medicine, Transylvania University, Brasov, Romania, Municipality of Salerno, Salerno, Italy, Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain, EPAR U707 INSERM, Paris, France, EPAR UMR-S UPMC, Paris VI, Paris, France, ISGLoBAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra (UPF), Barcelona, Spain, Kyomed, Montpellier, France, Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina, Regione Liguria, Genoa, Italy, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Telbios SRL, Milan, Italy, Alergologo, Belem, Brazil, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalarara, Mexico, Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, iQ4U Consultants Ltd, London, United Kingdom, Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University, Bonn, Germany, Empirica Communication and Technology Research, Bonn, Germany, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark, Argentine Association of Respiratory Medicine, Buenos Aires, Argentina, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, Allergist, La Rochelle, France, Centre Hospitalier Valenciennes, Valenciennes, France, Chief of the University Pneumology Unit- AOU Molinette, Hospital City of Health and Science of Torino, Torino, Italy, Pharmacist of COFASER - Consorzio Farmacie Servizi-Salerno, Salerno, Italy, Centro Médico Zambrano Hellion, Monterrey, Mexico, Gesundheitsregion KölnBonn - HRCB Projekt GmbH, Kohln, Germany, Service de pneumologie, CHU et université d'Auvergne, Clermont-Ferrand, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil, Mayor of Sarno and President of Salerno Province, Anesthesiology Service, Sarno 'Martiri del Villa Malta' Hospital, Sarno, Italy, S. Allergologia, S. Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, ASA - Advanced Solutions Accelerator, Clapiers, France, Celentano Pharmacy, Massa Lubrense, Italy, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, S.O.S Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Specialist Social Worker, Sorrento, Italy, ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey, Argentine Federation of Otorhinolaryngology Societies, Buenos Aires, Argentina, Service de Pneumologie, UMR INSERM, UMR1087and CNR 6291, l'institut du thorax, University of Nantes, Nantes, France, Department of Health, Social Services and Public Safety, Belfast, United Kingdom, Fondazione Bruno Kessler (FBK), Trento, Italy, Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, Alergologa, Guadalarara, Mexico, FIMMG (Federazione Italiana Medici di Medicina Generale), Milan, Italy, UCIBIO, REQYULTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), Porto, Portugal, Ecole des Mines, Alès, France, Vice Président de la CME - Centre Hospitalier, Valenciennes, France, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, GARD/WHO Executive Committee and Federal University of Bahia, Bahia, Brazil, Department of Pediatric, Imperial College London, London, United Kingdom, Azienda Provinciale per i Servizi Sanitari di Trento (APSS-Trento), Trento, Italy, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France, Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France, AQuAS, Barcelona, Spain & EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Social Workers Coordinator, Sorrento, Italy, Peercode DV, Gerdermalsen, Netherlands, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Department of Otolaryngology, University of Crete School of Medicine, Heraklion, Greece, Medical Faculty, Vilnius University, Vilnius, Lithuania, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Aguascalientes, Chihuaha, Mexico, Alergologo, Playa del Carmen, Mexico, Andalusian Agency for Healthcare Quality, Seville, Spain, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Center for Health Technology and Services Research- CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal, Allergist, Reims, France, Regional Hospital of ISSSTE, Puebla, Mexico, Alergologo, Guadalarara, Mexico, Allergy Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico, Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, Department of Internal Medicine, Section of Allergology, Erasmus MC, Rotterdam, Netherlands, Member of the Brazilian Society of Pediatrics and Society of Immunization, Representative of GINA (Global Initiative Against Asthma), Brasilia, Brazil, Allergy Clinic, Hospital Regional del ISSSTE ‘Lic. López Mateos’, Mexico City, Mexico, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc – National eHealth Centre, Olomouk, Czech Republic, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Centich: centre d'expertise national des technologies de l'information et de la communication pour l'autonomie, Gérontopôle autonomie longévité des Pays de la Loire, Conseil régional des Pays de la Loire, Centre d'expertise Partenariat Européen d'Innovation pour un vieillissement actif et en bonne santé, Nantes, France, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, Alergologo, Ensenada, Mexico, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Libra Foundation, Buenos Aires, Argentina, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Allergology Department, Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau (APHP, Paris), Paris, France, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Immunology and Allergy Division, Department of Chest Diseases, School of Medicine, Hacettepe University, Ankara, Turkey, Allergy Centre, Tampere University Hospital, Tampere, Finland, Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany, GARD, Geneva, Switzerland, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Department of Respiratory Medicine, Faculty of Medicine and Dentistry, University Hospital, Olomouc, Czech Republic, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy, Clínica de Alergia, Asma y Pediatría, Hospital Médica Sur, México City, Mexico, Presidente CMMC, Milano, Italy, Head of the Allergy Department of Pedro de Elizalde Children's Hospital, Buenos Aires, Argentina, Faculdade de Medicina da Universidade Federal da Bahia, Salvador de Bahia, Brazil, Sifmed, Milano, Italy, Promotor B3 Action GRoup EIP on AHA and Senior Fellow, International Foundation for Integreted Care, Aberystwyth, United Kingdom, Tech Life Valley, Diepenbeek, Belgium, Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium, University of Guadalajara, Guadalara, Mexico, Faculty of Medicine, Institute of Biomedical Imaging and Life Sciences (IBILI), University of Coimbra, Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, Hospital Regional Siglo XXI, Mexico City, Mexico, Alergologo, Veracruz, Mexico, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, CIRFF, Federico II University, Naples, Italy, Caisse d'assurance retraite et de la santé au travail du Languedoc-Roussillon (CARSAT-LR), Montpellier, France, Regione Piemonte, Torino, Italy, Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisboa, Portugal, Institute of Medical Statistics, Informatics and Epidemiology, Medical Faculty, University of Cologne, Cologne, Germany, Laboratory of General Pathology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Clinical & Experimental Respiratory Immunoallergy, ENT Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain, Department of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy, MedScript Ltd, Dundalk, Co. Louth, Ireland, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Head of Respiratory Medicine, Alassia Children's Hospital, Center for Allergy and Immunology, Santa Fe, Argentina, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Allergy and Respiratory Diseases, IRCCS San Martino Hospital-IST-University of Genoa, Genoa, Italy, Department of Pneumology, CHU Grenoble, Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal, Sociologist, Municipality, Sorrento, Italy, Vice-Presidente of IML, Milano, Italy, Alergista, Recife, Brazil, Centre of Pneumology, Coimbra University Hospital, Coimbra, Portugal, Alergologo, Mexico City, Mexico, Medical University of Graz, Graz, Austria, Allergy Unit, Presidio Columbus, Rome, Catholic University of Sacred Heart, Rome, Italy, IRCCS Oasi Maria S.S., Troina, Italy, Association of Finnish Pharmacists, Helsinki, Finland, Allergist, Vitoria, Brazil, Departement of Internal Medicine, University Hospital, Olomouc, Czech Republic, IML (Lombardy Medical Initiative), Bergamo, Italy, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Center for Life Course Health Research, Helsinki University Hospital, Helsinki University, University of Oulu, Oulu, Finland, Public Health Institute of Vilnius University, Vilnius, Lithuania, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of ENT, Medical University of Graz, Graz, Austria, Division on Pharmacy and Devices Policy, Campania Region, Naples, Italy, Pneumology and Allergy Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland, Allergy Clinic, Terveystalo, Turku, Finland, Vilnius University Clinic of Children's Diseases and Public Health Institute, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, FILHA, Finnish Lung Association, Helsinki, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Department of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany, EIP on AHA Coordinator, Region of Southern Denmark, Odense, Denmark, Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden, Queen's University, Belfast, United Kingdom, Celal Bayar University Department of Pulmonology, GARD Executive Committee, Manisa, Turkey, Universidad Católica de Córdoba, Córdoba, Argentina, and EC-CNECT-H2, European Commission, Brussels, Belgium
- Subjects
humanities - Abstract
The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives whilst ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study was to transfer innovation from an app developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve the understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will be: (i) to assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) to study the phenotypic characteristics and treatment over a 1-year period of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) to follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2018
18. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study
- Author
-
Bousquet, J. and Devillier, P. and Anto, J.M. and Bewick, M. and Haahtela, T. and Arnavielhe, S. and Bedbrook, A. and Murray, R. and van Eerd, M. and Fonseca, J.A. and Morais Almeida, M. and Todo Bom, A. and Menditto, E. and Passalacqua, G. and Stellato, C. and Triggiani, M. and Ventura, M.T. and Vezzani, G. and Annesi-Maesano, I. and Bourret, R. and Bosse, I. and Caimmi, D. and Cartier, C. and Demoly, P. and Just, J. and Portejoie, F. and Siroux, V. and Viart, F. and Bergmann, K.C. and Keil, T. and Klimek, L. and Mösges, R. and Pfaar, O. and Shamai, S. and Zuberbier, T. and Mullol, J. and Valero, A. and Spranger, O. and Tomazic, P.V. and Kowalski, M.L. and Kuna, P. and Kupczyk, M. and Raciborski, F. and Samolinski, B. and Toppila-Salmi, S.K. and Valovirta, E. and Cruz, A.A. and Sarquis-Serpa, F. and da Silva, J. and Stelmach, R. and Larenas-Linnemann, D. and Rodriguez Gonzalez, M. and Burguete Cabañas, M.T. and Kvedariene, V. and Valiulis, A. and Chavannes, N.H. and Fokkens, W.J. and Ryan, D. and Sheikh, A. and Bachert, C. and Hellings, P.W. and VandenPlas, O. and Ballardini, N. and Kull, I. and Melén, E. and Westman, M. and Wickman, M. and Bindslev-Jensen, C. and Eller, E. and Bosnic-Anticevich, S. and O'Hehir, R.E. and Agache, I. and Bieber, T. and Casale, T. and Gemicioğlu, B. and Ivancevich, J.C. and De Vries, G. and Sorensen, M. and Yorgancioglu, A. and Laune, D. and MACVIA working group, MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité, Berlin, Germany, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Suresnes, France, ISGloBAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, iQ4U Consultants Ltd, London, United Kingdom, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Kyomed, Montpellier, France, MedScript Ltd, Dundalk, Ireland, Peercode DV, Gerdermalsen, Netherlands, Faculdade de Medicina, Center for Health Technology and Services Research- CINTESIS, MEDIDA, Lda, Universidade do Porto, Porto, Portugal, Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisboa, Portugal, Imunoalergologia, Faculty of Medicine, Centro Hospitalar Universitário de Coimbra, University of Coimbra, Coimbra, Portugal, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Allergy and Respiratory Diseases, Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Medical School Saint Antoine, UPMC Sorbonne Universités, Paris, France, Centre Hospitalier, Valenciennes, France, Allergist, La Rochelle, France, CHRU de Montpellier, UMR-S 1136, IPLESP, Equipe EPAR, UPMC Paris 06, Sorbonne Universités, Paris, France, ASA - Advanced Solutions Accelerator, Clapiers, France, Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Paris, France, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, UPMC Univ Paris 06, Sorbonne Universités, Paris, France, INSERM, IAB, U 1209, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Université Grenoble Alpes, Université Joseph Fourier, Grenoble, France, Department of Dermatology and Allergy, Comprehensive Allergy-Centre-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Medical Faculty, Institute of Medical Statistics, and Computational Biology, University of Cologne, Cologne, Germany, Rhinology Unit & Smell Clínic, ENT Department, Hospital Clinic, University of Barcelona, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Department of Immunology, Rheumatology and Allergy, HARC, Medical University of Lodz, Lodz, Poland, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland, Terveystalo Allergy Clinic, Turku, Finland, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, GARD Executive Committee, Salvador, Brazil, Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericordia de VitoriaEsperito Santo, Brazil, Nucleo de Alergia, Hospital Universitario Polydoro Ernani de Sao Thiago, Federal University of Santa Catarina (HU-UFSC), Florioanopolis, Brazil, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico City, Mexico, Centro Médico Zambrano Hellion, Monterrey, Mexico, Departement of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Clinic of Infecious, Chest Diseases, Dermatology and Allergology, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Clinic of Infecious, Chest Diseases, Dermatology and Allergology, Institute of Clinical Medicine, Vilnius, Lithuania, Department of Public Health, Clinic of Children's Diseases, Institute of Health Sciences, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Asthma UK Centre for Applied Research, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet, Stockholm, Sweden, Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden, Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark, Woolcock Institute of Medical Research, Sydney Local Health District, University of Sydney, Glebe, NSW, Australia, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, Transylvania University, Brasov, Romania, Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Department of Paediatric and Adolescent Medicine, University Hospital of North Norway, Tromsø, Norway, Department of Clinical Medicine, Paediatric Research Group, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway, Department of Pulmonology, Celal Bayar University, Manisa, Turkey, and GARD Executive Committee, Manisa, Turkey
- Abstract
Background: Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary. Methods: We undertook a 1-year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels
- Published
- 2018
19. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control
- Author
-
Caimmi, D., Baiz, N., Tanno, L. K., Demoly, P., Arnavielhe, S., Murray, R., Bedbrook, A., Bergmann, K. C., De Vries, G., Fokkens, W. J., Fonseca, J., Haahtela, T., Keil, T., Kuna, P., Mullol, J., Papadopoulos, N., Passalacqua, G., Samolinski, B., Tomazic, P. V., Valiulis, A., van Eerd, M., Wickman, M., Annesi-Maesano, I., Bousquet, J., Agache, I., Angles, R., Anto, J. M., Asayag, E., Bacci, E., Bachert, C., Baroni, I., Barreto, B. A., Bedolla-Barajas, M., Bertorello, L., Bewick, M., Bieber, T., Birov, S., Bindslev-Jensen, C., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Bosnic-Ancevich, S., Bosse, I., Bourret, R., Bucca, C., Buonaiuto, R., Caiazza, D., Caillot, D., Caimmi, D. P., Camargos, P., Canfora, G., Cardona, V., Carriazo, A. M., Cartier, C., Castellano, G., Chavannes, N. H., Ciaravolo, M. M., Cingi, C., Ciceran, A., Colas, L., Colgan, E., Coll, J., Conforti, D., Correira de Sousa, J., Cortés-Grimaldo, R. M., Corti, F., Costa, E., Courbis, A. L., Cruz, A., Custovic, A., Dario, C., da Silva, M., Dauvilliers, Y., De Blay, F., Dedeu, T., De Feo, G., De Martino, B., Di Capua, S., Di Carluccio, N., Dray, G., Dubakiene, R., Eller, E., Emuzyte, R., Espinoza-Contreras, J. M., Estrada-Cardona, A., Farrell, J., Ferrero, J., Fontaine, J. F., Forti, S., Gálvez-Romero, J. L., Garcia Cruz, M. H., García-Cobas, C. I., Gemicioğlu, B., Gerth van Wijck, R., Guidacci, M., Gómez-Vera, J., Guldemond, N. A., Gutter, Z., Hajjam, J., Hellings, P., Hernández-Velázquez, L., Illario, M., Ivancevich, J. C., Jares, E., Joos, G., Just, J., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Khaltaev, N., Klimek, L., Kull, I., Kuna, T. P., Kvedariene, V., Kolek, V., Krzych-Fałta, E., Kupczyk, M., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Lessa, M., Levato, G., Lewis, L., Lieten, I., Lipiec, A., Louis, R., Luna-Pech, J. A., Magnan, A., Malva, J., Maspero, J. F., Mayora, O., Medina-Ávalos, M. A., Melen, E., Menditto, E., Millot-Keurinck, J., Moda, G., Morais-Almeida, M., Mösges, R., Mota-Pinto, A., Muraro, A., Noguès, M., Nalin, M., Napoli, L., Neffen, H., O'Hehir, R., Olivé Elias, M., Onorato, G., Palkonen, S., Pépin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Pozzi, A. C., Prokopakis, E. P., Raciborski, F., Rizzo, J. A., Robalo-Cordeiro, C., Rodríguez-González, M., Rolla, G., Roller-Wirnsberger, R. E., Romano, A., Romano, M., Salimäki, J., Serpa, F. S., Shamai, S., Sierra, M., Sova, M., Sorlini, M., Stellato, C., Stelmach, R., Strandberg, T., Stroetman, V., Stukas, R., Szylling, A., Tibaldi, V., Todo-Bom, A., Toppila-Salmi, S., Tomazic, P., Trama, U., Triggiani, M., Valero, A., Valovirta, E., Vasankari, T., Vatrella, A., Ventura, M. T., Verissimo, M. T., Viart, F., Williams, S., Wagenmann, M., Wanscher, C., Westman, M., Young, I., Yorgancioglu, A., Zernotti, E., Zurbierber, T., Zurkuhlen, A., De Oliviera, B., Senn, A., Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), KYomed INNOV [Montpellier], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Amsterdam UMC - Amsterdam University Medical Center, Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, Hospital CUF Descobertas, Helsinki University Hospital [Finland] (HUS), University of Wuerzburg, Barlicki University Hospital, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Royal Manchester Children's Hospital, University of Manchester [Manchester], General Children's Hospital of Athens P & A Kyriakou, Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria 'San Martino' (IRCCS AOU San Martino), Medical University of Warsaw - Poland, Medical University of Graz, Vilnius University Clinic of Children's Diseases, European Academy of Paediatrics (EAP/UEMS-SP), Sachs’ Children and Youth Hospital [Stockholm, Sweden], Caimmi, D., Baiz, N., Tanno, L. K., Demoly, P., Arnavielhe, S., Murray, R., Bedbrook, A., Bergmann, K. C., De Vries, G., Fokkens, W. J., Fonseca, J., Haahtela, T., Keil, T., Kuna, P., Mullol, J., Papadopoulos, N., Passalacqua, G., Samolinski, B., Tomazic, P. V., Valiulis, A., van Eerd, M., Wickman, M., Annesi-Maesano, I., Bousquet, J., Agache, I., Angles, R., Anto, J. M., Asayag, E., Bacci, E., Bachert, C., Baroni, I., Barreto, B. A., Bedolla-Barajas, M., Bertorello, L., Bewick, M., Bieber, T., Birov, S., Bindslev-Jensen, C., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Bosnic-Ancevich, S., Bosse, I., Bourret, R., Bucca, C., Buonaiuto, R., Caiazza, D., Caillot, D., Caimmi, D. P., Camargos, P., Canfora, G., Cardona, V., Carriazo, A. M., Cartier, C., Castellano, G., Chavannes, N. H., Ciaravolo, M. M., Cingi, C., Ciceran, A., Colas, L., Colgan, E., Coll, J., Conforti, D., Correira de Sousa, J., Cortés-Grimaldo, R. M., Corti, F., Costa, E., Courbis, A. L., Cruz, A., Custovic, A., Dario, C., da Silva, M., Dauvilliers, Y., De Blay, F., Dedeu, T., De Feo, G., De Martino, B., Di Capua, S., Di Carluccio, N., Dray, G., Dubakiene, R., Eller, E., Emuzyte, R., Espinoza-Contreras, J. M., Estrada-Cardona, A., Farrell, J., Ferrero, J., Fontaine, J. F., Forti, S., Gálvez-Romero, J. L., Garcia Cruz, M. H., García-Cobas, C. I., Gemicioğlu, B., Gerth van Wijck, R., Guidacci, M., Gómez-Vera, J., Guldemond, N. A., Gutter, Z., Hajjam, J., Hellings, P., Hernández-Velázquez, L., Illario, M., Ivancevich, J. C., Jares, E., Joos, G., Just, J., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Khaltaev, N., Klimek, L., Kull, I., Kuna, T. P., Kvedariene, V., Kolek, V., Krzych-Fałta, E., Kupczyk, M., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Lessa, M., Levato, G., Lewis, L., Lieten, I., Lipiec, A., Louis, R., Luna-Pech, J. A., Magnan, A., Malva, J., Maspero, J. F., Mayora, O., Medina-Ávalos, M. A., Melen, E., Menditto, E., Millot-Keurinck, J., Moda, G., Morais-Almeida, M., Mösges, R., Mota-Pinto, A., Muraro, A., Noguès, M., Nalin, M., Napoli, L., Neffen, H., O'Hehir, R., Olivé Elias, M., Onorato, G., Palkonen, S., Pépin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Pozzi, A. C., Prokopakis, E. P., Raciborski, F., Rizzo, J. A., Robalo-Cordeiro, C., Rodríguez-González, M., Rolla, G., Roller-Wirnsberger, R. E., Romano, A., Romano, M., Salimäki, J., Serpa, F. S., Shamai, S., Sierra, M., Sova, M., Sorlini, M., Stellato, C., Stelmach, R., Strandberg, T., Stroetman, V., Stukas, R., Szylling, A., Tibaldi, V., Todo-Bom, A., Toppila-Salmi, S., Tomazic, P., Trama, U., Triggiani, M., Valero, A., Valovirta, E., Vasankari, T., Vatrella, A., Ventura, M. T., Verissimo, M. T., Viart, F., Williams, S., Wagenmann, M., Wanscher, C., Westman, M., Young, I., Yorgancioglu, A., Zernotti, E., Zurbierber, T., Zurkuhlen, A., De Oliviera, B., Senn, A., Adult Psychiatry, AII - Inflammatory diseases, and Ear, Nose and Throat
- Subjects
medicine.medical_specialty ,Allergy ,Population level ,MASK ,Visual Analog Scale ,Visual analogue scale ,Intraclass correlation ,allergic rhinitis ,allergy ,control ,visual analogue scale ,Immunology and Allergy ,Immunology ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Allergic ,Cronbach's alpha ,Internal consistency ,medicine ,Humans ,Public Health Surveillance ,030212 general & internal medicine ,Reproducibility of Results ,Rhinitis, Allergic ,Smartphone ,Software ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Reliability (statistics) ,Rhinitis ,business.industry ,Asthma symptoms ,ta3121 ,medicine.disease ,Surgery ,030228 respiratory system ,Physical therapy ,allergic rhiniti ,business - Abstract
Background Visual Analogue Scale (VAS) is a validated tool to assess control in allergic rhinitis patients. Objective The aim of the present study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control. Methods Each user filled 4 different VAS measuring overall, nasal, ocular and asthma symptoms at least once. Following COSMIN guidelines, we evaluated internal consistency, (Cronbach's alpha-coefficient and test-retest), reliability (intraclass correlation coefficients), sensitivity and acceptability, of the MASK-Rhinitis VAS. Results Between August 1st, 2015 and July 31st, 2016, the app was used 14,612 times in 15 countries. 1,225 users used it more than once, during the evaluated period. The tool resulted to be statistically satisfactory, showing excellent internal consistency (Cronbach's test >0.84, test-retest >0.7), reliability (>0.9) and acceptability. In addition, the tool had a good sensitivity when users (n=521) answered the VAS twice in less than three hours. Conclusions & Clinical Relevance The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level. This article is protected by copyright. All rights reserved.
- Published
- 2017
20. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: A SUNFRAIL report
- Author
-
Bousquet, J. and Onorato, G.L. and Bachert, C. and Barbolini, M. and Bedbrook, A. and Bjermer, L. and De Sousa, J.C. and Chavannes, N.H. and Cruz, A.A. and De Manuel Keenoy, E. and Devillier, P. and Fonseca, J. and Hun, S. and Kostka, T. and Hellings, P.W. and Illario, M. and Ivancevich, J.C. and Larenas-Linnemann, D. and Millot-Keurinck, J. and Ryan, D. and Samolinski, B. and Sheikh, A. and Yorgancioglu, A. and Agache, I. and Arnavielhe, S. and Bewick, M. and Annesi-Maesano, I. and Anto, J.M. and Bergmann, K.C. and Bindslev-Jensen, C. and Bosnic-Anticevich, S. and Bouchard, J. and Caimmi, D.P. and Camargos, P. and Canonica, G.W. and Cardona, V. and Carriazo, A.M. and Cingi, C. and Colgan, E. and Custovic, A. and Dahl, R. and Demoly, P. and De Vries, G. and Fokkens, W.J. and Fontaine, J.F. and Gemicioǧlu, B. and Guldemond, N. and Gutter, Z. and Haahtela, T. and Hellqvist-Dahl, B. and Jares, E. and Joos, G. and Just, J. and Khaltaev, N. and Keil, T. and Klimek, L. and Kowalski, M.L. and Kull, I. and Kuna, P. and Kvedariene, V. and Laune, D. and Louis, R. and Magnan, A. and Malva, J. and Mathieu-Dupas, E. and Melén, E. and Menditto, E. and Morais-Almeida, M. and Mösges, R. and Mullol, J. and Murray, R. and Neffen, H. and O'Hehir, R. and Palkonen, S. and Papadopoulos, N.G. and Passalacqua, G. and Pépin, J.L. and Portejoie, F. and Price, D. and Pugin, B. and Raciborski, F. and Simons, F.E.R. and Sova, M. and Spranger, O. and Stellato, C. and Todo Bom, A. and Tomazic, P.V. and Triggiani, M. and Valero, A. and Valovirta, E. and Vandenplas, O. and Valiulis, A. and Van Eerd, M. and Ventura, M.T. and Wickman, M. and Young, I. and Zuberbier, T. and Zurkuhlen, A. and Senn, A., Contre les MAladies Chroniques Pour un VIeillissement, Actif en France Europ. Innov. Partnership on Active and Healthy Ageing Ref. Site, Montpellier, France, INSERM U 1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Regione Emilia Romagna - Agenzia Sanitaria e Sociale, Reference Site of the European Innovation Partnership on Healthy and Active Ageing, Bologna, Italy, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, GARD Executive Committee, Salvador, Brazil, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bilbao Bizkaia, Spain, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Versailles, France, Center for Health Technology and Services Research- CINTESIS, Faculdade de Medicina, Universidade Do Porto, Porto, Portugal, Allergy Unit, CUF Porto Instituto and Hospital, Porto, Portugal, Public Health Agency Northern Ireland, Belfast, United Kingdom, Department of Geriatrics, Medical University of Lodz, Healthy Ageing Research Centre (HARC), Lodz, Poland, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium, Division for Health Innovation, Campania Region, Federico II University Hospital Naples, RandD and DISMET, Naples, Italy, Allergy and Immunology Department, Santa Isabel, Buenos Aires, Argentina, Clínica de Alergia, Asma y Pediatría, Hospital Médica sur, Mexico, Mexico, Caisse Assurance Retraite et Santé Au Travail Languedoc-Roussillon (CARSAT-LR), Montpellier, 34000, France, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Asthma UK Centre for Applied Research, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Pulmonology, Celal Bayar University, Manisa, Turkey, GARD Executive Committee, Manisa, Turkey, Faculty of Medicine, Transylvania University, Brasov, Romania, Kyomed, Montpellier, France, IQ4U Consultants Ltd, London, United Kingdom, EPAR U707 INSERM, Paris and EPAR UMR-S UPMC, Paris VI, Paris, France, Centre for Research in Environmental Epidemiology (CREAL), ISGLoBAL, Barcelona, Spain, IMIM, Hospital Del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, Laval's University, Quebec City, Canada, Hôpital de la Malbaie, Quebec City, Canada, CHRU de Montpellier, Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Paris, 75013, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil, Personalized Medicine Clinic Asthma and Allergy, Humanitas University, Humanitas Research Hospital, Rozzano Milan, Italy, Allergologia, S Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey, Department of Health, Social Services and Public Safety, Belfast, United Kingdom, Department of Pediatric, Imperial College London, London, United Kingdom, Peercode DV, Gerdermalsen, Netherlands, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Allergist, Reims, France, Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, Institute of Health Policy and Management IBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc, National EHealth Centre, Olomouc, Czech Republic, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark, Libra Foundation, Buenos Aires, Argentina, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Paris, France, UPMC Univ Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, Paris, 75013, France, GARD, Geneva, Switzerland, Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology Rheumatology and Allergy, Medical University of Lodz, HARC, Lodz, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet Stockholm, Stockholm, Sweden, Division of Internal Medicine Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Clinic of Infectious Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium, Service de Pneumologie, UMR INSERM, UMR1087 and CNR 6291, L'Institut du Thorax, University of Nantes, Nantes, France, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Ageing at Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, CIRFF, Federico II University, Naples, Italy, Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisbon, Portugal, Institute of Medical Statistics, Informatics and Epidemiology, Medical Faculty, University of Cologne, Cologne, Germany, Clinical and Experimental Respiratory Immunoallergy, ENT Department, Hospital Clínic, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Spain, Medical Communications Consultant, MedScript Ltd, Dundalk Co Louth, Ireland, Argentina Center for Allergy and Immunology, Alassia Children's Hospital, Santa Fe, Santa Fe, Argentina, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, M13 9WL, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital PandA Kyriakou, University of Athens, Athens, 11527, Greece, Allergy and Respiratory Diseases, IRCCS San Martino Hospital, IST-University of Genoa, Genoa, Italy, CHU Grenoble, La Tronche, France, Observational and Pragmatic Research Institute, Singapore, Singapore, Optimum Patient Care, Cambridge, United Kingdom, Academic Centre of Primary Care, University of Aberdeen, Aberdeen, United Kingdom, Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, University Hospital Olomouc, Olomouc, Czech Republic, Global Allergy and Asthma Platform GAAPP, Altgasse 8-10, Vienna, 1130, Austria, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department Hospital Clínic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Queen's University Belfast, Belfast, United Kingdom, Gesundheitsregion KölnBonn-HRCB Projekt GmbH, Kohln, Germany, EC-CNECT-H2, European Commission, Brussels, Belgium, and CHU Montpellier, 371 Avenue du Doyen Gaston Giraud, Montpellier Cedex 5, 34295, France
- Abstract
A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices. © 2017 The Author(s).
- Published
- 2017
21. Hábitos e problemas do sono dos dois aos dez anos: estudo populacional
- Author
-
Silva, Filipe Glória, Silva, Cláudia Rocha, Braga, Lígia Barbosa, Neto, Ana Serrão, and Hospital Cuf Descobertas
- Subjects
lcsh:R5-920 ,lcsh:RJ1-570 ,lcsh:Pediatrics ,lcsh:Medicine (General) - Abstract
Introdução: Embora seja cada vez mais reconhecida a importância do sono na criança, existem poucos dados recentes sobre esta matéria em Portugal, com amostras representativas e questionários validados. Objetivos: Os objetivos deste estudo foram avaliar os hábitos e problemas do sono em crianças dos dois aos dez anos e estabelecer dados de referência para a versão portuguesa do Children’s Sleep Habits Questionnaire (CSHQ-PT). Métodos: Trata-se de um estudo populacional, transversal. O CSHQ-PT foi entregue aos pais de 2257 crianças recrutadas em creches, jardins de infância e escolas das áreas da Grande Lisboa, Península de Setúbal e Alentejo, regiões onde reside um terço das crianças portuguesas de dois a dez anos. Resultados: Foram incluídos no estudo os questionários relativos a 1450 crianças. A idade média das crianças foi 6,5 (desvio padrão 2,3) anos. A prevalência de problemas do sono referidos pelos pais foi de 10,4%, sem diferenças significativas entre subgrupos de nível educacional dos pais nem entre zonas de média-alta e baixa densidade populacional. Estes problemas do sono mostram-se associados sobretudo à duração do sono, resistência em ir para a cama, ansiedade associada ao sono, despertares noturnos e parassónias. A baixa prevalência de problemas do sono identificados pelos pais contrasta com cotações elevadas no CSHQ-PT que traduzem comportamentos-problema mais frequentes. Considerando valores de referência de outros países, verificou-se que 10% das crianças tinham uma duração do sono dois desvios-padrão abaixo da média. A menor duração do sono mostrou associação com a sonolência diurna. Conclusão: Os problemas comportamentais do sono e a privação de sono são prevalentes em Portugal, pelo que existem oportunidades de intervenção nesta área., Portuguese Journal of Pediatrics, Vol. 44 No. 5 (2013)
- Published
- 2014
22. Severe Chronic Allergic (and related) Diseases: a uniform approach- a MeDALL- GA(2)LEN-ARIA Position Paper
- Author
-
WHO Collaborating Center for Asthma, Rhinitis, Bousquet, J, Anto, Jm, Demoly, P, Schünemann, Hj, Togias, A, Akdis, M, Auffray, C, Bachert, C, Bieber, T, Bousquet, Pj, Carlsen, Kh, Casale, Tb, Cruz, Aa, Keil, T, Lodrup Carlsen KC, Maurer, M, Ohta, K, Papadopoulos, Ng, Roman Rodriguez, M, Samolinski, B, Agache, I, Andrianarisoa, A, Ang, Cs, Annesi Maesano, I, Ballester, F, Baena Cagnani CE, Basagaña, X, Bateman, Ed, Bel, Eh, Bedbrook, A, Beghe', Bianca, Beji, M, Ben Kheder, A, Benet, M, Bennoor, Ks, Bergmann, Kc, Berrissoul, F, Bindslev Jensen, C, Bleecker, Er, Bonini, S, Boner, Al, Boulet, Lp, Brightling, Ce, Brozek, Jl, Bush, A, Busse, Ww, Camargos, Pa, Canonica, Gw, Carr, W, Cesario, A, Chen, Yz, Chiriac, Am, Costa, Dj, Cox, L, Custovic, A, Dahl, R, Darsow, U, Didi, T, Dolen, Wk, Douagui, H, Dubakiene, R, El Meziane, A, Fonseca, Ja, Fokkens, Wj, Fthenou, E, Gamkrelidze, A, Garcia Aymerich, J, Gerth van Wijk, R, Gimeno Santos, E, Guerra, S, Haahtela, T, Haddad, H, Hellings, Pw, Hellquist Dahl, B, Hohmann, C, Howarth, P, Hourihane, Jo, Humbert, M, Jacquemin, B, Just, J, Kalayci, O, Kaliner, Ma, Kauffmann, F, Kerkhof, M, Khayat, G, Koffi N'Goran, B, Kogevinas, M, Koppelman, Gh, Kowalski, Ml, Kull, I, Kuna, P, Larenas, D, Lavi, I, Le, Lt, Lieberman, P, Lipworth, B, Mahboub, B, Makela, Mj, Martin, F, Martinez, Fd, Marshall, Gd, Mazon, A, Melen, E, Meltzer, Eo, Mihaltan, F, Mohammad, Y, Mohammadi, A, Momas, I, Morais Almeida, M, Mullol, J, Muraro, A, Naclerio, R, Nafti, S, Namazova Baranova, L, Nawijn, Mc, Nyembue, Td, Oddie, S, O'Hehir, Re, Okamoto, Y, Orru, Mp, Ozdemir, C, Ouedraogo, Gs, Palkonen, S, Panzner, P, Passalacqua, G, Pawankar, R, Pigearias, B, Pin, I, Pinart, M, Pison, C, Popov, Ta, Porta, D, Postma, Ds, Price, D, Rabe, Kf, Ratomaharo, J, Reitamo, S, Rezagui, D, Ring, J, Roberts, R, Roca, J, Rogala, B, Romano, A, Rosado Pinto, J, Ryan, D, Sanchez Borges, M, Scadding, Gk, Sheikh, A, Simons, Fe, Siroux, V, Schmid Grendelmeier PD, Smit, Ha, Sooronbaev, T, Stein, Rt, Sterk, Pj, Sunyer, J, Terreehorst, I, Toskala, E, Tremblay, Y, Valenta, R, Valeyre, D, Vandenplas, O, van Weel, C, Vassilaki, M, Varraso, R, Viegi, G, Wang, Dy, Wickman, M, Williams, D, Wöhrl, S, Wright, J, Yorgancioglu, A, Yusuf, Om, Zar, Hj, Zernotti, Me, Zidarn, M, Zhong, N, Zuberbier, T., Beghe', B., Fthenou, E., Boudier, Anne, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), IMIM-Hospital del Mar, Generalitat de Catalunya, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, CIBER Epidemiologia y Salud Publica, CIBER de Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra [Barcelona] (UPF), WHO Collaborating Center for Asthma and Rhinitis, Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Pharmacoepidemiologie et évaluation de l'impact des produits de santé sur les populations, Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Génomique fonctionnelle et biologie systémique pour la santé, Institut des Sciences Biologiques du CNRS, Upper Airway Research Laboratory (URL), Ghent University Hospital, Department of Dermatology and Allergy, VU University Medical Center [Amsterdam], Department of Paediatrics, University of Oslo (UiO)-Oslo University Hospital [Oslo], Division of Allergy and Immunology, Department of Medicine, Creighton University, ProAR - FMB, Federal University of Bahia School of Medicine, Epidemiology and Health Economics, Instittute of Social Health-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Dermatology, Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Allergy Department, 2nd Pediatric Clinic, Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Public Hospital Medical Service, Ministry of Health [Mozambique], Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Public Health Research (CSISP), University of Valencia, Respiratory Medicine, Università degli studi di Genova = University of Genoa (UniGe)-School of Specialization, Faculty of Medicine, Catholic University, Health Sciences Faculty, University of Cape Town, Department of Pulmonology, University of Amsterdam [Amsterdam] (UvA)-Academic Medical Centre, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Service de Pneumologie Allergologie, Hôpital La Rabta [Tunis], Service de Pneumologie, Hôpital Abderrahmen Mami, National Asthma Centre, National Institute of Diseases of the Chest and Hospital (NIDCH), Pneumologie / Anesthésie - réanimation / Oxygénothérapie, Hôpital AKS Phnom Penh-Hôpital Provincial de Siemreap, Department of Dermatology and Allergy Center, Odense University Hospital, Center for Genomics and Personalized Medicine, Wake Forest University, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Università degli studi di Verona = University of Verona (UNIVR), Institut de cardiologie et de pneumologie, Université Laval [Québec] (ULaval)-Centre Hospitalier de Laval (CH Laval), Department of Respiratory Medicine and Thoracic Surgery, University of Leicester-Institute for Lung Health, Department of Paediatric Respiratory Medicine, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], Department of Medicine, University of Wisconsin School of Medicine and Public Health, Department of Pediatrics, Universidade Federal de Minas Gerais [Belo Horizonte] (UFMG)-Medical School, Allergy & Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe)-Department of Internal Medicine (DIMI), Allergy & Asthma Associates, University of California [Irvine] (UC Irvine), University of California (UC)-University of California (UC), Deputy Scientific Director, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Department of Thoracic Surgery, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), National Cooperative Group of Pediatric Research on Asthma, Asthma Clinic and Education Center of the Capital Institute of Pediatrics, Service des Premiers Soins, Université Montpellier 1 (UM1), Osteopathic College of Medicine, Nova Southeastern University (NSU), Respiratory Research Group, University of Manchester [Manchester]-School of Translational Medicine, Department of Respiratory Diseases, Aarhus University Hospital, Department of Dermatology and Allergy Biederstein, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Service de pneumologie, Centre hospitalier de la région d'Annecy, Service de pneumo-allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Allergy Centre, Vilnius University Antakalnis Hospital, Société Marocaine des Maladies Respiratoires, Centre of Respiratory Diseases and Allergy-Centre commercial Nadia, Allergy Division, Hospital S. João-Centre for Research in Health Technologies and Information Systems (CINTESIS)-Biostatistics and Medical Informatics Department-Porto University Medical School, Department of Otorhinolaryngology, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Department of Social Medicine, University of Crete [Heraklion] (UOC)-Faculty of Medicine, Health Care, Minister Of Labour-Ministry of Labor, Health and Social Affairs, Section of Allergology, Erasmus Medical Centre, Epidemiology and Biostatistics Division, University of Arizona-Associate Research Scientist, Respiratory Sciences-Arizona Respiratory Center, Helsinki University Hospital-Skin and Allergy Hospital, Centre Hospitalier de Bigorre [Tarbes]-Association Franco-Libanaise de Pneumologie (AFLP), Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Leuven, Engineering and the Environment, University of Southampton, Paediatrics and Child Health, University College Cork (UCC), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de l'Asthme et des Allergies [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Pediatric Allergy and Asthma Unit, Ihsan Dogramaci Children's Hospital-Hacettepe University School of Medicine, Institute for Asthma and Allergy, George Washington University Medical School, Department of Epidemiology, University of Groningen [Groningen]-University Medical Center Groningen [Groningen] (UMCG)-Groningen Research Institute for Asthma and COPD (GRIAC), Université Saint-Joseph de Beyrouth (USJ)-Faculté de Médecine-Hôtel-Dieu de France, Service des Maladies Respiratoires, CHU de Cocody-UFR des Sciences Médicales, Pediatric Pulmonology, Allergology & Epidemiology, University of Groningen [Groningen]-University Medical Center Groningen [Groningen] (UMCG)-Beatrix Children's Hospital-Groningen Research Institute for Asthma and COPD, Department of Clinical Immunology and Allergy, Medical University of Łódź (MUL)-Faculty ot Medicine, Centre for Allergy Research, Karolinska Institutet [Stockholm], Department of Clinical Science and Education, Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Hospital Medica Sur, Physiology Department, University of Medicine and Pharmacy, Division of Allergy Immunology, Department of Medicine-The University of Tennessee Health Science Center [Memphis] (UTHSC), university of dundee asthma - allergic rhinitis - COPD - beta-2-adrenoceptor, University of Dundee, Pulmonary and allergy unit, American University of Sharjah-Rashid Hospital-Dubai Health Authority (DHA), Association Franco-Vietnamienne de Pneumologie (AFVP), Centre Hospitalier de Compiègne (CHC), Arizona Respiratory Center, Department of Medicine, Clinical Immunology and Allergy, University of Mississippi Medical Center (UMMC), Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Allergy & Asthma Medical Group & Research Center, University of California [San Diego] (UC San Diego), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Internal Medicine, Tishreen University School of Medicine, Association Franco-Marocaine de Pathologie Thoracique (AFMAPATH), Collège National des Pneumologues Marocains, Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Immunoallergy Department, Hospital CUF Descobertas, Rhinology Unit & Smell Clinic, Universitat de Barcelona (UB)-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Department of Medicine-Hospital Clinic-ENT Department, Allergy Unit, Università degli Studi di Padova = University of Padua (Unipd)-Department of Paediatrics, Section of Otolaryngology-Head & Neck Surgery (OHNS), University of Chicago, Clinique des maladies respiratoires, centre hospitalo-universitaire Mustapha Pacha d'Alger (CHUMA), Scientific Center for Children's Health, Russian Academy of Medical Sciences (RAMS), Laboratory of Allergology and Pulmonary Diseases, University of Groningen [Groningen]-University Medical Center Groningen [Groningen] (UMCG)-Department of Pathology and Medical Biology-GRIAC Research Institute, ENT Department, University of Kinshasa (UNIKIN), Bradford Neonatology, Bradford Teaching Hospitals NHS Foundation Trust-Bradford Institute for Health Research, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Chiba University Hospital, Asthme Rhinite allergique, Pharmacie, Division of Pediatric Allergy and Immunology, marmara university, Pédiatrie, Centre Hospitalier National Pédiatrique Charles de Gaulle (CHNP-CDG), European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Department of Allergology and Clinical Immunology, Charles University [Prague] (CU)-Medical Faculty in Pilsen, Immunopharmacology, Nippon Medical School-Medical Research Council Clinical, Laboratoire du Sommeil et de l'Effort, Société de Pneumologie de Langue Française (SPLF)-Clinique St George, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinic of Allergy and Asthma, Medical University Sofia-Alexander's University Hospital, Regional Health Service - Lazio, Primary Care Respiratory Medicine, University of Aberdeen-Department of General Practice and Primary Care-General Practice Airways Group (GPIAG), Department of Pulmonary Medicine, Leiden University Medical Center (LUMC), Pneumalgia, Centre Hospitalier Regional-Espace Francophone de Pneumologie (EFP)-Société de Pneumologie de l'Océan Indien (SPOI), Association Franco-Algérienne de Pneumologie (AFAP), Espace Francophone de pneumologie de la SPLF, Department of Pneumology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic de Barcelona-Institut Clínic del Tórax (ICT)-CIBER de Enfermedades Respiratorias (CIBERES)-University of Barcelona, Allergology and Clinical Immunology, Medical University of Silesia (SUM)-Chair and Clinical Department of Internal Diseases, UCSC-Allergy Unit, Complesso Integrato Columbus-Department of Internal Medicine and Geriatrics, Hospital da Luz, Medical Centre, Woodbrook Medical Centre, Research Fellow, University of Aberdeen-Department of General Practice, Centro Médico Docente La Trinidad, Department of Pharmacology, University College of London [London] (UCL)-The Royal National Throat, Nose and Ear Hospital, Primary Care Research & Development, University of Edinburgh-Centre for Population Health Sciences, Section of Allergy & Clinical Immunology, University of Manitoba [Winnipeg]-Department of Pediatrics & Child Health, Allergy Unit - Department of Dermatology, Julius Center for Health Sciences and Primary Care, University Medical Center [Utrecht], National Centre of Cardiology and Internal Medicine, Ministry of Health Kyrgyz Republic, School of Medicine, Pontifícia Universidade Católica, Department of ENT and Pediatrics, Finnish Institute of Occupational Health, Department of Obstetrics and Gynaecology, Université Laval [Québec] (ULaval)-Faculty of Medicine, Christian Doppler Laboratory for Allergy Research, Medizinische Universität Wien = Medical University of Vienna-Division of Immunopathology-Department of Pathophysiology and Allergy Research-Center for Pathophysiology, Infectiology and Immunology, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Department of Chest Medicine, Mont-Godinne Hospital-Catholic University of Louvain de Mont-Godinne, Department of Primary and Community Care, Radboud University Medical Center [Nijmegen], Epidemiology Unit, National Research Council (CNR)-Institute of Biomedicine and Molecular Immunology (IBIM), Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Department of Otolaryngology, National University of Singapore (NUS)-Yong Loo Lin School of Medicine, Karolinska Institutet [Stockholm]-Sachs' Children's Hospital, GLP Analytical Facility, School of Pharmacy, Department of Dermatology Division of Immunology, Allergy and Infectious Diseases (DIAID), Medical University of Vienna (MUW), Celal Bayar University School of Medicine, Allergy and Asthma Clinics, The Allergy and Asthma Institute, Department of Paediatrics and Child Health, Respiratory and Allergic Diseases, University Clinic of Respiratory and Allergic Diseases Golnik, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases-Guangzhou Medical College, Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], In collaboration with the WHO Collaborating Center for Asthma and Rhinitis, University of Genoa (UNIGE)-School of Specialization, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, University of Verona (UNIVR), Medical School-Federal University of Minas Gerais, University of Genoa (UNIGE)-Department of Internal Medicine (DIMI), University of California [Irvine] (UCI), University of California-University of California, Catholic University Rome, University of Amsterdam [Amsterdam] (UvA)-Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Centre Hospitalier de Bigorre (Tarbes)-Association Franco-Libanaise de Pneumologie (AFLP), CUF-Descobertas Hospital, Universita degli Studi di Padova-Department of Paediatrics, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Centro Medico-Docente La Trinidad, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]-Instittute of Social Health, Department of Internal Medicine (DIMI)-University of Genoa (UNIGE), Medical University of Silesia-Chair and Clinical Department of Internal Diseases, Dermatology, Internal Medicine, Immunology, Hôpital Arnaud de Villeneuve, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Center for Research in Environmental Epidemiology ( CREAL ), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Universitat Pompeu Fabra [Barcelona], WHO(OMS), Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Institute of Allergy and Infectious Diseases [Bethesda], National Institutes of Health ( NIH ), Swiss Institute of Allergy and Asthma Research ( SIAF ), University of Zürich [Zürich] ( UZH ), Upper Airway Research Laboratory ( URL ), University Medical Center, University of Oslo ( UiO ) -Oslo University Hospital, Charite-Universitatsmedizin Berlin [Berlin]-Instittute of Social Health, Medical School-Charité - University Medicine Berlin, Medical University of Warsaw-Faculté de Pharmacie de Paris, Ministry of Health, Epidémiologie des maladies infectieuses et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Center for Public Health Research ( CSISP ), University of Genoa ( UNIGE ) -School of Specialization, University of Amsterdam [Amsterdam] ( UvA ) -Academic Medical Centre, University of Southampton [Southampton]-School of Medicine, Hôpital La Rabta [Tunis), Wake Forest University Health Sciences, CNR, Rome, Italy and Department of Medicine-Second University of Naples, Università degli Studi di Verona, Université Laval-l'Hôpital Laval, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, University of Genoa ( UNIGE ) -Department of Internal Medicine (DIMI), Southern California Research, Université Montpellier 1 ( UM1 ), Nova Southeastern University, Technische Universität München [München] ( TUM ), Academic Medical Center [Amsterdam] ( AMC ), University of Amsterdam [Amsterdam] ( UvA ) -University of Amsterdam [Amsterdam] ( UvA ), University of Crete ( UOC ) -Faculty of Medicine, University of Southampton [Southampton], UUniversity College Cork - National University of Ireland, Cork (UCC), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Antoine Béclère, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], University of Groningen [Groningen]-University Medical Center Groningen-Groningen Research Institute for Asthma and COPD (GRIAC), Université Saint-Joseph de Beyrouth ( USJ ) -Faculté de Médecine-Hôtel-Dieu de France, University of Groningen [Groningen]-University Medical Center Groningen-Beatrix Children's Hospital-Groningen Research Institute for Asthma and COPD, Medical University of Łódź ( MUL ) -Faculty ot Medicine, Medical University of Łódź ( MUL ) -Barlicki University Hospital, Department of Medicine-University of Tennessee College for Medicine, Association Franco-Vietnamienne de Pneumologie ( AFVP ), University of Mississippi Medical Center, University of California [San Diego] ( UC San Diego ), Association Franco-Marocaine de Pathologie Thoracique ( AFMAPATH ), Epidémiologie Environnementale : Impact Sanitaire des Pollutions ( EA 4064 ), Université Paris Descartes - Paris 5 ( UPD5 ), Universitat de Barcelona ( UB ) -Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Department of Medicine-Hospital Clinic-ENT Department, Section of Otolaryngology-Head & Neck Surgery ( OHNS ), University of Groningen [Groningen]-University Medical Center Groningen-Department of Pathology and Medical Biology-GRIAC Research Institute, University Hospital of Kinshasa, European Federation of Allergy ( EFA ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Bioenergétique fondamentale et appliquée ( LBFA ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Department of General Practice and Primary Care-General Practice Airways Group (GPIAG)-University of Aberdeen, Association Franco-Algérienne de Pneumologie ( AFAP ), Department of General Practice-University of Aberdeen, University College of London [London] ( UCL ) -The Royal National Throat, Nose and Ear Hospital, University Medical Center Utrecht, Faculty of Medicine-Laval University [Québec], Medical University of Vienna-Division of Immunopathology-Department of Pathophysiology and Allergy Research-Center for Pathophysiology, Infectiology and Immunology, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, National University of Singapore ( NUS ) -Yong Loo Lin School of Medicine, Department of Dermatology Division of Immunology, Allergy and Infectious Diseases ( DIAID ), Secretary General of the Global Allergy and Asthma European Network ( GA2LEN ), Network of Excellence, Charité - Universitätsmedizin Berlin, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK (BIHR), Universiteit Leiden-Universiteit Leiden, and Medizinische Universität Wien = Medical University of Vienna
- Subjects
MESH: Asthma ,severity ,MESH: Comorbidity ,Comorbidity ,Severity of Illness Index ,urticaria ,MESH : Chronic Disease ,MESH: Practice Guidelines as Topic ,MESH : Dermatitis, Atopic ,MESH: Urticaria ,risk ,216-31 [Rhinitis ,atopy ,allergen Int Arch Allergy Immunol. 2012,158(3)] ,atopic dermatitis ,MESH : Rhinitis ,MESH: Rhinitis ,[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie ,Effective primary care and public health [NCEBP 7] ,Immunoglobulin E - Asthma - Rhinitis - Rhinosinusitis - Urticaria - Atopic dermatitis ,MESH : Practice Guidelines as Topic ,Practice Guidelines as Topic ,MESH : Comorbidity ,MESH : Severity of Illness Index ,IgE ,MESH: Sinusitis ,MESH : Urticaria ,MESH: Hypersensitivity ,macromolecular substances ,MESH : Asthma ,Dermatitis, Atopic ,rhinitis ,SDG 3 - Good Health and Well-being ,MESH: Dermatitis, Atopic ,MESH: Severity of Illness Index ,Hypersensitivity ,Humans ,Sinusitis ,rhinosinusitis ,MESH : Hypersensitivity ,MESH: Humans ,MESH: Chronic Disease ,MESH : Humans ,Asthma ,Atopic dermatitis ,Immunoglobulin E ,Rhinitis ,Rhinosinusitis ,Urticaria ,asthma ,allergy ,MESH : Sinusitis ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Chronic Disease ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,control - Abstract
Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies. Copyright (C) 2012 S. Karger AG, Basel
- Published
- 2012
23. Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: a Multidisciplinary Viewpoint by Portuguese Experts.
- Author
-
Fontes E Sousa M, Campainha S, Marques ID, Dinis R, Inácio JR, Mendes JJ, Luís R, Ferreira AM, Racha-Pacheco R, Rolo R, Sousa G, and Cortes P
- Abstract
Drug-induced interstitial lung disease (DI-ILD) is a significant complication in patients undergoing treatment with certain anti-cancer therapies, with incidence rates rising, particularly with newer drugs such as trastuzumab-deruxtecan, which may impact their safe and effective use. Although the exact pathophysiological mechanisms remain unknown, and different drugs may induce lung damage through different pathways, the most recognized mechanisms are cytotoxic- and immune-mediated effects. Multidisciplinary teams play a crucial role in the diagnosis, management, and prevention of DI-ILD. Given the wide variability in the onset of DI-ILD, which may occur within the first few days of treatment or months after, patient education and clinician training are essential for early detection and improved outcomes. Moreover, the diagnostic confirmation requires the exclusion of alternative causes through clinical, imaging and bronchoscopy evaluation. Treatment strategies largely depend on the grade of severity of the clinical manifestations of DI-ILD, ranging from interruption or discontinuation of the offending drug to corticosteroid therapy and hospitalization for appropriate monitoring. Nonetheless, further research is needed to better understand the impact of emerging anti-cancer drugs on DI-ILD and to establish standardized management protocols., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
- Author
-
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Kulac I, Lee MMY, Lewis GD, Ma CS, Michels M, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, and Olivotto I
- Subjects
- Humans, Male, Female, Middle Aged, Double-Blind Method, Aged, Treatment Outcome, Adult, Exercise Tolerance drug effects, Symptom Burden, Benzylamines, Uracil analogs & derivatives, Cardiomyopathy, Hypertrophic drug therapy, Cardiomyopathy, Hypertrophic complications
- Abstract
Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined., Objectives: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten., Methods: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient <30 mm Hg and <50 mm Hg, respectively), relief in limiting symptoms (≥1 improvement in NYHA functional class and/or ≥10-point change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score), enhanced exercise capacity (≥1.5 mL/kg/min change in peak oxygen uptake), and ≥50% reduction in N-terminal pro-B-type natriuretic peptide. Eligibility for septal reduction therapy was also evaluated., Results: At 24 weeks, patients treated with aficamten vs placebo showed significant improvement in limiting symptoms (71% vs 42%), were more likely to have complete hemodynamic response (68% vs 7%), demonstrated enhanced exercise capacity (47% vs 24%), and showed a decrease ≥50% in N-terminal pro-B-type natriuretic peptide (84% vs 8%) (P ≤ 0.002 for all). An improvement in ≥1 of these outcome measures was achieved in 97% of patients treated with aficamten (vs 59% placebo), including 23% on aficamten who achieved all 4 outcomes compared with none in placebo. Among 32 patients receiving aficamten and 29 patients receiving placebo who were eligible for septal reduction therapy, 28 (88%) from the aficamten group were no longer eligible at 24 weeks compared with 15 (52%) from the placebo group (P = 0.002)., Conclusions: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818)., Competing Interests: Funding Support and Author Disclosures The SEQUOIA-HCM study was funded by Cytokinetics, Incorporated. Dr Maron has received consultant/advisor fees from Imbria, Edgewise, and BioMarin; and has received steering committee fees for SEQUIOA-HCM from Cytokinetics. Dr Masri has received consultant/advisor fees from Tenaya, Attralus, Cytokinetics, Bristol Myers Squibb, and Ionis; and has received research grants from Ionis, Akcea, Pfizer, Ultromics, and the Wheeler Foundation. Dr Nassif has received research and grant support from AstraZeneca and Cytokinetics; and has received consulting/advisory fees from Vifor and Cytokinetics. Dr Barriales-Villa has received consultant/advisor fees from MyoKardia/Bristol Myers Squibb. Dr Arad has received consulting and lecture fees from Bristol Myers Squibb. Dr Cardim has received consultant/advisor fees from Cytokinetics, Bristol Myers Squibb, Pfizer, Menarini, Boehinger Ingelheim, and Bial. Dr Coats has received speaker fees from Alnylam and Roche; and has received advisor fees from Cytokinetics. Dr Düngen has received grants from Novartis, CSL Behring, and Cytokinetics. Dr Garcia-Pavia has received speakers’ bureau fees from Pfizer, AstraZeneca, Novo Nordisk, Ionis, Bridgebio, Bristol Myers Squibb, Intelllia, and Alnylam; has received consulting/advisor fees from Pfizer, Alnylam, MyoKardia/Bristol Myers Squibb, Cytokinetics, Neuroimmune, Intellia, Ionis, Bridgebio, Lexeo, Rocket, Attralus, and AstraZeneca; and has received research/educational grants to his institution from Pfizer, AstraZeneca, Novo Nordisk, BridgeBio, and Alnylam. Dr Hagège has received consulting/advisor fees from Alnylam, Amicus Therapeutics, Bayer, MyoKardia/Bristol Myers Squibb, Pfizer, and Sanofi Genzyme; and has received steering committee fees for SEQUOIA-HCM from Cytokinetics. Dr Januzzi is funded in part by the Hutter Family Professorship; is a Trustee of the American College of Cardiology; has served as a board member for Imbria Pharmaceuticals; has served as a Director at Jana Care; has received grant support from Abbott, Applied Therapeutics, HeartFlow, Innolife, and Roche Diagnostics; has received consulting fees from Abbott, Beckman, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Merck, Roche Diagnostics, and Siemens; and has participated in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, CVRx, Intercept, and Takeda. Dr Lee has received research grants through his institution from AstraZeneca, Boehringer Ingelheim, and Roche Diagnostics; has been a member of a Clinical Endpoints Committee for Bayer; and has been a member of the Trial Steering Committee for Cytokinetics. Dr Lewis has received research funding from the National Institutes of Health (R01-HL 151841, R01-HL131029, and R01-HL159514), American Heart Association (15GPSGC-24800006), Amgen, Cytokinetics, Applied Therapeutics, AstraZeneca, and SoniVie; has received honoraria for advisory boards from Pfizer, Merck, Boehringer Ingelheim, Novartis, American Regent, Cyclerion, Cytokinetics, and Amgen; and has received royalties from UpToDate for scientific content authorship related to exercise physiology. Dr Michels has received consulting/advisor fees from Bristol Myers Squibb, Cytokinetics, and Pfizer; and has received research grant funding from Bristol Myers Squibb. Dr Olivotto has received speakers’ bureau fees from Bristol Myers Squibb, Amicus, and Sanofi Genzyme; has received consulting/advisor fees from Bristol Myers Squibb, Cytokinetics, Sanofi Genzyme, Amicus, Bayer, Tenaya, Rocket Pharma, and Lexeo; and has received research grant funding from Bristol Myers Squibb, Cytokinetics, Sanofi Genzyme, Amicus, Bayer, Menarini International, Chiesi, and Boston Scientific. Dr Oreziak has received investigator fees from Cytokinetics and MyoKardia/Bristol Myers Squibb. Dr Owens has received consulting/advisor fees from Cytokinetics, Bristol Myers Squibb/MyoKardia. Dr Spertus is the principal investigator of grants from the NIH, Abbott Vascular, and the American College of Cardiology Foundation; has received consulting fees from Janssen, Novartis, Amgen, Myokardia, AstraZeneca, Bayer, and Merck; has served on the Scientific Advisory Board of United Healthcare and the Board of Directors for Blue Cross Blue Shield of Kansas City; owns the copyright to the KCCQ, SAQ, and PAQ; and has an equity interest in Health Outcomes Sciences. Dr Solomon has received consulting/advisor fees from Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, DiNAQOR, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Puretech Health; and has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI. Dr Tfelt-Hansen has received consulting fees from Leo Pharma, MicroPort, and Johnson and Johnson. Ms van Sinttruije is a patient advisory committee member and a SEQUOIA-HCM Steering Committee member for Cytokinetics. Dr Watkins has received consulting/advisor fees from Cytokinetics, BioMarin, and BridgeBio. Drs Jacoby, Heitner, Kupfer, Malik, and Meng and Ms Wohltman are employees of Cytokinetics Incorporated and hold stock in Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
- Author
-
Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, and Solomon SD
- Subjects
- Humans, Female, Male, Middle Aged, Double-Blind Method, Aged, Ventricular Function, Left drug effects, Ventricular Function, Left physiology, Stroke Volume drug effects, Stroke Volume physiology, Treatment Outcome, Benzylamines, Uracil analogs & derivatives, Cardiomyopathy, Hypertrophic drug therapy, Cardiomyopathy, Hypertrophic physiopathology, Cardiomyopathy, Hypertrophic diagnostic imaging, Echocardiography methods
- Abstract
Background: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO
2 ) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM), a phase 3, multicenter, randomized, double-blinded, placebo-controlled study., Objectives: The authors sought to evaluate the effect of aficamten on echocardiographic measures of cardiac structure and function in SEQUOIA-HCM., Methods: Serial echocardiograms were performed over 28 weeks in patients randomized to receive placebo or aficamten in up to 4 individually titrated escalating doses (5-20 mg daily) over 24 weeks based on Valsalva LVOT gradients and left ventricular ejection fraction (LVEF)., Results: Among 282 patients (mean age 59 ± 13 years; 41% female, 79% White, 19% Asian), mean LVEF was 75% ± 6% with resting and Valsalva LVOT gradients of 55 ± 30 mm Hg and 83 ± 32 mm Hg, respectively. Over 24 weeks, aficamten significantly lowered resting and Valsalva LVOT gradients, and improved left atrial volume index, lateral and septal e' velocities, and lateral and septal E/e' (all P ≤ 0.001). LV end-systolic volume increased and wall thickness decreased (all P ≤ 0.003). Aficamten resulted in a mild reversible decrease in LVEF (-4.8% [95% CI: -6.4% to -3.3%]; P < 0.001) and absolute LV global circumferential strain (-3.7% [95% CI: 1.8%-5.6%]; P < 0.0010), whereas LV global longitudinal strain was unchanged. Several measures, including LVEF, LVOT gradients, and E/e' returned to baseline following washout. Among those treated with aficamten, improved pVO2 and reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) were associated with improvement in lateral e' velocity and septal and lateral E/e' (all P < 0.03), whereas improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores (KCCQ-CSS) was associated with a decrease in both LVOT gradients (all P < 0.001)., Conclusions: Compared with placebo, patients receiving aficamten demonstrated significant improvement in LVOT gradients and measures of LV diastolic function, and several of these measures were associated with improvements in pVO2 , KCCQ-CSS, and NT-proBNP. A modest decrease in LVEF occurred yet remained within normal range. These findings suggest aficamten improved multiple structural and physiological parameters in oHCM without significant adverse changes in LV systolic function. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818)., Competing Interests: Funding Support and Author Disclosures The SEQUOIA-HCM trial is funded by Cytokinetics, Incorporated. Representatives of Cytokinetics have been involved in the design and conduct of the study reported in this paper. Study design and data analysis was supported by the funder and aided by coauthors. Manuscript drafting was completed independently but reviewed by the funder. Dr Wang is supported by a ACC/Merck Research Fellowship. Dr Hegde’s and Dr Wang’s institutions have received fees for core lab services from Cytokinetics and Bristol Myers Squibb. Dr Masri has received research grants from Pfizer, Ionis, Attralus, and Cytokinetics; and has received fees from Cytokinetics, BMS, Eidos/BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Prothena, BioMarin, AstraZeneca, and Tenaya. Dr Nassif has received research and grant support from AstraZeneca and Cytokinetics; and has received consulting/advisory fees from Vifor and Cytokinetics. Dr Barriales-Villa has received consultant/advisor fees from MyoKardia/Bristol Myers Squibb. Dr Cardim has received speaker fees from Cytokinetics and Bristol Myers Squibb. Dr Coats has received speaker fees from Alnylam and Pfizer; and has received advisory fees from Cytokinetics and Roche Diagnostics. Dr Kramer has received research grants from Cytokinetics, BMS, and Eli Lilly; and is a consultant for Eli Lilly. Dr Maron has received consultant/advisor fees from Imbria and Takeda; and has received steering committee fees for SEQUOIA-HCM from Cytokinetics, Incorporated. Dr Michels’ institution has received a research grant from Bristol Myers Squibb; has received consultant/ advisor fees from Cytokinetics and Bristol Myers Squibb/Myokardia and Alnylam; and has received speaker fees from Bristol Myers Squibb and Pfizer. Dr Olivotto has received research grants from Bristol Myers Squibb, Cytotinetics, Sanofi, Benzyme, Amicus, Bayer, Menarini International, Chiesi, and Boston Scientific; has received consulting fees from Bristol Myers Squibb, Amicus, Sanofi, and Genzyme; and has served as an Advisory Board member for Cytokinetics, Bristol Myers Squibb, Chiesi, and Rocket Pharma. Dr Saberi has received consultant/advisor fees from Bristol Myers Squibb; and has received research grants from Cytokinetics, Bristol Myers Squibb, Cytokinetics, Novartis, and Actelion Pharmaceuticals. Drs Jacoby, Heitner, Kupfer, Meng, and Malik, and Ms Wohltman are employees of and hold stock in Cytokinetics, Incorporated. Dr Solomon has received research grants from Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/Bridgebio, Gossamer, GSK, Ionis, Lilly, NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
26. Enhancing precision in hysteroscopic surgery: The role of intraoperative ultrasound.
- Author
-
Ferreira de Castro L, Santos I, Laganà AS, de Vree B, van Herendael BJ, and Djokovic D
- Subjects
- Humans, Female, Ultrasonography, Interventional methods, Pregnancy, Ultrasonography methods, Uterine Diseases surgery, Uterine Diseases diagnostic imaging, Uterus diagnostic imaging, Uterus surgery, Uterine Myomectomy methods, Hysteroscopy methods
- Abstract
Hysteroscopy stands as the gold-standard approach for managing intrauterine pathology. However, in complex clinical cases, hysteroscopic evaluation alone may prove insufficient for the safest and successful patient management. Intraoperative ultrasound (IOUS) has emerged as a valuable adjunct to hysteroscopic surgery, offering real-time visualization of endometrial cavity, uterine walls and instruments within the uterine cavity, enabling precise delineation of anatomical structures, and helping to assess the extent of pathology during intricate interventions. This review aims to comprehensively assess the applications, efficacy and utility of IOUS in hysteroscopic surgery. Available evidence indicates that in hysteroscopic myomectomy, IOUS significantly reduces the risk of uterine perforation, particularly in submucosal FIGO 2 myomas, and enhances the likelihood of a single-step procedure. During hysteroscopic metroplasty, ultrasound guidance decreases the chance of incomplete uterine septum resection. In the hysteroscopic management of severe Asherman syndrome, IOUS reduces the risk of uterine perforation or false passage. For cesarean scar pregnancy (CSP), ultrasound is crucial in defining the most appropriate surgical approach and is effective in guiding the hysteroscopic treatment of endogenic CSP. The use of IOUS in hysteroscopy proves valuable in complex cases where the risk of uterine perforation or incomplete procedure is increased., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
- Author
-
Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Vilarrasa E, Llamas-Velasco M, Alessandri-Bonetti M, Messina F, Bruni M, Di Brizzi EV, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Stratigos AJ, Nogueira M, Peris K, and Torres T
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Age Factors, Adult, Dermatologic Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Psoriasis drug therapy, Interleukin-17 antagonists & inhibitors, Interleukin-23 antagonists & inhibitors
- Abstract
Background: Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available., Objectives: To evaluate the drug survival of interleukin (IL)-23 or the IL-17 inhibitors approved for the treatment of moderate-to-severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival., Methods: This retrospective multicentric cohort study included adult patients with moderate-to-severe psoriasis, dissecting two-patient subcohorts based on age: elderly versus younger adults. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis., Results: We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log-rank p < 0.006). This difference was significant for treatment courses involving IL-23 inhibitors (p < 0.001) but not for those with IL-17 inhibitors (p = 0.2). According to both uni- and multi-variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062-1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010-1.422; p = 0.0377). Anti-IL-23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368-0.735; p < 0.001). Being previously treated with IL-17 inhibitors increased the probability of discontinuation., Conclusions: Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors., (© 2024 European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
28. Recommendations for the implementation of a national lung cancer screening program in Portugal-A consensus statement.
- Author
-
Fernandes MGO, Dias M, Santos R, Ravara S, Fernandes P, Firmino-Machado J, Antunes JP, Fernandes O, Madureira A, Hespanhol V, Rodrigues C, Vicente CA, Alves S, Mendes G, Ilgenfritz R, Pinto BS, Alves J, Saraiva I, Bárbara C, Cipriano MA, Figueiredo A, Uva MS, Jacinto N, Curvo-Semedo L, and Morais A
- Subjects
- Humans, Portugal epidemiology, Mass Screening methods, Consensus, Smoking Cessation, Lung Neoplasms diagnosis, Lung Neoplasms diagnostic imaging, Early Detection of Cancer methods, Early Detection of Cancer standards, Tomography, X-Ray Computed methods
- Abstract
Lung cancer (LC) is a leading cause of cancer-related mortality worldwide. Lung Cancer Screening (LCS) programs that use low-dose computed tomography (LDCT) have been shown to reduce LC mortality by up to 25 % and are considered cost-effective. The European Health Union has encouraged its Member States to explore the feasibility of LCS implementation in their respective countries. The task force conducted a comprehensive literature review and engaged in extensive discussions to provide recommendations. These recommendations encompass the essential components required to initiate pilot LCS programs following the guidelines established by the World Health Organization. They were tailored to align with the specific context of the Portuguese healthcare system. The document addresses critical aspects, including the eligible population, methods for issuing invitations, radiological prerequisites, procedures for reporting results, referral processes, diagnostic strategies, program implementation, and ongoing monitoring. Furthermore, the task force emphasized that pairing LCS with evidence-based smoking cessation should be the standard of care for a high-quality screening program. This document also identifies areas for further research. These recommendations aim to guarantee that the implementation of a Portuguese LCS program ensures high-quality standards, consistency, and uniformity across centres., Competing Interests: Declaration of competing interest The authors have no conflicts of interest., (Copyright © 2024 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. World Heart Federation Cholesterol Roadmap: The Portuguese case.
- Author
-
Abreu A, Dores H, Gonçalves L, Franco F, Silveira C, Proença G, Teresa Timóteo A, Cardim N, Pedro M, Fiuza M, Ferreira D, Bento L, Patrício L, Caldeira D, Bravo Baptista S, Santos J, Rocha E, Raimundo A, Catarino C, Carrageta M, Mexia R, Araújo F, Pereira H, Santos R, and Pinto FJ
- Subjects
- Humans, Portugal, Cholesterol blood, Cardiovascular Diseases prevention & control
- Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the major cause of premature death and disability; effective cardiovascular (CV) risk prevention is fundamental. The World Heart Federation (WHF) Cholesterol Roadmap provides a framework for national policy development and aims to achieve ASCVD prevention. At the invitation of the WHF, a group of experts from the Portuguese Society of Cardiology (SPC), addressed the cholesterol burden at nationally and discussed possible strategies to include in a Portuguese cholesterol roadmap. The literature review showed that the cholesterol burden in Portugal is high and especially uncontrolled in those with the highest CV risk. An infographic scorecard was built to include in the WHF collection, for a clear idea about CV risk and cholesterol burden in Portugal, which would also be useful for health policy advocacy. The expert discussion and preventive strategies proposal followed the five pillars of the WHF document: awareness improvement; population-based approaches for CV risk and cholesterol; risk assessment/population screening; system-level approaches; surveillance of cholesterol and ASCVD outcomes. These strategies were debated by all the expert participants, with the goal of creating a national cholesterol roadmap to be used for advocacy and as a guide for CV prevention. Several key recommendations were outlined: include all stakeholders in a multidisciplinary national program; create a structured activities plan to increase awareness in the population; improve the quality of continuous CV health education; increase the interaction between different health professionals and non-health professionals; increment the referral of patients to cardiac rehabilitation; screen cholesterol levels in the general population, especially high-risk groups; promote patient self-care, engage with patients' associations; use specific social networks to spread information widely; create a national database of cholesterol levels with systematic registry of CV events; redefine strategies based on the evaluation of results; create and involve more patients' associations - invert the pyramid order. In conclusion, ASCVD and the cholesterol burden remain a strong global issue in Portugal, requiring the involvement of multiple stakeholders in prevention. The Portuguese cholesterol roadmap can provide some solutions to help urgently mitigate the problem. Population-based approaches to improve awareness and CV risk assessment and surveillance of cholesterol and ASCVD outcomes are key factors in this change. A call to action is clearly needed to fight hypercholesterolemia and ASCVD burden., (Copyright © 2024. Publicado por Elsevier España, S.L.U.)
- Published
- 2024
- Full Text
- View/download PDF
30. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
- Author
-
Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, and Irvine AD
- Abstract
Importance: The Measure Up 1, Measure Up 2, and AD Up studies demonstrated the efficacy and adverse events of upadacitinib through 52 weeks in adults and adolescents with atopic dermatitis (AD); however, longer-term outcomes (longer than 1 year) in adolescents have not previously been available., Objective: To evaluate the efficacy and adverse events of upadacitinib in adolescent patients with moderate to severe AD through 76 weeks., Design, Setting, and Participants: The Measure Up 1, Measure Up 2, and AD Up trials are ongoing double-blind, placebo-controlled phase 3 randomized clinical trials including adolescents (aged 12 to 17 years) with moderate to severe AD. Data were collected from August 2018 to April 2022, and data were analyzed from June 2022 to September 2023., Interventions: Adolescents were randomized 1:1:1 to receive once-daily oral upadacitinib, 15 mg; upadacitinib, 30 mg; or placebo, either alone (Measure Up 1 and Measure Up 2 trials) or with topical corticosteroids (AD Up). At week 16, placebo-treated patients were rerandomized to receive upadacitinib, 15 mg, or upadacitinib, 30 mg, daily., Main Outcomes and Measures: Coprimary end points assessing efficacy included achievement of 75% reduction or more in the Eczema Area and Severity Index Score (EASI-75) from baseline, Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear (0) or almost clear (1) with 2 grades or more of improvement, and Worst Pruritus Numerical Rating Scale (WP-NRS) improvement of 4 points or greater through week 76 for participants with a WP-NRS score of 4 points or higher at baseline., Results: From all studies, 542 adolescents were included; of these, 284 (52.4%) were female. At week 76, among patients in the Measure Up 1, Measure Up 2, and AD Up trials, EASI-75 was achieved by 89.1%, 84.4%, and 87.8% of adolescents taking upadacitinib, 15 mg, respectively, and by 96.1%, 93.6%, and 82.7% of adolescents taking upadacitinib, 30 mg, indicating maintenance or improvement of EASI-75 across 76 weeks with upadacitinib. Efficacy measured by achievement of vIGA-AD score of 0 or 1 and WP-NRS improvement of 4 points or more from baseline was similarly maintained or improved through week 76 for adolescents taking upadacitinib, 15 mg or 30 mg. Long-term outcomes in Measure Up 1, Measure Up 2, and AD Up participants were consistent with the known adverse event profile of upadacitinib (herpetic infection: 4.0, 1.9, and 1.1 events per 100 patient-years, respectively; creatine kinase elevation: 11.6, 11.0, and 7.1 events per 100 patient-years); no new signals were observed with either dose., Conclusions and Relevance: In this study assessing 3 randomized clinical trials, long-term treatment of adolescents with moderate to severe AD with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks., Trial Registrations: Measure Up 1 trial: ClinicalTrials.gov Identifier: NCT03569293; Measure Up 2 trial: NCT03607422; AD Up trial: NCT03568318.
- Published
- 2024
- Full Text
- View/download PDF
31. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up).
- Author
-
Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, and Eyerich K
- Abstract
Background: Atopic dermatitis (AD) is a chronic skin disease characterized by intense itch and eczematous skin lesions. Some patients continue to experience flares and substantial clinical burden despite ongoing systemic treatment., Objectives: This study assessed the efficacy and safety of once-daily upadacitinib (UPA), initiated at 15 mg and dose-escalated to 30 mg based on clinical response, compared with dupilumab (DUPI) per its label. Week 16 primary analysis results are presented., Methods: Level Up is a phase 3b/4 global, randomized, open-label, efficacy assessor blinded study evaluating UPA vs DUPI in adolescents and adults with moderate-to-severe AD who had inadequate response to systemic therapy or when use was inadvisable. Patients were randomized to UPA or DUPI for 16 weeks of treatment (Period 1). Patients on UPA started on 15 mg and were dose-escalated to 30 mg if they did not achieve an Eczema Area and Severity Index reduction of at least 50% (EASI 50) or a ≥4-point Worst Pruritus Numerical Rating Scale (WP-NRS) improvement on/after Week 4, or EASI 75 on/after Week 8. The primary endpoint was simultaneous achievement of EASI 90 and WP-NRS 0/1 at Week 16. Ranked secondary endpoints included skin and itch responses at varying response levels and timepoints. Safety measures were assessed throughout the study., Results: Superior efficacy in achieving simultaneous EASI 90 and WP-NRS 0/1 response at Week 16 was demonstrated with UPA vs DUPI (19.9% vs 8.9%, respectively; p<0.0001). UPA showed superiority vs DUPI for all ranked secondary endpoints, with post-hoc analyses exhibiting higher itch response rates as early as Day 2. No new safety signals were identified during this period., Conclusion: Treatment of moderate-to-severe AD with UPA, initiated at 15 mg and dose escalated based on clinical response, demonstrated superiority vs DUPI per its label for the primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and little to no itch (WP-NRS 0/1) at Week 16, with all ranked secondary endpoints demonstrating superiority at varying skin and itch response levels and timepoints. There were no new safety signals identified compared to the previously reported safety profiles of UPA and DUPI., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.)
- Published
- 2024
- Full Text
- View/download PDF
32. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
- Author
-
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, and Passaro A
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Injections, Subcutaneous, Aged, 80 and over, Mutation, Acrylamides administration & dosage, Progression-Free Survival, Administration, Intravenous, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung mortality, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms mortality, Lung Neoplasms pathology, ErbB Receptors genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols adverse effects
- Abstract
Purpose: Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor ( EGFR )-mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy., Patients and Methods: Patients with EGFR -mutated advanced NSCLC who progressed after osimertinib and platinum-based chemotherapy were randomly assigned 1:1 to receive subcutaneous or intravenous amivantamab, both combined with lazertinib. Coprimary pharmacokinetic noninferiority end points were trough concentrations (C
trough ; on cycle-2-day-1 or cycle-4-day-1) and cycle-2 area under the curve (AUCD1-D15 ). Key secondary end points were objective response rate (ORR) and progression-free survival (PFS). Overall survival (OS) was a predefined exploratory end point., Results: Overall, 418 patients underwent random assignment (subcutaneous group, n = 206; intravenous group, n = 212). Geometric mean ratios of Ctrough for subcutaneous to intravenous amivantamab were 1.15 (90% CI, 1.04 to 1.26) at cycle-2-day-1 and 1.42 (90% CI, 1.27 to 1.61) at cycle-4-day-1; the cycle-2 AUCD1-D15 was 1.03 (90% CI, 0.98 to 1.09). ORR was 30% in the subcutaneous and 33% in the intravenous group; median PFS was 6.1 and 4.3 months, respectively. OS was significantly longer in the subcutaneous versus intravenous group (hazard ratio for death, 0.62; 95% CI, 0.42 to 0.92; nominal P = .02). Fewer patients in the subcutaneous group experienced infusion-related reactions (IRRs; 13% v 66%) and venous thromboembolism (9% v 14%) versus the intravenous group. Median administration time for the first infusion was reduced to 4.8 minutes (range, 0-18) for subcutaneous amivantamab and to 5 hours (range, 0.2-9.9) for intravenous amivantamab. During cycle-1-day-1, 85% and 52% of patients in the subcutaneous and intravenous groups, respectively, considered treatment convenient; the end-of-treatment rates were 85% and 35%, respectively., Conclusion: Subcutaneous amivantamab-lazertinib demonstrated noninferiority to intravenous amivantamab-lazertinib, offering a consistent safety profile with reduced IRRs, increased convenience, and prolonged survival.- Published
- 2024
- Full Text
- View/download PDF
33. Functional evaluation after cortical button fixation for distal biceps ruptures - Is there any difference between manual or non-manual workers?
- Author
-
Batista A, Moura N, Sarmento M, Coelho T, Gomes D, Ramos R, and Cartucho A
- Abstract
Background: This study aims to compare clinical and functional results after distal biceps tendon repair in manual workers vs. non-manual workers., Methods: This is a retrospective comparative study which refers to 57 cases with distal biceps tendon rupture, divided in manual workers (24 elbows) and non-manual workers (33), that were treated by a single incision with cortical button and interference screw fixation. Included cases have a minimum of 3 months follow-up, post-operative X-ray and signed informed consent for the investigation., Results: Supination and flexion strength was higher in manual workers vs. non-manual workers (p-value=0.192 and 0.878, respectively). Nine patients showed loss of range of motion, concerning supination and pronation, and this was correlated to worse functional scores. Functional scores tend to be superior in non-manual workers. Ten patients had heterotopic ossification and 20 patients reported lateral antebrachial cutaneous nerve neuropraxia; one had both. Most of them had a full recovery., Conclusion: According to clinical evaluation and post-operative scores, the performed surgical procedure provides good to excellent mid-term functional results. Nevertheless, there were not any differences between manual or non-manual workers., (Copyright © 2024 SECOT. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
34. [Correction to the Article "Recommendations for Reducing the Environmental Impact of Inhalers in Portugal: Consensus Document", Published on Acta Med Port 2024 Sep;37(9):654-661].
- Author
-
Campos LS, Rosa P, Carreiro Martins P, Xavier B, Leuschner P, M Marques MI, Albino J, and Robalo Cordeiro C
- Published
- 2024
- Full Text
- View/download PDF
35. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX model: Portuguese multicenter study.
- Author
-
Borges AL, Brito M, Ambrósio P, Condeço R, Pinto P, Ambrósio B, Mahomed F, Gama JMR, Bernardo MJ, Gouveia AI, and Djokovic D
- Subjects
- Humans, Female, Portugal, Retrospective Studies, Prospective Studies, Middle Aged, Adult, Sensitivity and Specificity, Aged, CA-125 Antigen blood, ROC Curve, Logistic Models, Predictive Value of Tests, Reproducibility of Results, Diagnosis, Differential, Adnexal Diseases diagnostic imaging, Ultrasonography methods, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms pathology, Ovarian Neoplasms classification, Ovarian Neoplasms blood
- Abstract
Objectives: To externally and prospectively validate the International Ovarian Tumor Analysis (IOTA) Simple Rules (SRs), Logistic Regression model 2 (LR2) and Assessment of Different NEoplasias in the adneXa (ADNEX) model in a Portuguese population, comparing these approaches with subjective assessment and the risk-of-malignancy index (RMI), as well as with each other. This study also aimed to retrospectively validate the IOTA two-step strategy, using modified benign simple descriptors (MBDs) followed by the ADNEX model in cases in which MBDs were not applicable., Methods: This was a prospective multicenter diagnostic accuracy study conducted between January 2016 and December 2021 of consecutive patients with an ultrasound diagnosis of at least one adnexal tumor, who underwent surgery at one of three tertiary referral centers in Lisbon, Portugal. All ultrasound assessments were performed by Level-II or -III sonologists with IOTA certification. Patient clinical data and serum CA 125 levels were collected from hospital databases. Each adnexal mass was classified as benign or malignant using subjective assessment, RMI, IOTA SRs, LR2 and the ADNEX model (with and without CA 125). The reference standard was histopathological diagnosis. In the second phase, all adnexal tumors were classified retrospectively using the two-step strategy (MBDs + ADNEX). Sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios and overall accuracy were determined for all methods. Receiver-operating-characteristics curves were constructed and corresponding areas under the curve (AUC) were determined for RMI, LR2, the ADNEX model and the two-step strategy. The ADNEX model calibration plots were constructed using locally estimated scatterplot smoothing (LOESS)., Results: Of the 571 patients included in the study, 428 had benign disease and 143 had malignant disease (prevalence of malignancy, 25.0%), of which 42 had borderline ovarian tumor, 93 had primary invasive adnexal cancer and eight had metastatic tumors in the adnexa. Subjective assessment had an overall sensitivity of 97.9% and a specificity of 83.6% for distinguishing between benign and malignant lesions. RMI showed high specificity (95.6%) but very low sensitivity (58.7%), with an AUC of 0.913. The IOTA SRs were applicable in 80.0% of patients, with a sensitivity of 94.8% and specificity of 98.6%. The IOTA LR2 had a sensitivity of 84.6%, specificity of 86.9% and an AUC of 0.939, at a malignancy risk cut-off of 10%. At the same cut-off, the sensitivity, specificity and AUC for the ADNEX model with vs without CA 125 were 95.8% vs 98.6%, 82.5% vs 79.7% and 0.962 vs 0.960, respectively. The ADNEX model gave heterogeneous results for distinguishing between benign masses and different subtypes of malignancy, with the highest AUC (0.991) for discriminating benign masses from primary invasive adnexal cancer Stages II-IV, and the lowest AUC (0.696) for discriminating primary invasive adnexal cancer Stage I from metastatic lesion in the adnexa. The calibration plot suggested underestimation of the risk by the ADNEX model compared with the observed proportion of malignancy. The MBDs were applicable in 26.3% (150/571) of cases, of which none was malignant. The two-step strategy using the ADNEX model in the second step only, with and without CA 125, had AUCs of 0.964 and 0.961, respectively, which was similar to applying the ADNEX model in all patients., Conclusions: The IOTA methods showed good-to-excellent performance in the Portuguese population, outperforming RMI. The ADNEX model was superior to other methods in terms of accuracy, but interpretation of its ability to distinguish between malignant subtypes was limited by sample size and large differences in the prevalence of tumor subtypes. The IOTA MBDs are reliable in identifying benign disease. The two-step strategy comprising application of MBDs followed by the ADNEX model if MBDs are not applicable, is suitable for daily clinical practice, circumventing the need to calculate the risk of malignancy in all patients. © 2024 International Society of Ultrasound in Obstetrics and Gynecology., (© 2024 International Society of Ultrasound in Obstetrics and Gynecology.)
- Published
- 2024
- Full Text
- View/download PDF
36. Changing human hair fibre colour and shape from the follicle.
- Author
-
Matamá T, Costa C, Fernandes B, Araújo R, Cruz CF, Tortosa F, Sheeba CJ, Becker JD, Gomes A, and Cavaco-Paulo A
- Subjects
- Humans, Adult, Female, Male, Cosmetics, Transcriptome, Middle Aged, Scalp, Prospective Studies, Hair Follicle metabolism, Hair Color genetics, Hair
- Abstract
Introduction: Natural hair curvature and colour are genetically determined human traits, that we intentionally change by applying thermal and chemical treatments to the fibre. Presently, those cosmetic methodologies act externally and their recurrent use is quite detrimental to hair fibre quality and even to our health., Objectives: This work represents a disruptive concept to modify natural hair colour and curvature. We aim to model the fibre phenotype as it is actively produced in the follicle through the topical delivery of specific bioactive molecules to the scalp., Methods: Transcriptome differences between curly and straight hairs were identified by microarray. In scalp samples, the most variable transcripts were mapped by in situ hybridization. Then, by using appropriate cellular models, we screened a chemical library of 1200 generic drugs, searching for molecules that could lead to changes in either fibre colour or curvature. A pilot-scale, single-centre, investigator-initiated, prospective, blind, bilateral (split-scalp) placebo-controlled clinical study with the intervention of cosmetics was conducted to obtain a proof of concept (RNEC n.92938)., Results: We found 85 genes transcribed significantly different between curly and straight hair, not previously associated with this human trait. Next, we mapped some of the most variable genes to the inner root sheath of follicles, reinforcing the role of this cell layer in fibre shape moulding. From the drug library screening, we selected 3 and 4 hits as modulators of melanin synthesis and gene transcription, respectively, to be further tested in 33 volunteers. The intentional specific hair change occurred: 8 of 14 volunteers exhibited colour changes, and 16 of 19 volunteers presented curvature modifications, by the end of the study., Conclusion: The promising results obtained are the first step towards future cosmetics, complementary or alternative to current methodologies, taking hair styling to a new level: changing hair from the inside out., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [The authors Artur Cavaco-Paulo, Teresa Matamá, Cristiana Chaves and Bruno Fernandes are inventors of the international patent application WO 2021/260667 A2, “Composition of hair follicle modulation, methods and uses thereof”, published on 30 December 2021. Artur Cavaco-Paulo is the co-founder of SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd, born as a spin-off company of the University of Minho, where he holds the position of CSO. The other authors declare no other competing interests]., (Copyright © 2024. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
37. Which stakeholders should be addressed to promote Geriatric Medicine among healthcare professionals, educationalists and policy-makers in European countries? - the PROGRAMMING COST 21,122 action experience.
- Author
-
Savas S, Demiral Yilmaz N, Kotsani M, Piotrowicz K, and Duque S
- Subjects
- Humans, Europe, Administrative Personnel, Female, Aged, Male, Stakeholder Participation, Geriatrics education, Health Personnel education
- Abstract
Background: Geriatric Medicine (GM), concerned with well-being and health of older adults, can play a crucial role in the alignment of healthcare systems to the needs of the aged populations. However, countries have varying GM development backgrounds. The goal of PROGRAMMING- COST 21,122 Action is to propose the content of education and training activities in GM for healthcare professionals across various clinical settings, adapted to local context, needs, and assets. Defining relevant stakeholders and addressing them on both an international as well as a country-specific level is crucial for this purpose. In this paper we are describing the methods used in the PROGRAMMING Action 21,122 to map the different categories of stakeholders to be engaged in the Action., Methods: Through conceptualizing a model for stakeholders by literature research, and online discussion group meetings, a synthesis for the potential stakeholders was defined as a template, and pilot applications were requested from participant countries., Results: There were 24 members from 14 countries (6 males/18 females) of multidisciplinary professions involved in this study. A model for the list of stakeholders to be addressed was developed and, after seven online discussion meetings, a consensus framework was provided. Invited countries completed the templates to pilot such operationalization., Conclusion: Our framework of stakeholders will support the research coordination and capacity-building objectives of PROGRAMMING, including the participation into the assessment of educational needs of healthcare professionals. Identified stakeholders will also be mobilized for purposes of dissemination and maximization of the Action's impact. By defining and mapping multidisciplinary stakeholders involved in older people's care specific to countries, particularly where GM is still emerging, GM tailored educational activities will be facilitated and optimally targeted., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
38. Is there a place for dorsal hemiepiphysiodesis of the first metatarsal in the treatment of pes cavovarus?
- Author
-
Domingues LS, Norte S, Thusing M, and Neves MC
- Abstract
The objective of this study is to describe and evaluate dorsal hemiepiphysodesis of the first metatarsal as an osteotomy replacement technique. Retrospective analysis of patients with pes cavovarus (PCV) treated in our center with dorsal hemiepiphysodesis of the first metatarsal. Meary's angle, calcaneal pitch, and Moreau Costa Bartani were compared pre and post-operatively and the ratio between width and foot length was monitored. Between May 2012 and May 2022, eight patients (14 feet) with PCV underwent dorsal hemiepiphysiodesis of the first metatarsal combined with the Steindler procedure. Four patients (50%) were male. The average age for boys at surgery was 10.75 years (10-11) and for girls was 9.75 years (8-11). Most patients (87.5%) had idiopathic PCV and 12.5% had a neurological PCV. Median follow-up was 4.3 years (1.5-10) and a benefit was seen in all patients in Moreau Costa Bartani angle (112.64° vs. 120.59°; P value = 0.003), calcaneal pitch (26.48° vs. 25.36°; P value = 0.091) and Meary's angle (10.60° vs. 5.36°; P value = 0.008) after surgery. Supination improvement was also shown (0.21 vs. 0.24; P value = 0.039). Despite the limited number of patients, the results demonstrated that dorsal hemiepiphysiodesis of the first metatarsal can be a valid alternative to osteotomy of the base of the first metatarsal, with less morbidity and a gradual and dynamic correction throughout growth., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
39. Editorial: Patients-oriented treatments for chronic inflammatory skin diseases.
- Author
-
Mastorino L, Ribero S, Burlando M, and Mendes-Bastos P
- Abstract
Competing Interests: LM declare to have acted as speakers and/or consultants for Almirall, LeoPharma, AbbVie, PM-B has received honoraria for acting as a consultant and/or as a speaker for AbbVie, Pfizer, Janssen-Cilag, Leo-Pharma, Novartis, Eli-Lilly, Sanofi, Regeneron, Teva, L'Oreal, Pierre Fabre, Cantabria Labs, Bayer, Viatris, Organon, Evelo Biosciences, and CS Labs; he has also worked as a Principal Investigator in Clinical Trials supported by AbbVie, Amgen, Biogen, Janssen, Pfizer, Novartis, and Sanofi. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
- Published
- 2024
- Full Text
- View/download PDF
40. [Recommendations for Reducing the Environmental Impact of Inhalers in Portugal: Consensus Document].
- Author
-
Campos LS, Rosa P, Carreiro Martins P, Xavier B, Leuschner P, M Marques MI, Albino J, and Robalo Cordeiro C
- Subjects
- Portugal, Humans, Environment, Metered Dose Inhalers, Carbon Footprint, Nebulizers and Vaporizers
- Abstract
This consensus document addresses the reduction of the environmental impact of inhalers in Portugal. It was prepared by the Portuguese Council for Health and the Environment and the societies representing the specialties that account for these drugs' largest volume of prescriptions, namely the Portuguese Society of Pulmonology, the Portuguese Society of Allergology and Clinical Immunology, the Portuguese Society of Pediatrics, the Portuguese Society of Internal Medicine, the Portuguese Association of General and Family Medicine and also a patient association, the Respira Association. The document acknowledges the significant impact of pressurized metered-dose inhalers on greenhouse gas emissions and highlights the need to transition to more sustainable alternatives. The carbon footprint of pressurized metered-dose inhalers and dry powder inhalers in Portugal was calculated, and the level of awareness among prescribing physicians on this topic was also estimated. Finally, recommendations were developed to accelerate the reduction of the ecological footprint of inhalers.
- Published
- 2024
- Full Text
- View/download PDF
41. Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine.
- Author
-
Froes F, Timóteo A, Almeida B, Raposo JF, Oliveira J, Carrageta M, Duque S, and Morais A
- Subjects
- Aged, Aged, 80 and over, Humans, Chronic Disease, Geriatrics standards, Portugal, Pulmonary Medicine standards, Societies, Medical standards, Influenza Vaccines administration & dosage, Influenza Vaccines adverse effects, Influenza, Human prevention & control, Vaccination standards
- Abstract
Influenza affects millions of people worldwide each year and can lead to severe complications, hospitalizations, and even death, especially among vulnerable populations such as older adults and those with chronic medical conditions. Annual vaccination is considered the most effective measure for preventing influenza and its complications. Despite the widespread availability of influenza vaccines, however, vaccination coverage rates remain suboptimal in several countries. Based on the latest scientific evidence and expert opinions on influenza vaccination in older people and patients with chronic disease, the Portuguese Society of Pulmonology (SPP), the Portuguese Society of Diabetology (SPD), the Portuguese Society of Cardiology (SPC), the Portuguese Society of Geriatrics and Gerontology (SPGG), the Study Group of Geriatrics of the Portuguese Society of Internal Medicine (NEGERMI-SPMI), and the Portuguese Society of Infectious Diseases and Clinical Microbiology (SPDIMC) discussed best practices for promoting vaccination uptake and coverage and drew up several recommendations to mitigate the impact of influenza. These recommendations focus on the efficacy and safety of available vaccines; the impact of influenza vaccination on older adults; patients with chronic medical conditions, namely cardiac and respiratory conditions, diabetes, and immunosuppressive diseases; and health care professionals, optimal vaccination timing, and strategies to increase vaccination uptake and coverage. The resulting position paper highlights the critical role that vaccinations play in promoting public health, raising awareness, and encouraging more people to get vaccinated., Competing Interests: Conflicts of interest FF received personal fees and non-financial support from Sanofi, MSD, AstraZeneca and GSK. AT has no interests to declare. BA received lecture fees and honoraria from Lilly, Boehringer Ingelheim, Menarini Diagnostic, Roche Diagnostic, Sanofi and Novonordisk. JFR received personal fees from Sanofi JO received lecture and scientific consultancy fees from Gilead Sciences, Sanofi Portugal, MSD and Viiv HealthCare SD received lecture fees and honoraria from Sanofi, GSK and Pfizer. MC received personal fees from GKS, Ferrer, Sanofi and Tecnimede. AM received personal fees and non-financial support from Boheringer Ingelheim, Sanofi, MSD, AstraZeneca and Bial., (Copyright © 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. The balance between thrombosis and bleeding after mitral valve surgery: The need for robust evidence.
- Author
-
Azevedo Guerreiro R
- Subjects
- Humans, Postoperative Complications etiology, Postoperative Hemorrhage etiology, Cardiac Surgical Procedures adverse effects, Mitral Valve surgery, Thrombosis etiology
- Published
- 2024
- Full Text
- View/download PDF
43. Allergic contact dermatitis to sodium metabisulphite in a rotigotine transdermal therapeutic system.
- Author
-
Antunes-Duarte S, Sun L, Sousa D, and Alpalhão M
- Published
- 2024
- Full Text
- View/download PDF
44. Therapeutical Usefulness of PD-1/PD-L1 Inhibitors in Aggressive or Metastatic Pituitary Tumours.
- Author
-
Lopes-Pinto M, Lacerda-Nobre E, Silva AL, and Marques P
- Abstract
Therapeutic options for pituitary neuroendocrine tumours (PitNETs) refractory to temozolomide are scarce. Immune checkpoint inhibitors (ICIs), particularly inhibitors of the programmed cell death-1 (PD-1) pathway and its ligand (PD-L1), have been experimentally used in aggressive or metastatic PitNETs. We aimed to study the therapeutic usefulness of anti-PD-1 drugs in patients with aggressive or metastatic PitNETs. Published cases and case series involving patients with PitNETs treated with PD-1/PD-L1 inhibitors were reviewed. Demographic data, clinical-pathological features, previous therapies, drug dosage and posology, and the best radiological and biochemical responses, as well as survival data, were evaluated. We identified 29 cases of aggressive ( n = 13) or metastatic ( n = 16) PitNETs treated with PD-1/PD-L1 inhibitors. The hypersecretion of adrenocorticotropic hormone (ACTH) was documented in eighteen cases (62.1%), seven were prolactinomas (24.1%), and four were non-functioning PitNETs. All patients underwent various therapies prior to using ICIs. Overall, a positive radiological response (i.e., partial/complete radiological response and stable disease) was observed in eighteen of twenty-nine cases (62.1%), of which ten and four were ACTH- and prolactin-secreting PitNETs, respectively. Hormonal levels reduced or stabilised after using ICIs in 11 of the 17 functioning PitNET cases with available data (64.7%). The median survival of patients treated with ICIs was 13 months, with a maximum of 42 months in two ACTH-secreting tumours. Among 29 patients with PitNETs treated with PD-1/PD-L1 inhibitors, the positive radiological and biochemical response rates were 62.1% and 64.7%, respectively. Altogether, these data suggest a promising role of ICIs in patients with aggressive or metastatic PitNETs refractory to other treatment modalities.
- Published
- 2024
- Full Text
- View/download PDF
45. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
- Author
-
Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, and Abraham TP
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Double-Blind Method, Dose-Response Relationship, Drug, Adult, Atrial Fibrillation drug therapy, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Benzylamines, Uracil analogs & derivatives, Cardiomyopathy, Hypertrophic physiopathology, Cardiomyopathy, Hypertrophic drug therapy, Cardiomyopathy, Hypertrophic diagnosis, Ventricular Function, Left drug effects, Stroke Volume drug effects
- Abstract
Background: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM)., Methods and Results: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5-20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site-interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8-24), and washout (weeks 24-28), and included major adverse cardiac events, new-onset atrial fibrillation, implantable cardioverter-defibrillator discharges, LVEF <50%, and treatment-emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5-, 10-, 15-, and 20-mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by -0.9% (95% CI, -1.3 to -0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per-protocol dose reduction for site-interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment-emergent adverse events were similar between treatment groups, including atrial fibrillation., Conclusions: A site-based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA-HCM., Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05186818.
- Published
- 2024
- Full Text
- View/download PDF
46. Hypertrophic cardiomyopathy: Paradigm shifts in the last 30 years (Part 2).
- Author
-
Cardim N
- Subjects
- Humans, Time Factors, Cardiomyopathy, Hypertrophic history
- Published
- 2024
- Full Text
- View/download PDF
47. Pembrolizumab-Induced Ketoacidosis: A Case Report.
- Author
-
Guimarães F, Polishchuk N, and Almeida Martins C
- Abstract
Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have transformed immuno-oncology by demonstrating efficacy against various cancers, including small-cell lung carcinoma and HER2-positive gastric cancer. Despite their benefits, ICIs can provoke immune-related adverse events, with endocrinopathies being rare but carrying significant complications. We report a case of pembrolizumab-induced diabetic ketoacidosis (DKA) in an 87-year-old woman with advanced gastric carcinoma and no prior diabetes history. The patient presented with acute hyperglycemia and metabolic acidosis and was found to have low C-peptide levels without other autoimmune markers typically associated with type 1 diabetes. This case highlights the need for awareness of pembrolizumab as a potential trigger for DKA, especially in patients without a prior diabetes diagnosis. While the management of DKA remains the same, identifying the precipitating factor allows for a comprehensive diagnostic workup and effective long-term management, maintaining the patient's quality of life. This case highlights the complexities of managing DKA in ICI therapy and illustrates the importance of distinguishing between classical DKA presentations and those related to ICIs., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Guimarães et al.)
- Published
- 2024
- Full Text
- View/download PDF
48. The Knowledge Acquired by Parents in Pregnancy Monitoring Consultations.
- Author
-
Cerdeira R and Zangão O
- Subjects
- Humans, Female, Pregnancy, Cross-Sectional Studies, Adult, Male, Surveys and Questionnaires, Referral and Consultation, COVID-19, Parents psychology, Health Knowledge, Attitudes, Practice
- Abstract
(1) Pregnancy surveillance nursing consultations in the pandemic context have undergone some changes, namely the restriction of accompanying persons. In this sense, assessing the knowledge acquired by parents in pregnancy surveillance is of great importance. Since there are no studies on the subject in the period before the pandemic, we will only assess the knowledge acquired by parents in pregnancy monitoring. (2) For this reason, the aim of our study is to evaluate the knowledge acquired by parents in pregnancy surveillance. (3) This study is descriptive, cross-sectional and quantitative in nature, with a sample of 196 couples. A questionnaire was administered about the knowledge acquired by parents in pregnancy surveillance nursing consultations. (4) Pregnant mothers and their partners reported having some knowledge. The classification was assessed using a questionnaire with quantifiable response options from 1 to 5 points. Items with a score of 1 indicate a low level of knowledge and 5 indicates a higher level of knowledge. (5) We can verify that the level of knowledge acquired by the pregnant mother during the pregnancy surveillance nursing consultation is higher than the level of knowledge acquired by the father during the same consultation. Most parents consider it important to receive information through the pregnancy surveillance nursing consultations carried out by Maternal and Obstetric Health Nurse Specialists (midwives).
- Published
- 2024
- Full Text
- View/download PDF
49. An international delphi survey and consensus meeting to define the risk factors for ureteral stricture after endoscopic treatment for urolithiasis.
- Author
-
Moretto S, Saita A, Scoffone CM, Talso M, Somani BK, Traxer O, Angerri O, Liatsikos E, Ulvik Y, Cracco CM, Keller EX, Pietropaolo A, Tailly T, Corrales M, De Coninck V, Nagele U, Ferretti S, Kronenberg P, Carmignani L, Osther PJ, Goumas IK, Ajayi L, Acquati P, Perez-Fentes D, Herrmann TRW, and Buffi NM
- Subjects
- Humans, Risk Factors, Constriction, Pathologic, Postoperative Complications etiology, Iatrogenic Disease, Internationality, Consensus, Delphi Technique, Urolithiasis surgery, Ureteroscopy adverse effects, Ureteral Obstruction surgery, Ureteral Obstruction etiology
- Abstract
Purpose: Iatrogenic ureteral strictures (US) after endoscopic treatment for urolithiasis represent a significant healthcare concern. However, high-quality evidence on the risk factors associated with US is currently lacking. We aimed to develop a consensus statement addressing the definition, risk factors, and follow-up management of iatrogenic US after endoscopic treatment for urolithiasis., Methods: Utilizing a modified Delphi method, a steering committee developed survey statements based on a systematic literature review. Then, a two-round online survey was submitted to 25 experts, offering voting options to assess agreement levels. A consensus panel meeting was held for unresolved statements. The predetermined consensus threshold was set at 70%., Results: The steering committee formulated 73 statements. In the initial survey, consensus was reached on 56 (77%) statements. Following in-depth discussions and refinement of 17 (23%) statements in a consensus meeting, the second survey achieved consensus on 63 (86%) statements. This process underscored agreement on pivotal factors influencing US in endoscopic urolithiasis treatments., Conclusions: This study provides a comprehensive list of categorized risk factors for US following endoscopic urolithiasis treatments. The objectives include enhancing uniformity in research, minimizing redundancy in outcome assessments, and effectively addressing risk factors associated with US. These findings are crucial for designing future clinical trials and guiding endoscopic surgeons in mitigating the risk of US., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
50. Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.
- Author
-
Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I, and Bechara FG
- Abstract
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with a profound disease burden. In recent years, the advent of biologic therapies has improved the treatment landscape for patients with moderate to severe HS. In this new therapeutic era, the role of the general practitioner (GP) in HS treatment is becoming more important than ever. This review discusses how to recognize and diagnose HS by detailing common symptoms. HS can also present with multiple comorbidities. The GP's role in screening for and treating these important comorbidities is pivotal. This review highlights the HS treatment landscape, with a specific focus on what the GP can recommend. The three approved biologics for treating HS include adalimumab, secukinumab and bimekizumab; the benefits and concerns of biologics in everyday clinical practice are detailed. In summary, this review serves as a HS management guide for GPs, with a particular focus on the biologic treatment landscape., Competing Interests: PM-B has received honoraria for acting as a consultant and/or as a speaker for Regeneron, Sanofi Genzyme, AbbVie, Pfizer, Janssen-Cilag, Leo Pharma, Novartis, Eli Lilly, Teva, L’Oreal, Pierre Fabre, Cantabria Labs, Organon, Viatris, Evelo Biosciences, and CS Labs. PM-B is/has been a principal investigator in clinical trials supported by AbbVie, Amgen, Biogen, Janssen, Novartis, Pfizer, and Sanofi. FaB has received honoraria for consultancy/or as speaker for Pfizer, Novartis, Janssen, AbbVie, UCB Pharma, Leo Pharma, and Almirall. MV has served as an advisory board member and/or consultant and has received fees/speaker’s honoraria and/or has participated in clinical trials for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. AM-L has received consultancy/speaker’s honoraria and/or travel grants and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Eli Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB Pharma. NT and IA are employees and stockholders at Novartis Pharma AG, Switzerland. FGB has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Incyte Corporation, JanssenCilag GmbH, Merck, Mölnlycke, MoonLake, Novartis Pharma GmbH,Sanofi, Sitala, UCB Pharma and Dr. Wolff. The authors declare that this study received funding from Novartis Pharma AG. The funder had the following involvement in the study: medical writing support and facilitated discussions which culminated in the conception of this narrative review. The funder had no role in the review design or decision to publish., (Copyright © 2024 Mendes-Bastos, Benhadou, Venturini, Molina-Levya, Thomas, Alarcon and Bechara.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.